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ABSTRACT
Myotonic dystrophy (DM) is an autosomal dominant inherited multisystemic
neuromuscular disease. The molecular mechanism for DM is mediated by toxic RNAs
containing expanded repeat units. DMI is caused by a CTG repeat expansion in 3'-
UTR of the DMPK gene while DM2 is caused by CCTG repeat in intronl of the ZNF9
gene. The molecular features of DM are formation of RNA foci, co-localisation of
MBNL proteins with ribonuclear foci, splicing defects of a subset of pre-mRNAs with
elevation ofCUGBPI in DMl.
In order to develop therapy for DM, assays were designed based on the molecular
characteristics of the disease to screen compounds. Two primary assays were based on
disruption of nuclear foci and on correction of misregulated splicing involving intron2
CLCNI.
The first part of this report deals with the development of a nuclear foci assay and
splicing construct assay. Both assays were optimised in HTS and utilized in screens
for molecules that clear nuclear foci from DM cells and correct misregulated splicing
in intron2 of CLCNI respectively. High throughput screens of kinase and phosphatase
inhibitor libraries using the nuclear foci assay and CLCNI splicing construct assay
yielded two positive hits: protein kinase C inhibitors designated in the compound
library as D8 (hypericin) and D9 (Ro-31-8220).
The second part of this thesis deals with the confirmation of compound hits obtained
from the primary screen. I examined two aspects: mutant DMPKtranscript entrapment
in nucleus and splicing defects associated with the disease. A BpmJ restriction assay
was used to test the effect of compounds on mutant DMPK transcripts showed that
both D8 and D9 were unable to release the mutant transcript into the cytoplasm. D8
demonstrated efficacy in reversing spliceopathy in alternative splicing assays of JR,
SERCAI MBNLI and MBNL2 while D9 did not have this effect except on MBNLI
which showed a very minor efficacy.
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CHAPTER ONE: INTRODUCTION
1.1 History and Occurence
Myotonic dystrophy was first identified in 1909 by Steinert. The disease was
mainly defined by delay in muscle relaxation after contraction, commonly
referred to as myotonia, with weakness and degeneration of muscles. Other
phenotypes associated with the disease include cataracts, cardiac disease,
digestive problems, excessive sleeping, premature balding and insulin
resistance (Harper 2001).
Myotonic dystrophy (DM) is the most common form of muscular dystrophy
in adults and is inherited as an autosomal dominant neuromuscular disease. The
condition is a multisystemic disease with complex aetiology that also affects
the heart (Harper 2001). There are two forms of DM namely: myotonic
dystrophy type 1 (DM1) and myotonic dystrophy type 2 (DM2). DM results
from two transcribed and unrelated mutations.
DM occurs in around one in every 8000 adult persons in the population. DM
type 1 accounts for 98% of DM patients (Brook et. aI. 1992; Mahadevan et. aI.
1992). The molecular mechanism for the pathogenesis of DM was first
identified in 1992 as mutation resulting in expanded CTG triplet repeat units in
the 3'-UTR of the dystrophia myotonica protein kinase (DMPK) gene which is
present on Chromosome 19 (Brook et al, 1992; Fu et al, 1992; Mahadevan et
al, 1992). In 1995, a gene neighbouring DMPK called SIX5, which was
previously referred to as DM locus-associated homeodomain protein
1
(DMAHP), was reported to be affected by DM1 mutation (Boucher et aI,
1995).
The other form of DM which is referred to as DM2 is less common and
shares similar disease phenotype as well as molecular phenotype (Harper
2001). DM2 was first identified in 1994 as similar to DMI but without the
CTG expansion mutation (Ricker et aI, 1994; Thornton et aI, 1994). Many
symptoms of DM1 were also associated with DM2 including, myotonia and
slight muscle weakness in proximal muscles, in contrast to distal muscles
found in DMI. Hence the new syndrome was described as proximal myotonic
myopathy or PROMM (Ricker et aI, 1994) and was subsequently referred to as
proximal myotonic dystrophy (Udd et aI, 1997). Those referred to as having
PROMM, proximal myotonic dystrophy and DM2 were associated with the
same locus (Ranum et al, 1998; Liquori et al, 2001). Ranum et al (1998)
mapped DM2locus to a 10 centiMorgan region on chromosome 3. Subsequent
mapping ofDM2 was found on chromosome 3q21.3 (Ricker et aI, 1999).
The DM2 mutation was reported to be an unstable CCTO repeat expansion in
intronl of the zinc finger protein 9 gene (ZNF9), formerly referred to as CNBP
(Liquori et al 2001).
1.2 Classification and features of OM
DM is classified into 2 major forms based on clinical features and
manifestations namely: DMI and DM2. Both forms of DM are multisystemic
with similar effects on organ systems. However, there are differences in
symptoms between DMI and DM2 and they include age of onset, absence of
2
congenital forms in DM2, mode of muscle weakness, and very little association
of the nervous system with DM2 (Machuca-Tzili et al, 2005).
OM 1 can be classified into three forms based on the age of onset, degree of its
severity and clinical features: congenital, classical and minimal DM.
The congenital form of DM 1 occurs at birth and in a severe manner. Its
symptoms manifest as neonatal hypotonia, facial displegia, joint contractures,
frequent fatal respiratory failure, feeding difficulties and delay in development.
There is a high risk of dying from congenital DMI during the neonatal period
and those that survive show non-progressive psychomotor retardation and go
on to develop features of adult-type classical form of DMI (Harper 200 I).
The classical form of the disease is the most common type and exhibits
symptoms between the ages of 20 to 40 years in life manifesting with slow
progression over time. The major feature of this disease form is myotonia with
delayed relaxation of patients' muscles after contraction due to repetitive
discharges of action potential; progressive muscular weakness (dystrophy) and
wasting (Harper 2001).
Figure 1.1: Contraction of fist (A) by a myotonic patient demonstrating difficulty in
relaxing muscles of the hand (B) after a grip (from Pelargonio et ai, 2002)
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The minimal forms of the disease, which start later in life, over the age of 50,
and shows very mild degree of muscle weakness and myotonia or cataracts
(Harper 2001).
Figure 1.2: Patient with adult onset DM! displaying features of facial muscle weakness
and atrophy (from Machuca- Tzili et aI, 2005)
Furthermore, the disease causes central nervous system disorders with
cognitive impairment, mental retardation and attentive disorders and
sometimes affects the heart leading to conduction system abnormalities,
supraventricular and ventricular arrhythmias and to a lesser extent myocardial
dysfunction as well as ischaemic heart disease (Pelargonio et al, 2002).
Hypogammaglobulinaemia has also been associated with both forms of the
disease (Day and Ranum 2005).
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1.3 Unstable Repeat Expansion Disorders (UREDs)
Short repeat units normally stable in mitosis and meiosis, as weIl as through
generations, could become unstable and undergo expansions beyond a
threshold repeat number resulting in hereditary disorder. This occurence of
triplet repeat expanded units was proposed as the genetic basis for OMI and
this concept was used to identify tetranucleotide repeat units in DM2. Since
1991, up to 30 unstable repeat expansion disorders have been identified
(Machuca-Tzili et ai, 2005).
UREOs are classified into two major forms namely: those whose expanded
units are in untranslated region of the gene (table 1.1) and those with mutations
in coding (table 1.2) region (Machuca- Tzili et ai, 2005). For disorders whose
expanded repeats occur in noncoding untranslated region, the mutations are
proposed to disrupt transcription, RNA processing and translation. In the
second group whose mutations occur in coding region, it has been proposed to
involve CAG or GCG codons resulting in abnormaIly long polyglutamine or
polyalanine tract which results in a mutated protein with undesired properties
such as neutral toxicity (Machuca-Tzili et al, 2005).
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Disorder Mode of Repeat Normal Pathogenic
Inheritance Unit
DMI Autosomal (CTG)n 5-37 50-above
Dominant 3000
FRDA Autosomal (GAA)n 6-32 200-1700
Friedreich's Recessive
ataxia
SCA8 Autosomal (CTG)n 16-92 100-127
Spinocerebellar Dominant
ataxia 8
PPP2R2B Autosomal (CAG)n 7-45 55-78
Spinocerebeller Dominant
ataxia 12
FMR I Fragile X-linked (CGG)n 6-52 230-2000
XA
FMR2 Fragile X-linked (CGG)n 4-39 200-900
XE
FAM IIA X-linked (CGG)n 7-40 306-1008
Fragile XF
CBL2 Jacobsen Sporadic (CCG)n II 100-1000
syndrome
Table 1.1: List of non-coding triplet repeat expansion diseases (adapted from Machuca-
Tzili et aI, 2005)
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Disorder Mode of Repeat Normal Pathogenic
Inheritance Unit
Huntington disease Autosomal (CAO)n 10-34 40-121
(HD) Dominant
Spinobulbar X-linked (CAO)n 9-36 38-62
muscular
dystrophy
ATXI Autosomal (CAO)n 6-39 40-82
Spinocerebellar Dominant
ataxia 1
ATX2 Autosomal (CAO)n 13-33 32-3000
Spinocerebellar Dominant
ataxia 2
ATX3 Autosomal (CAO)n 13-44 55-84
Spinocerebellar Dominant
ataxia 3
CACNAIA Autosomal (CAO)n 4-18 20-29
Spinocerebellar Dominant
ataxia 6
SCA7 Autosomal (CAO)n 4-35 37-306
Spinocerebellar Dominant
ataxia 7
TBP Autosomal (CAO)n 25-42 47-63
Spinocerebellar Dominant
ataxia 17
Dentatoru bral- Autosomal (CAO)n 3-35 49-88
pallidoluysian Dominant
atrophy
Infantile spasm X-linked (OCO)n 10-16 17-23
syndrome
Cleidocranial Autosomal (OCO)n 11,17 27
dysplasia Dominant
Epicantus inversus Autosomal (OCO)n 14 >14
syndrome type II Dominant
Hand- foot-genital Autosomal (OCO)n 18 24,26
syndrome Dominant
Synpolydactyly Autosomal (OCO)n 15 22-29
Dominant
PABP2 Autosomal (OCO)n 6-7 8-13
Dominant
Holoprosencephaly Autosomal (OCO)n 15 25
Dominant
Table 1.2: List of triplet repeat expansion diseases involving those in the codmg regions
(adapted from Machuca- Tzili et aI, 2005)
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1.3.1 The Genetic Basis of OM
The underlying genetic basis for both types of myotonic dystrophy is the
occurrence of repeat expansions in untranslated region of unrelated genes
occurring at different loci.
DMI is caused by mutations leading to microsatellite repeat expansions of
CTO in the non-coding 3' untranslated region of DMPK gene (Brook et ai,
1992). Unaffected individuals have variable numbers of repeats which ranges
from 5 to 38 repeats while patients have CTO repeats of 50 up to 3000 (Brook
et ai, 1992 & Harper 2001). The length of microsatellite repeat expansion
correlates with severity of disease with the largest repeats associated with
severe congenital form of DM. The disease also shows an increase in repeat
expansion with age (Brook et ai, 1992) as well as generational expansion
between parents and children (Hunter et aI, 1992). The C'I'G repeat expansions
are unstable in mitotic divisions and this instability leads to mosaicism in
somatic as well as germ-line tissues (Harley et aI, 1992; Jansen, et aI, 1994;
Wong et al, 1995).
The second form of myotonic dystrophy (DM2) is caused by eeTa repeat
expansion in intron 1 of the ZNF9 gene (Liquori et al, 200 I). Repeat
tetranucleotide expansions in DM2 ranges from 75-11000 units (Harper 2001).
In DMI, C'I'G repeat expansions has been proposed to affect the expression of
the DMPK gene, leading to loss or decrease in its expression. This decreased
expression has been suggested to be due to defective processing of DMPK pre-
mRNA. Functional studies in support of this idea were carried out by Reddy
and co-workers (1996) in which they demonstrated that the loss of DMP K
expression could result in muscle disease in homozygous Dmpk knockout
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mouse which showed signs of late degree of myopathy. The loss of DMPK
expression did not manifest other associated symptoms such as myotonia and
cataracts that are seen in human patients.
In addition and to my knowledge, there is no functional study of eeTa repeat
units on mouse model for DM2.
1.3.2 Genetic Instability of Repeat Expansions in OM
Repeat expansions of C'I'G exhibit a high degree of somatic mosaicism as
well as differences between generations in DM1 patients (Martorell et ai, 1995;
Martorell et ai, 1998).
Somatic and germ-line tissue mosaicism involving C'TG repeat variation has
been reported (Jansen et al, 1994). In the above study, it was suggested that
these unstable C'TG repeat variability resulted from early embryonic mitosis
during somatic and germ-line tissue formation leading to intergenerational
changes in repeat expansion lengths among DM patients.
The larger eTG repeat expansion lengths are associated with cases of severe
congenital OM (Tsilfidis et ai, 1992). It was also observed that there was
association between cardiac involvement and C'I'G repeat length in OM
patients (Melacini et ai, 1995).
Evidence in support of this concept was demonstrated in a DM transgenic
mouse carrying expanded repeat by Seznec et al (2000), which exhibited
intergenerational repeat instability as well as somatic repeat instability which
was dependent on size and age.
Evidence from these studies point to the role of increased size of expanded
repeat lengths as a contributing factor to disease severity and progression.
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1.4 Molecular Models for Pathogenesis of OM
The molecular mechanism for OM has been proposed to involve three models
which include DMPK haploinsufficiency, chromatin structure and RNA gain-
of-function models.
1.4.1 DMPK Haploinsufficiency
In this model, the CTG repeat expansions in the 3' -UTR of the DMP K gene
affects its transcription or cause transcripts containing expanded CTG repeats
to be retained in the nucleus (Davis et aI, 1997). This leads to reduced levels of
OMPK protein.
Studies have reported decreased levels of OMPK protein from OM 1 allele (Fu
et al, 1993; Furling et al, 2001; Novelli et al, 1993). However, the reduced
expression of OMPK has been reported to playa minor role in pathogenesis of
OMI (Fu et aI, 1993).
Studies involving transgenic mice testing the viability of haploinsufficiency
have shown that this model of disease mechanism does not account for OM 1
pathology. A study by Reddy et al (1996) on Dmpk knock-out mice removing
the first seven exons and replacing them with a neomycin cassette showed that
homozygous mice displayed minimal myopathy, muscle degeneration and
reduced skeletal muscle force while its heterozygous counterpart did not show
any OM symptoms. This was followed by another study showing Dmpk dosage
alterations in mice results in cardiac conduction abnormality (atrioventricular
block) which was more pronounced in homozygous than in heterozygous mice
(Berul et al, 1999; Berul et ai, 2000).
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Jansen et al (1996) developed Dmpk knock-out mice that resembled the one
used by Reddy et al (1996) in which a hygromycin cassette was used in place
of neomycin cassette. The mice only showed mild myopathy and altered
calcium levels (Benders et aI, 1997; Jansen et aI, 1996).
The evidence from these mice models suggest that DMPK haploinsufficiency
cannot explain most aspects of OMI pathogenesis as the mice did not display
unique features such as myotonia and cataracts.
1.4.2 Chromatin Structure Alteration Model
Studies on chromatin structure of DNA with C'TG repeats have suggested that
expansion mutations modify the chromatin structure and alter expression of
DMPK and neighbouring genes (Jansen et aI, 1996; Klesert et aI, 1997;
Michalowski et al, 1999; Otten and Tapscott, 1995; Thornton et aI, 1997).
Wang and ariffith (1994) demonstrated formation of hyperstable and
abnormally stronger nucleosomes by expanded C'TG repeats. It has been
suggested that C'I'G repeats result in the formation of more condensed
chromatin structures and consequently loss of DNase J sensitive site. Since
DNase J sensitivity indicates relaxed chromatin structure making it accessible
for transcription factors and RNA polymerase, the presence of C'I'G repeats
may block these processes to hinder transcription of DMP K and its
neighbouring genes (Otten and Tapscott 1995).
The eTG repeat-induced changes in chromatin structure affect expression of
neighbouring genes SIX5 and DMWD (dystrophia myotonic-containing WO
repeat motif) (Frisch et al, 2001). Other genes mapped around DMPK include
GIPR, 20-D7 and symplekin (Alwazzan et aI, 1998).
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Figure1.3: Schematic representation of DMPK and its flanking genes showing its
proximity to eTC repeats as proposed in this model
SIX5 (formerly DMAHP) is located immediately downstream of DMPK and
the repeat expansion forms part of the promoter region of SIX5 (figure 1.3).
SIX5 encodes the DM locus-associated homeodomain protein, homologous to
Drosophila sine oculis homeobox 5, which is involved in eye development
(Winchester et aI, 1999).
It has been reported that there is a reduction in SIX5 expression in DM I
patients in comparison with controls which leads to its involvement in cataract
formation in these patients (Alwazzan et aI, 1999; Klessert et aI, 1997;
Thornton et aI, 1997; Winchester et aI, 1999). An animal study involving
knock-out of six5 in mice by replacement of its first exon by p-galactosidase
reporter showed development of cataracts (Jansen et aI, 1996; Klessert et aI,
2000).
DMWD formerly known as 59 is located immediately upstream of DMPK. It
has been reported to be mainly expressed in adult mouse testis and brain and it
has been suggested that it may be associated with the mental retardation and
testicular symptoms observed in DM 1 (Jansen et aI, 1996). However, this
model does not account for the main phenotypes associated with both DM 1 and
DM2 patients.
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1.4.3 RNA dominant gain-of-function Mechanism
The hypothesis for this model first arose from studies that DMPK RNA with
expanded repeat units were trapped in the nucleus to form foci in patients' cells
(Taneja et ai, 1995; Davis et ai, 1997; Hamshere et ai, 1997). The study by
Taneja et al (1995) used CAG oligonucleotide probes to detect DMPK
transcripts with expanded repeats which gave bright foci in the nuclei of DM
patients' cells which were not detected in the fibroblasts of unaffected persons.
It was suggested that the concentration of mutant DMPK transcripts containing
repeat expanded units in the nucleus represented abnormal RNA processing
which could be indicative of the disease phenotype (figure 1.4).
CTG)n
~
CCTG)n
IV 11111
CUG)n
CCUG)n
RNA
Nucleus Cytoplasm
Disrupted
alternative
splicing
regulation
Disrupted
translation
regulation
Figure1.4: RNA-dominant gain-of-function model for OM aetiology (taken from Ranum
and Cooper, 2006) showing negative effects of expanded repeat RNA on alteration of
cellular functions
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Other evidence in support of the observation by Taneja et al (1995) comes
from the finding that mutant nMPK transcripts were found exclusively in the
nucleus and not in the cytoplasm of DM cells (Davis et ai, 1997) with a critical
repeat threshold number of between 80 to 400CTGs (Hamshere et aI, 1997).
Nuclear foci found in DM cells have been proposed to be formed due to
interactions between expanded CUG transcripts (for DM!) and expanded
CCUG repeat transcripts (for DM2) with certain RNA binding proteins (Miller
et ai, 2000; Fardaei et aI, 200 I).
It has been suggested that single stranded CTG repeats fold to form unusual
structures such as duplex hairpins (Wells 1996). A study has shown that RNA
containing expanded repeats within pathogenic lengths fold to form hairpin
structures which in tum interact with RNA binding proteins (Michalowski et ai,
1999). The interactions of the hairpin with RNA binding proteins prevent these
proteins from performing their normal cellular functions, causing them to
accumulate in the hairpins to form foci (Miller et aI, 2000).
One of the RNA binding proteins proposed to interact with expanded repeat
transcripts in foci is muscleblind-like proteins (MBNL). The MBNL has been
shown to colocalise with expanded CUG or CCUG repeats in nuclear foci
(Fardaei et aI, 2001; Fardaei et al 2002; Miller et ai, 2000). The most abundant
isoform of MBNL proteins (MBNL I) has been reported to be the major
determinant of nuclear foci formation in DM (Dansithong et al, 2005).
In a study to assess effect of expression of CTG repeats, a mouse myoblast
C2C 12 cell line was used to demonstrate that CUG expansion alone formed
foci but only CUG expansion in DMPK 3'-UTR was able to inhibit myoblast
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differentiation via reduced MyoO levels (Amack et aI, 1999; Amack
&Mahadevan, 2001). These studies were important as it provided a proof for
the contribution of expanded repeat RNA to OM-like features.
Several lines of evidence now support the RNA gain-of-function hypothesis
as the primary event in OM pathogenesis (Mankodi et aI, 2000; Mahadevan et
aI, 2006; Seznec et ai, 2001). Mouse models have been used to test the RNA
dominant negative function hypothesis in many studies (Mankodi et ai, 2000;
Seznec et aI, 2001; Mankodi et aI, 2002; Mahadevan et aI, 2006; Orengo et aI,
2008).
In one study, transgenic mice were generated expressing human skeletal
muscle alpha actin containing 250 CTG repeats in a mouse background
designated as HSA LR and these were observed to replicate OM features of
myotonia and myopathy while mice containing 5 CTG repeats did not have
OM phenotype (Mankodi et ai, 2000). Another study by Mahadevan and
colleagues (2006) used an inducible mouse model under control of tetracycline
inducible system to demonstrate that RNA toxicity and cardiac conduction
defects seen in OM could be reversible. In this study, mice with (CTG)s DMPK
3'-UTR and mutant (CTG)2oo DMPK 3'-UTR when induced with doxycycline,
both developed OM-like features such as cardiac conduction abnormalities and
abnormal RNA splicing. In addition, there was appearance of foci in (CTG)2oo
DMPK 3'-UTR mice but not in (CTG)s DMPK 3'-UTR. This mouse model
suggests that it has limitations for studying effect of CTG repeats because of
the presence of both splicing and cardiac conduction abnormalities in (CTG)s
DMPK 3'-UTR mice which does not correlate to that seen in unaffected
persons carrying 5CTG repeats.
15
Furthermore, Orengo et al (2008) used an inducible transgenic mice
containing DMPK 3'-UTR with 960 CTG repeats under tamoxifen induction to
show severe skeletal muscle degeneration, a feature of OM not seen in other
mouse models. In addition, the study showed splicing misregulation that was
responsive to only CUGBP I as opposed to those demonstrated by Mahadevan
et al (2006) and Mankodi et al (2002). Because this model did not demonstrate
misregulation of MBNL 1 responsive splicing events, it does not lend itself as a
good model for OM study.
Finally, Seznec et al (2001) developed two mice models for OM study with
one containing 300 CTG repeat (OM300) and the other having 20 CTG repeats
(OM20) both in its natural OMPK context obtained from OMI patient and
unaffected person. The OM300 mice displayed myotonia, presence of nuclear
foci, abnormal skeletal muscle histology and altered Tau protein isoforms
consistent with that seen in OM 1 patients which was absent in OM20 line. The
OM phenotypes obtained from this mouse model were consistent with that
reported in Mankodi et al (2000). Further studies involving HSA LR mouse has
been used to demonstrate Clcnl missplicing (Mankodi et aI, 2002), splicing
abnormalities of Mbnll, Sercal, Zasp,Cypher and m-Titin (Lin et al, 2006) as
well as in studying reversal of both missplicing and myotonia by Kanadia et al
(2006). The OM300 line has been reported to be utilized in therapeutic screens
(Mulders et aI, 2009). Both HSA LR and OM300 provide a good and reliable
model for use in studying OM as well as in therapeutic screening due to their
ability to recapitulate DM associated symptoms.
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1.5 Alternative Splicing Regulation
Alternative splicing is the mechanism that controls gene expression and
protein diversification through multiple RNA isoforms from a single pre-
mRNA. It is determined by additional factors such as cell cycle phase,
developmental stage, cell type, organ or tissue. In disorders such as OM, the
alternative splicing process is altered leading to alterations in relative
proportion of isoform obtained.
Alternative splicing influences cell fate decisions like apoptosis in mammals
as well as sexual differentiation in Drosophila and its misregulation has been
reported in human disease. Of the estimated 30,000 protein-coding genes in
human, most code for alternatively spliced transcripts and this accounts for the
difference between the number of human genes and human proteome
complexity (Lander et ai, 200 I).
In humans, most of the protein coding genes are separated by introns and the
production of functional mRNAs is determined by the accuracy of pre-mRNA
splicing in which introns are spliced out and exons joined together. The
excision of introns involves two transesterification reactions which occur in a
macromolecular complex (spliceosome) that consist of more than 100 proteins
and about five RNA species- U I, U2, U4, US, U6 among others (Nilsen, 2003).
Many regulatory elements direct and regulate. the process of alternative
splicing. They are normally referred to as splicing factors.
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1.5.1 Cis-acting Elements
Alternative splicing depends on the assembly of the basal splicing machinery
in spliceosome complexes within consensus sequences present in every 5' and
3' splice site boundary between introns and exons. The spliceosome functions
to identify and select splice sites, and also catalyse the sequential
transesterification reactions to remove introns and join exons together. The
effectiveness of the spliceosome to act on an exon depends on the strength of
the splice site which relates to its complementarity to consensus splice site
sequences, exon size, and availability of auxiliary cis elements. Exons that
have undergone alternative splicing are often small and possess weak 5' and 3'
sites, and their auxiliary elements serve to improve splice site recognition as
well as mediating selection of splice sites involved in specified cells
(McCullough and Berget, 1997).
Gene Exon Effect Sequence Location Trans- Ref.
acting
factor
Cardiac 5 exon cgcugcggc intronic MBNL Ho et al. 2004
troponin T skipping ( 18-26nt
in adult upstream)
cardiac
muscle
Insulin 11 Exon uuacucggacac Intronic CUG-BP Savkur et al.
Receptor skipping auguggccuccaa (52-95nt 2001
in non- gugucagagccag upstream)
muscle uggu
tissues
Microtubule 3 Varying Uuag Exonic Nova1, Arikan et al.
associated degree of SWAP, 2002
protein tau exon KSRP
skipping
in adult
CNS
Microtubule 10 Same ucaaaggauaauau Exonic unknown D'Souza&
associated caaa Schellenberg,
protein tau 2000
Microtubule 10 Same ucacacgu lntronic unkown D'Souza&
associated (11-18nt Schellenberg,
_protein tau Downstream 2002
Table 1.3: LIst of genes associated with DM with ItS alternative sphce site sequences and
its silencers which are trans-acting factors (adapted from Pozzoli & Sironi 2005)
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Auxiliary elements involved in controlling the use of alternative splice sites
have the following characteristics: they are small in size, have variable
sequence, are individually weak, and occur in multiple copies. The auxiliary
elements are mostly single-stranded with secondary structure reported to be
involved in the activity of a few elements (Blanchette and Chabot, 1997).
Auxilliary elements could be present in exons or introns and when they are
intronic, they can be present upstream, downstream or flank both sides of the
regulated exon.
Gene Splicing Element Sequence Location of Ref.
specificity involved element
CLCN-I Intron Enhancer UGUUUGUUUG Upstream of Charlet-B et al.
intron2 retention in UUUGUUUGUU exon3 2002
DM GUUUGUUUGU
UUGU
DMPK Specific for Enhancer (CUG)n upstream Tiscomia &
exon 16 developmental Mahadevan 2000
stage,
removed in
DM
Tau Misregulated Enhancer CCCAUGCG downstream D'Souza&
exon 10 inDM Schellenberg,
2002
. . ..Table 1.4: Auxiliary elements that regulate alternative sphcmg of genes associated with
DM (adapted from Ladd & Cooper, 2002)
Finally, auxiliary elements are involved in enhancing or repressing splice-site
selection. Based on their location and effect, they are referred to as exonic
splicing enhancers or silencers or intronic splicing enhancers or silencers.
1.5.2 Trans-acting Splicing Factors
Several exonic splicing enhancers are known to interact with serine/arginine
(SR) proteins, which is a family of essential splicing factors, to allow inclusion
of alternative exons having weak splice sites in their pre-mRNA by promoting
splicing of nearby introns (Wu and Maniatis, 1993; Zhu et aI, 2001). The
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activity of SR proteins on alternative splicing is countered by constitutive
splicing factor heterogenous nuclear ribonuclear protein A 1. The alternative
splicing of a few RNAs can be regulated in cell populations by altering the
ratios of constitutive splicing factors since overexpressing SR proteins or
hnRNP Al has been shown to have a similar effect on the splicing of
alternatively spliced pre-mRNAs in vitro or in transient transfection assays
(Zhu et al, 2001).
The hnRNPs are reported to be necessary for the many aspects of mRNA
biogenesis and metabolism. They are a group of RNA-binding proteins
involved in alternative splicing. Members of AlB type of hnRNPs are the most
abundant and are reported to be involved in splice site selection. Activation of
distal 5' splice sites has been suggested to be due to negative effect of hnRNP
A 1 on alternative splicing functions of splicing factors SF2/ASF or SC3S.
However, hnRNP A2 and B 1 have been reported to have greater splice
switching activities than hnRNP A 1 (Mayeda et aI, 1994).
Other trans-acting splicing factor are the CELF (CUG-BP and ETR3-like
factors) proteins also referred to as Bruno-like proteins which have a binding
preference for uridinelpurine repeat elements (Good et ai, 2000; Ladd et ai,
2001 and Takahashi et ai, 2000). CELF proteins are important because of their
role in misregulation of alternative splicing of many mRNAs in myotonic
dystrophy.
20
Splicing factor Protein Rezions Binding sites Tarzet eenes
ASF/SF2 RNA recognition RGAAGAAC HipK3, CaMKIlo
motif; arginine-
serine repeats-
containing domain
SC35 RNA recognition UGCUGUU AChE
motif; arginine-
serine repeats-
containing domain
SRp55 RNA recognition GGCAGCACCUG cTnT, CD44
motif; arginine-
serine repeats-
containing domain
hnRNP Al RNA recognition UAGGGAIU HipK3,SMN,c-H-ras
motif; arginine-
glycine-glycine
repeats
hnRNP A2IBI RNA recognition (UUAGGG)n HIV Tat, IKBKAP
motif; arginine-
glycine-glycine
repeats
hnRNP H RNA recognition GGGA, G-rich PLP, c-SRC, BcI-x
motif; arginine-
glycine-glycine
repeats; glycine-
tyrosine-arginine
rich domain
PTB RNA recognition UCUU,CUCUCU nPTB, c-SRC, Fas,
motif cTNT,CGAP,
NMDA.CLBC,
hnRNP Al
Cugbp RNA recognition U/G-rich cTNT, JR
motif
Cugbp2 RNA recognition U/G-rich cTnT, Tau. Cox-2
motif
Celf4 RNA recognition U/G-rich Mtmrl, cTnT
motif
Mbnll CCCH zinc finger YGCU(U/G)Y cTnT, JR.
domain Clen I,Tnnt3
Rbm4 RNA recognition CIU-rich MAPT, a-
motif; CCHC zinc tropomyosin, Tau
finger domain
Table 1.5: A subset of splicing regulatory factors and their respective binding sites on
target genes (adapted from Gabut et ai, 2008)
Many exons can be regulated by factors with antagonistic effect. These
antagonistic activities could be effected trans-acting factors that can act
alternatively as repressors and activators on different target RNAs. This
explains the interaction of CUG-BP and MBNL proteins in the regulation of
cardiac troponin T (Philips et aI, 1998) and insulin receptor pre-mRNAs
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(Savkur et aI, 2001). The alteration in the relative ratios of these protein factors
has been suggested to lead to defect in splicing patterns in DM (Philips et al,
1998; Savkur et aI, 200 I; Kalsotra et aI, 2008).
1.5.2.1 Splicing Factor Regulation in OM
Many proteins have been implicated in splicing misregulation in DM. They
include muscleblind-like protein, eVG-binding protein 1, heterogenous nuclear
ribonucleoprotein among others which will be discussed in the following
sections.
1.5.2.1.1 Muscleblind-like (MBNL)
This expanded repeat RNA-binding protein and splicing factor was first
identified in Drosophila melanogaster for its role in photoreceptor development
and terminal muscle differentiation (Artero et aI, 1998; Begemann et aI, 1997).
In humans, MBNL are homo logs to those of Drosophila and are of three types:
MBNU, MBNL2 and MBNL3. These MBNL proteins are encoded by
different genes. MENLl, MENL2 and MENL3 genes have been mapped to
chromosome 3, 13 and X respectively (Fardaei et aI, 2002). Each of the
muscleblind-like proteins exist in different splice isoforms with MBNU
having nine isoforms, MBNL2 has three alternative splice isoforms while
MBNL3 has six splice isoforms (Fardaei et aI, 2002;Kino et aI, 2004; Pascual
et ai, 2006). MBNLl was discovered for its affinity for binding to eva repeats
(Miller et aI, 2000). Subsequently, MBNL2 and 3 were found to colocalise
with RNA foci in DM 1 and DM2 cells (Fardaei et aI, 2001; Mankodi et aI,
2001; Miller et aI, 2000).
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The three muscleblind-Iike proteins are present in brain, heart, placenta, lung,
liver, kidney, pancreas and skeletal muscle. MBNL 1 and 2 are mostly
expressed in heart and skeletal muscle while MBNL3 is mainly expressed in
placenta (Fardaei et aI, 2002).
MBNL 1, the most abundant muscleblind-like protein, has been implicated in
pathogenesis of OM due to its sequestration by RNA expanded repeats (Miller
et aI, 2000). This proposal was validated by Kanadia et al (2003) using a mouse
knock-out for mbnll isoform (mbnll d3/d3) which replicated OM-like features
such as myotonia, cataracts and misregulation of splicing. A follow up study by
Kanadia et al (2006) involving adeno-associated virus (AA V)-mediated mbnll
overexpression in HSA LR mice showed that it reversed myotonia in skeletal
muscle as well as rescueing associated misregulated splicing in this mouse
model.
These data suggest that MBNL 1 downregulation is the major cause of OM. If
this is the case, by what mechanism does it influence the manifestation of OM
phenotype? The answer to this could lie in the function of MBNLl as a
regulator of alternative splicing.
One of the major molecular features of DM is misregulation of alternative
splicing. It has been reported that MBNLI depletion leads to misregulation of
splicing in many genes and in some cases it resulted in OM phenotypes
(Ranum and Cooper, 2006). MBNLl sequestration has been implicated in
misregulated splicing of CLCNJ, cTNT and IR leading to myotonia, cardiac
conduction defects and insulin resistance seen in OM patients (Charlet et aI,
2002b; Dansithong et aI, 2005; Ho et aI, 2004; Lin et aI, 2006).
23
The role for MBNLI in alternative splicing misregulation in DM was
demonstrated by Ho et al (2004) which showed that siRNA downregulation of
MBNLI in HeLa cells altered both cTNT and IR splicing. In addition, MBNLI
overexpression in DMI cultured myoblast was necessary to reverse IR splicing
defect (Dansithong et al, 2005). Consequently, AAV-mediated overexpression
of mbnll in HSALR skeletal muscle restored CLCNI splicing and rescued
myotonia (Kanadia et aI, 2006). Indeed, MBNLI is predominantly localised in
the nucleus where it switches from the cytoplasm during normal skeletal
muscle development (Lin et al, 2006), thus it has been suggested that MBNLI
sequestration by repeat expanded RNA disrupts a subset of spliceforms to
produce isoform ratios more typical of the embryo leading to multisystemic
symptoms in DMI.
Eventhough the MBNLI sequestration model for misregulated splicing and
DM pathogenesis has been confirmed in many studies, it does not completely
explain the mechanism for DM pathogenesis. One aspect of DM that is not
accounted for by loss of MBNLI function is the lack of muscle wasting in
mbnll ~3/~3 mice. In addition, MBNLI was observed to be sequestered by both
CAG and CUG formed foci but only CUG repeats were able to disrupt splicing
of cTNT and IR (Ho et al, 2005b). This suggests that other factors besides
MBNLI could contribute to these splicing defects.
1.5.2.1.2 CUG-BP1
The CUG binding protein (CUG-BP) was first identified for its ability to bind
to CUG repeat in a gel-shift assay (Timchenko et al, 1996a). CUG-BPI
belongs to the CELF (CUG-BP and ETR3-like factor) family, a splicing
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regulation group of RNA proteins (Timchenko et aI, 1996a; Timchenko et aI,
I996b; Ladd et aI, 2001) whose members are implicated in regulating
translation and In cell-specific splicing of transcripts during normal
development and disease (Ladd et aI, 2001).
Further studies on the interaction of CVG-BPI with expanded CUG repeats
have shown conflicting results to that reported by Timchenko et al (1996a).
CUG-BP 1 does not bind to the whole length of the hairpin of double-stranded
CUG repeats in DMPK RNA but only at its base when observed under electron
microscopy (Michalowski et aI, 1999) and shows non-colocalisation with
expanded repeat RNA foci in OMI and OM2 (Fardaei et aI, 2001). CUG-BP
has been demonstrated to be phosphorylated by protein kinase C (PKC) in
OMI to form the active isomers- CUG-BPI and CUG-BP2 (Kuyumcu-
Martinez et aI, 2007; Savkur et aI, 2001) which are involved in regulation of
alternative splicing.
CUG-BPI protein levels are not elevated in wild type and OM2 skeletal
muscles nor are they elevated in HSA LR mice skeletal muscle (Lin et aI, 2006).
However, they are increased in OMI muscle cultures (Savkur et aI, 2001). The
decrease in CUG-BP 1 in OM 1 mouse model (HSALR) as opposed to its levels
in OM 1 muscles could be due to expression of expanded CTG in its natural
context of DMPK 3'-UTR which might have signal for inducing its increase
(Amack et aI, 1999; Amack and Mahadevan, 2001; Orengo et al, 2008). The
level of CUG-BP 1 has been shown to increase in cultured fibroblasts and
myoblasts of OM 1 patients (Charlet et aI, 2002b; Philips et aI, 1998; Roberts et
aI, 1997; Savkur et aI, 200 I). To validate the point mentioned above, Lin et al
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(2006) had reported downregulation of CUa-BP I in wild type skeletal muscles
of mice within three weeks of its post-natal life.
CUa-BPI is involved in regulation of alternative splicing and its elevation in
OM I patients' results in misregulation or defects in splicing (Charlet et aI,
2002a; Charlet et al, 2002b; Philips et aI, 1998; Savkur et ai, 2002). Its
overexpression in wild type (normal) cells has been shown to promote
embryonic splice isoform expression in CLCN-I (Charlet et ai, 2002b; Faustino
and Cooper, 2003), IR and cTNT (Philips et ai, 1998; Savkur et al, 2001) 10
OM I patients.
Further studies on the effect of cua-BPI in alternative splicing in mouse
models make a case for its role in spliceopathy leading to OM-like symptoms
(Ho et ai, 2005a; Mahadevan et aI, 2006; Orengo et al, 2008). For example in a
study by Orengo et al (2008), it was observed that elevated levels of cua-
BPI was associated with misregulation of splicing in CLCN-l exon7a,
SERCAI exon 22 and CYPHER exonll in an inducible mouse model
expressing 960 CTa repeat expanded units in a DMPK 3'-UTR background.
Other splicing abnormalities specifically related to CUa-BPI regulation such
as Ank2, Capzb and Fxrl were also found in this model. OM-like splicing
defects were also reported in the heart and skeletal muscle by Ho et al (2005a)
in mice overexpressing CUa-BP I under control of mouse creatine kinase
promoter. These mice also replicated OM patterns of splicing for TNNT2
exon5, MTMRI fetal exon as well as CLCNI exon7a. This was further
confirmed in another study by Mahadevan et al (2006) using an inducible
mouse model overexpressing both CTa200 and C'I'G, in DMPK 3'-UTR
context. Both mice showed OM-like molecular symptoms which for C'TG,
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DMPK 3'-UTR was unusual and the cause for this effect is not clear. From
these studies by Orengo et al (2008) and Mahadevan et al (2006), it could be
suggested that DMPK 3'-UTR might have signals for triggering CVG-BPI
elevation which in tum led to DM splicing patterns.
CUG-BP I has been suggested to bind to UfG motifs of introns close to splice
sites of CLCN-J, IR and cTNT pre-mRNAs (Charlet et ai, 2002b; Philips et ai,
1998; Savkur et ai, 200 I). In the nuclei of DM cells, CVG-BP I is an
antagonistic regulator to MBNLl (Karlsotra et al, 2008) thus splicing
abnormalities might not be exclusively induced by CVG-BPI alone.
1.5.2.1.3 Heterogenous
(hnRNPs)
nuclear ribonucleoproteins
The hnRNPs are a large group of RNA-binding proteins occurring mainly in
the nucleus with a subset of them involved in shuttling between nucleus and
cytoplasm (Nakielny and Dreyfuss, 1999). The hnRNP AlB are the most
abundant of this group of splicing proteins and are involved in regulating splice
site selection (Mayeda et aI, 1994). This group consist of isoforms AliA IB,
A21B I, B2 and A3 which have similar RNA binding specificities (Mayeda et
ai, 1994). It has been reported that hnRNPA I associates with V2 and V4
snRNPs during spliceosomal assembly (Buvoli et ai, 1992).
Another type of hnRNP protein designated as hnRNP H has been suggested to
act as splicing repressor or activator in different contexts (Chen et ai, 1999;
Chou et al, 1999). In addition, hnRNP H has been implicated in inhibiting
nuclear transport of expanded repeat RNA by associating with it as well. as
interaction with branch point sequence (Kim et ai, 2005). To assess its role in
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alternative splicing, Paul et al (2006) demonstrated that hnRNP H
overexpression inhibits IR exon 11 retention in normal myoblasts. In addition,
the study showed that hnRNP H acts in synergy with CUG-BP 1 to misregulate
IR exon 11 splicing. Furthermore, the study by Paul et al (2006) observed that
hnRNP H whose levels are elevated in OM are recruited by MBNL 1 and
MBNL2 to form foci.
Another study by Fardaei et al (2001) reported that hnRNP C, another
member of this family of protein, does not colocalise with CUG expanded
repeats to form foci. Eventhough this group of proteins are known to be
involved in regulation of alternative splicing, evidence for its role in OM
pathology is limited and has not yet been well established.
1.5.2.1.4 Other splicing Factors
Many RNA-binding proteins and splicing factors have been demonstrated to
alter splicing in OM. The Polypyrimidine Tract Binding (PTB) protein and
PTB associated splicing factor (PSF) are known antagonists to CELF proteins
in splice site selection (Tiscornia and Mahadevan, 2000) which makes a case
for its role in splicing regulation in OM.
Warf et al (2009a) showed that U2 auxilliary factor (U2AF65) was inhibited
by MBNL 1 for splicing of exon5 in cTNT pre-mRNA via competition for the
binding of U2AF65 at the 3' end of intron 4.
1.5.3 Misregulation of Alternative Splicing
About 30% of alternative splicing has been reported to introduce premature
termination codons into mRNA resulting in nonsense-mediated decay (Lewis
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et al. 2003). Alternatively spliced mRNA expression can be determined by cell
type and developmental stage. Cell specific alternative splicing in most
systems involves the effects of antagonistic factors that could influence
different pathways.
In OM, misregulation of alternative splicing occurs in some splicing events
that are normally regulated developmentally and in the disease, they fail to
express the adult isoform mRNA in adult tissues. The developmental
regulation of transcripts could be absolute (involving exon 22 of SERCA1,
exon 7 of MBNLl, exon II of ZASP, exon5 of cTNT) or partial (in lTGBl
exon 17, CAPZB exon8). Instead the foetal mRNA and protein is expressed
which cannot function in adult tissues resulting OM phenotype.
Misregulated splicing in OM differs from aberrant splicing observed in other
genetic diseases because aberrant splicing results from mutations within exons
or splice site to create cryptic splice sites and expression of non-natural
mRNAs (Faustino and Cooper, 2003).
Myotonia and insulin resistance which are major symptoms in OM, are
associated with splicing misregulation of muscle-specific chloride channel
(CLCN-l) and insulin receptor (lR) respectively. Myotonia has been implicated
in reduced expression of CLCN-l in both patients and HSA LR mouse model
(Charlet et aI, 2002b; Mankodi et al. 2002). Patients with OM show manifest
reduction in expression of CLCN-I protein below lO% of normal levels
necessary to cause myotonia. This reduced CLCN-l protein expression is due
to misregulated alternative splicing of the CLCN-l gene (Charlet et aI, 2002b;
Mankodi et aI, 2002)
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Loss of functional CLCN-I protein in OM patients is due to the failure of the
gene to switch from embryonic splicing pattern, involving the inclusion of one
or both of two alternative exons, which alters the CLCN-I mRNA open reading
frame (Charlet et al. 2002b; Mankodi et aI, 2002).The CLCN-I mRNA
containing these misplaced exons could be degraded by non-sense mediated
decay.
OM patients also manifest an abnormal form of insulin resistance. This
insulin resistance is associated with inability to express IR splice variant (lR-B)
that normally occurs in adult skeletal muscle. Instead, OM patients express the
nonmuscle IR isoform (lR-A) which has a lower signalling ability than those
expressed in adult skeletal muscle and the expression of this isoform in OM
skeletal muscle cultures has been implicated in the decreased responsiveness to
insulin compared to control cultures from unaffected individuals (Savkur et aI,
2001).
Other studies have suggested the involvement of a missplicing event in
myotonic dystrophy that involves Z-band alternatively spliced POZ-domain
protein (Machuca- Tzili et aI, 2006 ;Lin et al. 2006). CYPHER (Lin et al. 2006).
and in dystrophin (Nakamori et aI, 2007).
Other misregulated splicing events observed in OM include those involving
cardiac troponin T (Philips et al. 1998), tau (Sergeant et al. 2001).
rnyotubularin-related protein 1 (Buj-Bello et aI, 2002). fast skeletal troponin T
(Kanadia et aI, 2003). N-methyl-O-aspartate receptor (Jiang et aI, 2004),
amyloid precursor protein (Jiang et al. 2004). SERCAI and SERCA2 (Kimura
et al. 2005) .
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Gene ExonlIntron DM feature References
Amyloid precursor protein Exon 7 Exon Jiang et ai,
exclusion 2004
Cardiac troponin T Exon5 Exon Philips et ai,
inclusion 1998
Chloride channel Intron 2 Intron Charlet et ai,
inclusion 2002b
Chloride channel Exon 7a Exon Charlet et aI,
inclusion 2002b
Mankodi et ai,
2002
Dystrophin Exon7I or 78 Exon Nakamori et al,
exclusion 2007
Fast skeletal troponin T Fetal exon Exon Kanadia et al,
inclusion 2003
Insulin Receptor Exon II Exon Savkur et ai,
exclusion 2001
Muscleblind-like 1 Exon 7 Exon Lin et ai, 2006
inclusion
Muscleblind-like 2 Exon 7 Exon incusion Lin et aI, 2006
M-titin Exon 5 Exon Lin et ai, 2006
inclusion
Myotubularin-related Exons 2.1 and Exon Buj-Bello et ai,
protein 2.2 exclusion 2002
Ho et aI, 2005a
N-methyl-D-aspartate Exon 5 Exon Jiang et aI,
receptor inclusion 2004
Ryanodine receptor Exon 70 (AS J) Exon Kimura et aI,
exclusion 2005
Sarcoplasmic/endoplasmic Exon 22 Exon Kimura et aI,
reticulum Ca2+ ATPase 1 exclusion 2005
Sarcoplasmic/endoplasmic Intron 19 Intron Kimura et ai,
reticulum Ca2+ ATPase 2 retention 2005
Tau Exon 2, 3 and Exon Sergeant et al,
10 exclusion 2001
Jiang et al,
2004
Tau Exon 6 Exon Leroy et aI,
exclusion 2006
Z-band alternatively Exon 6a Exon Machuca- Tzili
spliced protein inclusion et al, 2006
Z-band alternatively Exon 11 Exon Lin et al, 2006
spliced protein inclusion
Table 1.6: List of misregualted alternative splicing events in myotonic dystrophy
(adapted from Ranum and Cooper, 2006)
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Misregulated splicing of these groups of pre-mRNAs involves either intron
retention, exon exclusion or inclusion of exons containing stop codons. This
results in reduced expression of functionally irrelevant protein or truncated
proteins in myotonic dystrophy patients. The misregulated splicing events in
OM are discussed in detail below.
1.5.3.1 CLCN-1
The muscle-specific chloride channel (CLCN-I) is responsible for regulating
the flow of cr ions across the cell membrane in the sarcolemma of skeletal
muscle (Aromataris & Rychkov, 2006). Misregulation of CLCN-l is associated
with myotonia, a major symptom of OM. Myotonia in both patients and mouse
models (HSA LR) is linked to reduced CLCN-I protein expression (Charlet et aI,
2002b; Mankodi et al, 2002). Indeed, loss of CLCN-I in patients is caused by
inability to switch its splice isoforms from embryonic to adult pattern
(Mankodi et al, 2002).
The misregulated splicing of CLCN-I involves intron 2 retention which
contains a premature stop codon or inclusion of two novel exons located
between ex on 6 and 7 (Charlet et al, 2002b).
DM patient samples have intron 2 retained in CLCN-I mRNA as well as
retention of the novel exons. This leads to truncated mRNA which is
subsequently removed by nonsense mediated decay (NMD) leading to loss of
CLCN-I protein (Charlet et al, 2002b; Mankodi et al, 2002). Since CLCN-l is
developmentally regulated, its embryonic spliceforms retain intron 2 and two
novel exons (6aJ7a) which are absent in adult splice isoforms. Lueck et al
(2007) demonstrated in mice that clcn-l goes through a splicing transition
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within the first three weeks of postnatal life. During the transition process from
foetal to adult, Clen-/ splicing switches to isoforms having intact reading
frames and an increase in Clen-/ mRNA as well as its function. In contrast to a
DM mouse model (HSALR) used in the same study, it was shown that the
splicing transistion was absent with reduction in Clcn-I function and myotonic
discharges (Lueck et ai, 2007).
The finding in a DM mouse model by Lueck et al (2007) had also been
confirmed in a previous study by Mankodi et al (2002) using DM mouse with
similar background.
1.5.3.2 Insulin Receptor (IR)
The IR is a tetramer consisting of two a- and two ~- subunits. Its alpha
subunit interacts with insulin which causes intracellular units to be
autophosphorylated. IR RNA exhibits two alternative splice isoforms as a
result of inclusion or exclusion of a 36 nucleotide long exon 11 of a-subunits to
give isoforms designated as IR-A and IR-B. IR-A lack exon 11 while IR-B
retain it (Seino et ai, 1989). Furthermore, IR splice isoforms expression is
tissue-specific. The IR-A splice isoform which predominates in non-muscle
tissue has twice the affinity for insulin, decreased signalling capacity and twice
lower activity for tyrosine kinase while the IR-B splice isoform is mainly
expressed in tissues carrying out glucose homeostasis such as adipose tissue.
liver and skeletal muscle (Kellerer et al.1992; McClain 1991;Mosthaf et ai,
1990; Vogt et ai, 1991).
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It has been suggested that OM patients are associated with insulin resistance
(diabetes type 1) as a result of splicing abnormalities in JR. OMI muscle
cultures have been observed to have predominance of IR-A, the non-muscle
splice isoform with lower signalling capacity (Savkur et ai, 200 I; Savkur et ai,
2004). The IR-A isoform which lacks exon II necessary for its biochemical
activity was demonstrated to be due to MBNL I and MBNL2 depletion and/or
elevated level of CUG-BPI in OM 1 myoblasts (Dansithong et aI, 2005; Ho et
aI, 2004; Paul et ai, 2006). In addition, OM2 patient muscle displays similar JR
splicing abnormality found in OMI (Savkur et ai, 2004).
1.5.3.3 RYR and SERCA
The sarcoplasmic reticulum (SR) proteins Ryanodine receptor (RyRl) and
Sarcoplasmic/endoplasmic reticulum Ca2+-ATPase (SERCA) are responsible
for regulating calcium homeostasis in skeletal muscle (Kimura et ai, 2005).
The RyR is encoded by three genes: RyRl, RyR2 and RyR3. RyRl is abundant
in skeletal muscle; RyR2 is mainly expressed in heart muscle while RyR3
occurs in limited levels in immature skeletal muscles (Meissner et ai, 1994;
Giannini et aI, 1995; Sutko & Airey, 1996). RyRl splice variants are regulated
in a developmental and tissue-specific manner (Futatsugi et ai, 1995).
In OM 1 muscle cultures, RyRl splicing is altered resulting in the splice
isoform that lacks exon70 referred to as ASI(-) in contrast to ASl(+) having
exon70 that predominates in normal cultures (Kimura et ai, 2005).
The other SR protein SERCA is also encoded by three genes: SERCA1,
SERCA2 and SERCA3. Its spliced transcripts are regulated in a developmental
and tissue specific way to give isoforms differing in C-terminal regions.
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SERCAJ has two alternatively spliced isoforms: SERCAla which is the adult
splice isoform and SERCAlb which is the embryonic isoform are expressed in
fast-twitch (type2) skeletal muscle. SERCA2a occurs in slow-twitch (type 1)
skeletal muscle and cardiac muscles while SERCA2b is found in all tissues.
SERCA3 is found mainly in non-muscle tissues (Burk et ai, 1989; Lytton et ai,
1992).
OMI skeletal muscle cultures were observed to have a significant proportion
of embryonic isoform lacking exon22 (SERCAlb) in relation to controls
(Kimura et ai, 2005). This splicing abnormality was further confirmed in
HSA LR mice and SERCAJ was also found to be developmentally regulated in
mice (Kimura et ai, 2005; Lin et ai, 2006).
In addition, it was also found that the SERCA2d isoform containing full length
intron 19 occured at a lower level in OM 1 cells (Kimura et ai, 2005).
1.5.3.4 Cardiac Troponin T (cTNn
Cardiac troponin T (cTNT) is expressed mostly in cardiac muscles and its
splicing event in OM was first discovered in 1998. It had been shown that
cTNT was subject to developmental regulation. The embryonic splice isoform
includes exon 5 which is excluded in the adult isoform. In OM, there is a shift
towards the embryonic isoform having exon 5 (Philips et ai, 1998; Savkur et ai,
2001) and it has been demonstrated that overexpression ofCUO-BPI in normal
skeletal muscles induces a shift toward OM-like isoform for cTNT (Philips et
ai, 1998).
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To further confirm this, eUG-BPI overexpressing mice reproduce OM-like
splicing pattern for cTNTby increased exon 5 inclusion (Ho et aI, 2005a).
In addition, it has been suggested that cTNT splicing defects could be
responsible for cardiac abnormalities seen in OM patients (Philips et aI, 1998).
In another context, MBNL produces adult splicing patterns by excluding exon
5 through binding to introns upstream of alternatively spliced exons in cTNT
(Ho et aI, 2004). Recently, Warf et al (2009) demonstrated that MBNLl
controls cTNT exon5 splicing by competing with U2AF65 for binding to 3' end
ofintron4.
1.5.3.5 Fast Skeletal Troponin T (TNNT3)
The alternative splicing of this gene was found to include a fetal exon in OM
patients which was lacking in unaffected persons' muscle cultures (Kanadia et
al,2003).
Furthermore, this was confirmed In a muscleblind-like knock-out mouse
model (mbnl~3/~3) which showed OM-like splicing patterns for TNNT3
expressing fetal the exon isoform (Kanadia et ai, 2003).
1.5.3.6 Myotubularin-related protein1 (MTMR1)
}.f[MRI belongs to the phosphatase family of proteins suggested to be
involved in the myogenesis of differentiating myoblasts. It undergoes
developmental regulation with alternative splicing of two fetal isoforms (A and
B) that switches to an adult isoform e in adult skeletal muscle and cardiac
muscles during development (Buj-Bello et aI, 2002).
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It has been observed in differentiating congenital OMI muscle cells that there
has been a reduced level of isoform e with the presence of a novel abnormal
isoform G (Buj-Bello et aI, 2002). In confirmation of this, Ho et al (2005)
showed MTMR1 splicing abnormality similar to that expressed in OM patients
displaying predominance of A and B isoforms in a transgenic mice
overexepressing eVG-BPI. The splicing abnormality in these isoforms A and
B involves exon 2.1 which is present in isoform B but lacking in isoform A as
well as exon 2.2 (figure 1.5) which is only present in isoform C (Ho et aI,
2005).
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Figure 1.5: Exonic organisation of MTMRI gene indicating the various isoforms of its
transcripts formed by exons lying between exon 2 and 3 (adapted from Ho et al, 2005).
1.5.3.7 Muscleblind-like (MBNL)
This group of proteins is involved in the splicing of pre-mRNAs of many
genes and its function is altered in OM. Alternative splicing of MBNL1 occurs
at exon 3,5,7 and 9 to give nine splice isoforms. It has been shown to undergo
post-natal splicing transition to give MBNL 1 isoforms having different cellular
activities (Lin et aI, 2006).
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In DM, MBNLJ is to be defectively spliced at exon 7 resulting in the inclusion
of this exon in DM patients and its absence in controls (Botta et ai, 2008;
Cardani et ai, 2009; Lin et ai, 2006). Similarly, MBNL2 shows identical
splicing misregulation in exon 7 in DM (Lin et ai, 2006).
Further confirmation was demonstrated in a DM mouse model HSA LR
reproducing mbnll splicing defects similar to DM patients (Lin et ai, 2006). In
addition, MBNLJ was shown to undergo a post-natal splicing switch in wild
type mice (Lin et ai, 2006). The predominance of MBNU splice isoforms
containing exon 7 in DM may account for its localisation in the nucleus (Botta
et ai, 2008; Cardani et ai, 2009; Lin et ai, 2006).
1.5.3.8 Tau
Tau is expressed mainly in the brain and neurons. It is a microtubule
associated protein involved in microtubule network modulation. Tau also
interacts with tubulin during cytoskeleton formation (Buee et ai, 2000).
Alternative splicing of tau pre-mRNA exon 2, 3 and 10 generates six splice
isoforms in adult human brain. These exons are developmentally regulated and
foetal isoforms lack all the three exons (Andreadis et ai, 1992).
In DM, there is predominant expression of foetal isoform of tau in which one
or many of exons 2,3,6 and 10 are absent (Jiang et ai, 2004; Leroy et ai, 2006;
Sergeant et aI, 2001). Defects in exon 6 splicing has also been reported for DM
(Leroy et aI, 2006).
38
To validate the role of tau in OM, transgenic OM mouse model expressing
C'l'G repeats in DMP K 3' -UTR context displayed abnormal tau protein
expression consistent with observation in OM 1 patients (Seznec et ai, 2001).
1.5.3.9 Other Splicing abnormalities
N-methyl-O-aspartate receptor (NMDARl) exon 5 inclusion in OM 1 patients
is the most prominent effect of spliceopathy observed in the patient's brain
(Jiang et ai, 2004). Also occurring in the brain is the splicing defect in amyloid
precursor protein (APP) involving ex on 7 exclusion in OM) patients (Jiang et
al, 2004). Lin et al (2006) observed increased inclusion of M-line exon 5 in M-
Titin in comparison with controls. In addition, they also discovered that exon
11 inclusion of Z-band alternatively spliced protein (ZASP) in OM patients.
Another splicing variant of ZASP involving a novel exon 6a absent in normal
controls was observed in OM muscles (Machuca- Tzili et ai, 2006).
Dystrophin, a cytoskeletal structural protein involved in signalling in the
sarcolemma, is abnormally spliced at exons 71 or 78 resulting in exclusion of
these exons in OM I patients (Nakamori et ai, 2007).
Indeed, misregulated alternative splicing accounts for some of the major
symptoms in OM such as myotonia, insulin resistance among others. Splicing
defects in OM could provide clues and targets for therapeutic intervention
because of its contribution to the disease condition.
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1.5.4 Mechanism of Misregulated Splicing
cua expanded repeat RNAs have a trans effect and modify the normal
splicing forms of a group of pre-mRNAs. Mankodi and colleagues (2000)
demonstrated an alteration in the splicing of CLCN-l pre-mRNA in HSA LR
transgenic mice which has a repeat expansion in a non-DMPK RNA
background. Other evidence in support of cua repeat containing mRNA
inducing a splicing switch, comes from transient expression studies of cua
expanded repeat containing DMPK RNA in cell culture. Co-expression of
mRNA containing cua expanded repeats with splicing reporter minigene
constructs of cardiac troponin T (cTND and IR causes DM splicing isoform for
the alternative exons (Phillips et aI, 1998; Savkur et al, 2001; Charlet et aI,
2002b).
The mechanism by which cua repeat RNA induces a trans-dominant effect is
proposed to involve sequestration of one or more splicing regulators by RNA
containing large repeats leading to nuclear depletion and consequent loss-of-
function by these regulators. Evidence supporting this hypothesis comes from
the binding to cua repeats of two RNA-binding proteins involved in
alternative splicing (Miller et al 2000; Timchenko et aI, I996b). One of them is
CUa-BPI which belongs to the CELF group of six genes that encode proteins
regulating many post-transcriptional processes including translation initiation,
alternative splicing, RNA editing and mRNA stability. The second family of
cua repeat RNA binding proteins is the muscleblind-like (MBNL) of which
there are three members. MBNL proteins, as well as CUaBP, also control
alternative splicing regulation by its binding to specific sites within pre-
mRNA.
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Several studies have reported a functional role for the loss of MBNL in the
misregulation of splicing in DM. MBNL proteins were shown to bind to
expanded CUG repeat RNA which folds to form a hairpin structure having G-C
base pairs with bulged unpaired U residues (Napierala & Krzyzosiak, 1997).
The binding of MBNL was found to be proportional to the length of CUG
repeat (Miller et al. 2000) and is consistent with direct association of repeat
expansion with disease severity. In addition, it has been suggested that MBNL
proteins could bind directly to intronic elements to control cTNT and JR
splicing that are misregulated in DM (Ho et ai, 2004).
MBNL 1 loss-of-function CUGBP1 gain-of-function
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Figure1.6: Proposed mechanism for splicing misregulation by MBNLl and CUe-BPI
leading to DM phenotype (taken from Lee and Cooper, 2009)
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Evidences from several studies have also proposed a role for CUG-BPI in
abnormal splicing regulation of OM (Charlet et ai, 2002a; Dansithong et ai,
2005; Jiang et ai, 2004). In one study, CUG-BPI was identified by Timchenko
and co-workers (1996a) to bind to CUG repeat RNA. However, CUG-BP I
binds to short single stranded CUG repeats and this binding does not correlate
with the length of repeat RNA. CUG-BPI and other CELF protein family
members do not co localize with CUG repeat foci (Fardaei et ai, 200 I).
In alternative splicing regulation, three of the abnormal splicing regulation
events found in OM involving cTNT, IR and CLCN-J were observed to be
regulated by CUG-BP 1 (Charlet et al, 2002b; Phillips et al, 1998; Savkur et ai,
2001). In addition, the splice isoforms observed in these three genes correlate
with higher CUG-BPI activity. Studies have reported the elevation of CUG-
BP I protein steady-state levels in OM tissues and cell cultures (Dansithong et
aI, 2005; Savkur et al, 200 I). In addition, evidence supporting its role is the
decrease of CUG-BPI protein expression in mouse skeletal muscle and heart
after birth (Ladd et ai, 2005), which correlates with the normal developmental
splicing pattern regulation in tissues altered in OM. Overexpression of CUG-
BPI in heart and skeletal muscle of transgenic mice led to the foetal splicing
form of cTNT, CLCN-l, and myotubularin-related protein I (Ho et aI, 2005a).
MBNL and CUG-BPI have been implicated in the regulation of cTNT and IR
in OM. These two proteins act as antagonistic regulators of the cTNT and IR
splicing so that the splice isoforms found in OM correlate with loss of MBNL
and gain of CUG-BPI effects. The proposal above points to loss of MBNL
activity as the primary cause of splicing defects in OM while CUG-BP I could
be an antagonistic regulator.
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However, another proposal speculates that loss of activity by MBNL is not
the main event during the splicing defect observed in DM. This proposal comes
from transient transfection studies involving expression of CVG repeat-
containing RNA that leads to a splicing switch in trans with co-expression of
cTNT and IR minigenes (Philips et aI, 1998; Savkur et aI, 200 I). The splicing
of minigenes was used as a reporter of trans effects of CVG repeat RNA.
Mutations affecting CVG-BPI binding sites make cTNT and IR minigenes
resistant to trans effects of CVG repeat RNA, hence suggesting that binding of
CVG-BPI to cTNT and IR mRNAs is necessary for these co-expressed repeats
to influence splicing (Philips et aI, 1998; Savkur et aI, 2001). Furthermore,
mutation in cTNT minigene that is resistant to CVG-BPI or CVG repeat RNA
is responsive to MBNLl siRNA-mediated decrease efficiently like in
nonmutated mingene (Ho et aI, 2005b). These observations show that co-
expressed CVG repeat RNA does not reduce MBNL levels enough to change
the splicing pattern seen in wild type minigenes. MBNL depletion alone does
not account for the effect the CVG repeat RNAs could have on alternative
splicing of the wild type cTNT minigene. Previous studies however, show a
difference in phosphorylation status and nucleocytoplasmic distribution of
CVG-BPI (Roberts et aI, 1997). These changes could affect nuclear protein
steady state levels or RNA binding or splicing regulation.
RNA containing CVG repeats formed nuclear foci and were observed to
co localize with co-expressed GFP-MBNLl (Ho et aI, 2005a). Further studies
involving fluorescence recovery after photobleaching demonstrated in cell
culture that the affinity of GFP-MBNLl for CVG and CAG repeat were similar
(Ho et al, 2005a). These findings led to the view that co localization of MBNLI
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with RNA foci alone is not responsible for misregulated splicing in DM and
that trans effects of CUG repeats on splicing are more than just sequestration of
MBNU which may include other splicing factors.
Another study of the effects of RNA containing CUG repeats proposes that
both MBNL and CELF proteins regulate and control a subgroup of alternative
splicing events during developmental stages (Miller et aI, 2000). In accordance
with this hypothesis, is the loss of CELF protein expression at developmental
stages in several tissues and the idea that MBNL and CELF proteins are
antagonistic regulators of developmental stage splicing events both in normal
cells and in DM (figure 1.7).
Normal
(Adult)
DM1
(Embryonic)
-
Insulin
resistanceIR ,--I __ ....__--,
CIC-1 ,--I _""__--J CIC-l ~ ~ Myotonia
CTNT I\...-_-'--___.
Cardiac
defects?
Figure 1.7: Developmental regulation of alternative splicing by MBNLt and CUG-BPI
(taken from Lee and Cooper, 2009)
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1.6 Possible Targets for Therapeutic Intervention in OM
With the underlying mechanisms for DM pathogenesis which appear to be
mediated by toxic RNAs acquiring dominant negative function via
sequestering the splicing factor MBNL, possible targets targets for therapeutic
intervention would include: (1) disrupting interactions in foci between MBNL
and RNA CUG repeats in OM 1 or CCUG repeats in OM2; (2) destruction or
removal of mutant RNA containing repeat expansions; (3) correction of
misregulated splicing; (4) increased dosage of MBNL and (5) inhibition of
CUGBPI.
1.6.1 Disruption of RNA-MBNL Interactions
The RNA mediated disorder in DM 1 has been proposed to be caused by
expanded CUG repeats RNA trapped in the nucleus which in tum interacts
with MBNL to cause OM-like effects (Kanadia et aI, 2003; Mahadevan et aI,
2006). This event represents a viable target for therapeutic intervention in OM.
Several studies have carried out screens for inhibitory molecules that can
block MBNL 1 interactions with CUG or CCUG expanded repeats which could
provide clues to modifying disease phenotype (Arambula et aI, 2009; Gareiss et
aI, 2008; Lee et aI, 2009a; Lee et aI, 2009b; Mulders et aI, 2009; Pushechnikov
et aI, 2009; Wheeler et aI, 2009).
In a study by Arambula and co-workers (2009), the rational design of ligands
that selectively bind to CUG repeats in RNA at high affinity was shown to
displace MBNLI from MBNLI-poly(CUG) complex. Antisense
oligonucleotides (AON) such as 2-0-methyl-phosphorothioate-modified
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(CAG)7 AON has been reported to reduce ribonuclear complexes in RNA foci
(Mulders et ai, 2009).
In another study, a morpholino antisense oligonucleotide CAG25 has been
shown in a mouse model to bind to cva expanded RNA and inhibit its
interaction with MBNLl resulting in reduction of nuclear foci as well as
correction of misregulated alternative splicing of Clcnl to restore ion channel
function (Wheeler et ai, 2009).
Figure 1.8: Chemical Structure of Pentamidine
In a most recent study by Warf and colleagues (2009b). gel-shift-assay for
MBNL I-cva repeat showed a molecule pentamidine inhibited RNA CVG-
protein complex by competively displacing MBNLl. In addition, pentamidine
was shown to partially rescue splicing defects of insulin receptor and cardiac
troponin pre-mRNAs misregulated in DM.
Thus, MBNL I-CVG repeat interactions could provide a potential target for
modifying downstream effects such as missplicing and associated disease
phenotypes found in OM.
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1.6.2 Inhibition or Destruction of Mutant RNA
The toxic effect of expanded CVG or CCVG repeat RNA in myotonic
dystrophy disease phenotype makes it a potential functional target for therapy.
Compounds that can specifically target mutant RNA leading to its destruction,
removal or inhibition would be relevant to reversing disease phenotype. An
inducible mouse model of OM having expanded CTG repeat has demonstrated
that the disease phenotype is reversible (Mahadevan et ai, 2006).
In another study, degradation of expanded CVG repeats was tested usmg
retroviral mediated antisense gene therapy. The antisense RNA was shown to
be effective in degrading mutant DMPK RNA leading to its reduction. In
addition, myoblast function was restored and CVGBPI levels were reduced in
human OM 1 myoblasts (Furling et ai, 2003).
In another study, a hammerhead ribozyme was used to induce reduction of
DMPK nuclear foci via site-specific cleavage of mutant RNA resulting in
restoration of alternative splicing patterns of insulin receptor in OM 1
myoblasts (Langlois et ai, 2003).
Another approach to reducing expanded CVG repeat RNA would be to use
short interfering RNA (siRNA) which has been reported to be effective in
fibroblasts of OM 1 (Krol et ai, 2007).
These studies support the proposal that destruction of mutant RNA could be a
beneficial strategy for therapy in OM I. These approaches could also be applied
to OM2 cells to reduce expanded CCUG repeat RNA.
In OM2, the processing of the ZNF9 mRNA from the normal and mutant
alleles are similar because of removal of intron 1 containing mutant RNA,
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hence there is no degradation of ZNF9 mRNA (Margolis et ai, 2006).
However, the excised CCUG expanded repeat RNA which is intronic form
hairpins that trap MBNLl in a mechanism similar to CUG repeat in OMI and
targeting CCUG expanded repeat for degradation would also be useful for
therapy.
Another strategy for potential OM therapy would be inhibition of expanded
repeat transcripts to prevent their interaction with muscleblind-like protein in
order to make them available for cellular functions of regulating alternative
splicing.
Several studies have been carried out to identify inhibitors that can bind to
expanded CUG or expanded CCUG repeat RNA to prevent its interaction with
muscleblind-like proteins (Arambula et ai, 2009; Gareiss et al, 2008; Lee et ai,
2009; Pushechnikov et ai, 2009 and Warf et ai, 2009).
In a study by Wheeler et al (2009), a 25-mer morpholino antisense
oligonucleotides having CAG triplet repeats was designed to bind specifically
to CUG repeat RNA with high affinity leading to the release of MBNL 1 from
nuclear foci and subsequent degradation of RNA.
Ribonuclear foci formation in OM could be utilized in therapeutic
intervention of RNA-mediated disease. The development of cell-based assays
based on nuclear foci will allow screening of compounds and molecules in
high-throughput screens (HTS).
1.6.3 Correction of Spliceopathy
Studies have shown that defects in splicing of CLCN-J and IR lead to
myotonia and insulin resistance respectively- found in DM patients (Charlet et
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ai, 2002b; Mankodi et ai, 2002 and Savkur et ai, 2001). The abnormality in
splicing regulation of CLCN-l pre-mRNA involves inclusion of exon 7a
containing a premature stop codon into the mature transcript. Another splicing
misregulation in the same gene involves retention of intron 2 which contains a
termination codon (Charlet et ai, 2002b and Mankodi et ai, 2002).
Misregulation of splicing involving exon 7a and intron 2 leads to a truncated
transcript which is removed by nonsense-mediated decay or truncated,
functionally irrelevant CLCN-l protein.
Abnormal splicing of the insulin receptor transcript results in exclusion of
exon II to produce an isoform with lower signalling activity causing insulin
resistance and diabetes in DM patients (Savkur et al, 2001).
Correction of splicing abnormalities has become a potential target for
therapeutic intervention in OM. A proof-of-function study by Kanadia and co-
workers (2006) showed reversal of RNA missplicing for Clcn-I exon 7a,
Cypher exon II, Sercal exon22 and fetal exon of Tnnt3 in a OM mouse model
overexpressing MBNL 1.
Chemical agents such as morpholino antisense oligonucleotide (CAG25) have
been shown in a transgenic mouse model HSA LR to partially correct the defect
in Clcn-I leading to the restoration of ion channel function (Wheeler et ai,
2009). In a previous study, Wheeler and colleagues (2007) used a morpholino
antisense oligonucleotide (AON) that targets 3' splice site of C/cn-l exon 7a to
inhibit inclusion of this exon in a OM mouse model. This restored splicing
regulation of C/cn-l mRNA leading to an increase in level of Clcn-I mRNA
and protein.
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Finally, pentamidine was shown to reverse splicing defects in insulin receptor
and cardiac troponin in a HeLa cell model (Warf et al, 2009b). Chemical
agents that have the benefit to correct splicing defect would be beneficial in the
therapy of DM.
1.6.4 Increased Activity of MBNL 1
In OM, loss of MBNLl function leads to spliceopathy which has been
demonstrated to be due to negative effects of toxic RNA with expanded repeats
(Charlet et aI, 2002b; Kanadia et ai, 2003; Lin et ai, 2006).
A study to test the role of MBNL I in reversing spliceopathy and modifying
disease phenotype was carried out in HSA LR mouse model (Kanadia et ai,
2006). In this study, the mouse was injected with adena-associated virus
(AA V) overexpressing MBNL t. The overexpression of MBNL t protein was
demonstrated to restore normal splicing patterns resulting in reversal of
myotonia. This shows that the development of therapeutic agents based on
overexpressing MBNLt would be beneficial in treatment of OM.
1.6.5 Inhibition of CUG-BP1 activity
The RNA-mediated toxicity causes upregulation of CUGBPt activity in OM
via activation of Protein Kinase C (PKC) by expanded CUG repeats in OM I.
The hyperphosphorylation of CUGBPI results in its increased stability leading
to its increased levels and spliceopathy in OM 1 patients (Kuyumcu-Martinez et
al, 2007; Orengo et ai, 2008).
In a mouse model expressing 960 CUG repeats showing loss of MBNL I,
myotonia and splicing abnormalities; CUGBPI level was elevated as well as
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splicing abnormalities regulated only by CUGBPI were observed (Orengo et
al,2008).
Another study using a OMI mouse model expressing cardiac-specific
expanded CUG repeat RNA, the administration of PKC inhibitors improved
cardiac conduction abnormalities (Wang et ai, 2009). In addition, these
inhibitors reduced phophorylation of CUGBP I and decreased its protein levels
(Kuyumcu-Martinez et ai, 2007). Furthermore, there was reduction in splicing
defects regulated specifically by CUGBPI (Wang et ai, 2009). The use of PKC
inhibitors could provide another potential target for treatment of OM I.
1.7 Advances in Screening Assays Development for OM
Many OM therapeutic compound screens utilize RNA repeat units-MBNLl
interactions. In a study by Gareiss et al (2008), a fluorescently labelled RNA
repeat having the sequence Cy3-CCG-(CUG)IO-CGG was monitored for
interactions with a compound library in a technique referred to as resin-bound
dynamic combinatorial chemistry (RBDCC). The RBDCC. is a competitive
assay that utilizes the affinity of resin-bound compounds to bind the
fluorescently labelled RNA by competing with each other. The hit compounds
in this assay were identified by removing fluorescent resin beads indicating
that the compound in resin beads have bound to the fluorescent RNA.
These fluorescent beads were subsequently identified by mass spectral
analysis. For this assay, a resin-bound dynamic combinatorial library (RBDCL)
of 11325 molecules was made from 150 cysteine-containing building blocks
and four positive hits were obtained. The authors did not report whether the
compound hits obtained in this assay could reverse spJiceopathy associated
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with OM, nor whether the hits obtained in this assay are toxic when applied to
OM patients' cell cultures.
Gel-shift assays have been utilized in identifying compounds that inhibit eVG
expanded repeats interaction with MBNU (Warf et ai, 2009; Wheeler et ai,
2009). In a study by Wheeler et al (2009), a eAG25 antisense oligonucleotide
was demonstrated to bind eVG repeat hairpins by blocking eVG repeat-
MBNU complexes to form a stable eVG repeat-rnorpholino heteroduplex in a
gel-shift assay. Subsequently, Warf et al (2009) used a similar technique to
identify pentamidine as lead compound that disrupted MBNLl-eVG repeat
interactions in a gel-shift assay. However, gel-shift assays may not be
sufficient in screening therapy of OM as toxicity and side effects of compounds
cannot be determined hence any compounds identified in this way may need
further testing in cell cultures to assess their effects on cell viability as well as
in rescuing of splicing defects and foci clearance in OM patients' cells.
Another screening assay for identification of compounds that bind to eVG
repeats exploited isothermal titration calorimetry (lTC) to identify compounds
that could bind to T-T and V-V mismatches in eTG or eVG repeats by
forming hydrogen bonds (Arambula et aI, 2009). This assay was also shown to
disrupt complex structure formation between MBNL 1 and poly(CVG). It is not
possible to determine if assays of this nature can identify compounds with no
toxic or side effects unless applied to OM cells.
A modular design of ligands that bind to RNA repeat with high affinity and
specificity has been reported in a technique called Huisgen dipolar
cycloaddition reaction (HOCR) (Lee et al, 2009a; Lee et ai, 2009b;
Pushecnikov et ai, 2009; Disney et al, 2010). HoeR was used to direct ligands
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on microarray surfaces and its interaction with RNA repeats units were
analysed bioinformatically. Eventhough, molecules identified by this approach
were found to be permeable in mouse muscle cells C2C12, the issue is whether
their cellular uptake and localisation, especially with respect to repeat RNA in
nucleus would be effective in OM cells.
1.7.1 High Throughput Screening (HTS)
Thus far only one assay based on intron 2 splicing of CLCNI in OM cells has
been reported for its application in OM-related HTS which identified AKT V
(also known as protein kinase 8) inhibitor triciribine (O'Leary et aI, 20 I0).
However, this assay used in HTS was limited in its ability to determine the
level of compound effect on correcting intron 2 splicing in a quantitative
manner. In addition, the hit compound in this screen was not confirmed for its
effect on foci reduction as well as rescue of splicing defects in OM.
HTS is especially important in the development of OM therapy as it facilitates
screening on a large scale, libraries of compounds in a short time.
1.8 Aim of Study
The objective of this study is to design and develop cell-based assays that
could be utilized for screening molecules and compounds for OM therapy.
These assays have been designed based on molecular events that lead to OM
with the red arrows representing potential target for therapeutic intervention
(figure 1.9).
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Figure1.9: Schematic representation of molecular events leading to OM. The red arrows
indicate possible target for therapeutic screening
The assays developed fall into two major categories:
1) Primary assays that allow screening of large numbers of compounds on a
large scale in High Throughput Screens (HTS). Two assays were developed for
HTS namely: (a) Splicing construct assay and (b) Nuclear foci assay.
2) Secondary assays that permit validation of positive compound hits from
primary screening assays for their effect on mutant RNA transcripts and
spliceopathy. They include: (a) BpmI polymorphism assay (b) IR splicing assay
(c) SERCAI splicing assay and (d) MBNL splicing assay
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The splicing construct used in the primary assay was based on splicing of
transgenes in wild type and DM cells. The splicing construct involves
transgenes whose 5' and 3' ends were tagged with green fluorescent protein
(GFP) and Dioscorea red fluorescent protein (DsRed) respectively contained in
a plasmid vector (figure 2.1). The expression of GFP and DsRed proteins were
used as qualitative and quantitative measure of the splicing process in which
only of a GFP is expressed by cells if there is no splicing while both GFP and
DsRed is expressed in cells that splicing occurs (figure 1.9). The production of
only GFP by cells is due to the presence stop codon in intron 2 ofpGR-CLCN1
or frameshift in open reading frame by intron 19 of pGR-SERCA2 whose
retention leads to either truncated translation (pGR-CLCNl) or out of frame
translation (pGR-SERCA2).
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Figure 1.10: Schematic model of the splicing concept for transgene construct when
splicing occurs leading to intron exclusion (bottom right) to produce both GFP and
DsRed or no splicing (bottom left) resulting in intron inclusion to produce only GFP.
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The aim is to transfect the transgenes into both C2C 12 and OM cell lines and
OsRed/GFP ratio was used as reference in determining the rate of alternative
splicing in these cells. Cells with transgenes were selected to generate stable
clones for subsequent application in screening assays.
Based on the splicing concept, normal cells would produce equal ratios of
green and red fluorescent proteins which would indicate that intron is spliced
out while DM cells would show ratios of zero showing intron retention. The
transgene splicing under study are those involving intron 2 of skeletal muscle-
specific chloride channel (CLCN]) and intron 19 of sarcoplasmic/endoplasmic
reticulum Ca2+-ATPase (SERCA2) whose flanking exons alongside with
introns of interest were cloned into the vector.
The other primary assay based on interactions between RNA expanded
repeats and muscleblind-like proteins to form nuclear foci. Nuclear foci would
be used to screen for compounds that could disrupt RNA repeat-MBNL 1
interactions in nuclear foci of OM cells. As a parallel assay to nuclear foci,
GFP-tagged muscleblind-like (pGFP-MBNL) transfected into OM cells in
order to study its colocalisation with RNA repeat units in nuclear foci and
stable clones obtained from pGFP-MBNL would subsequently be used In
compound screens to identify molecules that can disrupt this colocalisation.
In secondary assays, validation of hit compounds from primary assays were
applied to assess their effect on mutant RNA transcript in Bpml polymorphism
assay involving Bpml restriction analysis (figure 1.11); as well as assessing by
RT-PCR its effectiveness in rescueing spliceopathy involving exon 11 of fR,
exon 22 of SERCA] and exon 7 of MENL] and MENL2.
56
Bpml polymorphic site
_ t
154bp normal allele in OM
8pml
~ 8pml
154bp _mutant allele in OM-- ......
Figure 1.11: Schematic diagram of the Bpml restriction assay for the presence of normal
and mutant DMPK transcripts
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CHAPTER TWO: MATERIALS AND
METHODS
All experiments were carried out under standard conditions and at room
temperature unless stated otherwise.
2.1 Microbiological Methods
All microbiological methods were carried out under aseptic conditions and
were performed in accordance with molecular cloning protocols by Sambrook
& Russell (2001).
2.1.1 Media
The medium used for microbiological work was Luria Broth, SOB and SOC
media. LB consist of 10gl1 Bacto-tryptone, 5g11yeast extract, 10gll,NaCI and
2mM NaOH(pH 7.0).The SOB medium was made up of 10g/1Bacto-tryptone,
5g11Bacto-yeast extract, 0.548g11 NaCI, 0.186g11 KCI and 2mM NaOH (pH
7.0). The SOC medium was prepared from SOB media by mixing 40mls of
SOB with 800J-l1of20% glucose followed by addition of200J-l1of 1M MgCh.
2.1.2 Antibiotics
Antibiotic used for selection was kanamycin which had previously been
dissolved and diluted in water to a stock concentration of 25mglml. The stock
antibiotics were stored at -20°C. The working concentration of the antibiotic
was 25J-lglmlin the selection procedure.
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2.1.3 Microbiological Plates
Petri dishes of 90mm in diameter were used as selection plates into which
kanamycin antibiotic was added to the LB medium to give a final concentration
of 25Jlglml.
2.1.4 Glycerol Stocks
For long term storage, bacterial cultures were prepared by picking single
colonies and immersed in test tubes containing 5mls of LB with kanamycin and
were subsequently put in a shaking incubator at 200rpm for S hours. The
bacterial cultures were then harvested by pelleting at 1000g for 10 minutes.
The cultures were resuspended in 420Jll LB medium and SOJllof SO%glycerol
was added. Vortexing was applied to the mixture which was frozen in liquid
nitrogen followed by storage at -70oe.
2.2 Tissue Culture Methods
These were carried out inside a laminar flow cabinet at room temperature.
With the exception of e2e12 lines, all fibroblast lines used for tissue culture
work had been previously telomerised to immortalise them.
2.2.1 Solutions, Antibiotics and Media
Solutions used for tissue culture study were Dulbeccos Modified Eagle's
Medium (DMEM) from GIBeO containing 4,500mglL glucose, L-glutamine
and pyruvate; Foetal Bovine Serum (FBS) from GIBeO;
Penicillin/Streptomycin from GIBeo containing 10,000 units of Penicillin G
and 10,000Jlg/ml streptomycin sulphate in 0.S5% saline; 50mglml Geneticin
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(G418) from GIBCO; Dimethyl Sulphoxide (DMSO) from Sigma; phosphate
buffer solution (DPBS) from GIBCO made up of Cach, MgCh and phosphate
buffer saline; lrng/ml doxycyclin from Clonetech; and 0.25% porcine Trypsin-
EDTA solutions from Sigma.
2.2.2 Cell Cultures
Cell lines used in the study include mouse muscle cells (C2CI2), DM2
fibroblast line, KAGOtelo; two wild type lines one of which contains inducible
MyoD, NlRAtelo and SBteloMyoD; and a DM 1 fibroblast cell line containing
inducible MyoD, KBteloMyoD which can be differentiated into myoblasts in
the presence of doxycyclin. All human fibroblasts used in this project had been
previously telomerised.
2.2.3 Tissue Culture Passage
C2C 12 cell lines and fibroblasts were visualized under the microscope to
determine their degree of confluency. Cells of 80-100% confluency were split
by passage. This involves removing the old media using serological pipettes
and washing the cells with 10mi PBS. This was followed by the addition of
2.0ml of 0.25% Trypsin-EDTA to the flask containing the cells and the flask
was subsequently incubated at 37°C and 5% CO2 for 5-10 minutes to dislodge
the monolayer of cells from the bottom of the flask as well as separate cells
from each other. The flask was visualized under the microscope for
dissociation of the cell monolayer and 8 ml of fresh complete medium was
added to the flask. The cells were then split and transferred to two or three
other sterile 75cm3 flask based on the original confluency. These procedures
60
were performed in a Walker laminar flow safety cabinet under aseptic
conditions.
2.2.4 Selection of Clones and Fibroblast Differentiation
Clones of human fibroblasts and C2C12 lines were selected after the cells
were transfected with transgene constructs. Selection of clones was carried out
in G418 under 200~glml for fibroblast and 600~g/ml for C2C 12 cells.
OM I fibroblasts used in this project had been previously infected with
Lentivirus containing a MyoO inducible vector and in the presence of
doxycyclin were induced to differentiate into myoblasts by addition of
doxycyclin to a concentration of'Zug/ml for 6-8 days.
2.2.5 Cryopreservation of Cells
The cryoprotectant used for preserving C2C12 lines and human fibroblasts
was dimethyl sulphoxide (OMSO) at the concentration of 10%. Confluent cells
were drained of medium and washed with PBS. This was followed by addition
of trypsin to the cells and incubation at 37°C for 5 minutes for the cells to
dissociate from each other. The cells were subsequently resuspended in 10ml
of complete media and the mix was transferred to a falcon tube and pelleted by
centrifugation at 1500 rpm for 3 minutes with the supernatant removed by
decantation. This was followed by resuspension of pellets in 1.5ml of 10%
OMSO in complete media and transferred into cryotubes for storage at -80°C.
The cells were subsequently transferred into liquid nitrogen after 24 hours.
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2.2.6 Defrosting and Growing Cells from Liquid Nitrogen
Cells lines frozen in liquid nitrogen vials were removed from the liquid
nitrogen storage tank and given a quick thaw by immediate incubation in a
water bath at 37°C for 5 minutes. The vial of cells was immediately removed
from the water bath and 1ml of pre-warmed complete media was added. The
solution was subsequently transferred into a universal tube containing 10ml of
complete media in order to reduce toxicity of the DMSO used in frozen cells.
This was followed by centrifugation of cells at 1000rpm for a minute and the
supernatant was removed. The cell pellets were resuspended in 10ml of
complete media so as to remove DMSO thereby reducing damage to cells. The
entire 10ml cell suspension was placed into a T-75 flask containing a further
10ml of complete media and incubated at 37°C/5% C02 overnight for growth.
2.2.7 Fixation of Cells
Cells were fixed prior to imaging in fluorescent and immunofluorescent
screens as well as in fluorescent in situ hybridisation staining (FISH). In both
fluorescent and immunofluorescent scans, cells were washed thrice with PBS
followed by methanol:acetone fixation for 5 minutes. Alternative fixation was
performed with 4% paraformaldehyde for FISH. Cells were subsequently
washed three times with PBS before FISH or mounted for fluorescent
screening. In fluorescent imaging, after washing with PBS, mount media
consisting of 50% glycerol in PBS was added to the cells on coverslips for
visualization under the fluorescence microscope.
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2.2.7.1 Immunofluorescence
Fibroblasts were seeded into 96-well plates and allowed to grow overnight to
80% confluency. The cells were then washed thrice with PBS. Fixation of the
cells was performed using ice cold methanol:acetone (50:50) for 5 minutes.
Cells were subsequently washed thrice with PBS and blocked for non-specific
reaction with 10% BSA in PBS for an hour at 37°C followed by three washes
in PBS. The cells were incubated with 30-40IAI of the primary MBNLl
antibody diluted four times in PBS at 37°C for an hour. This was followed by
washing with PBS three times and the cells were subjected to incubation for an
hour with 40lAi fluorescent secondary antibody, Alexa 488 goat anti-mouse
IgO, which had been diluted four hundred times in 1% horse serum, 1% FBS
and 0.1% BSA in PBS. This was followed by washes with PBS and the
addition of Hoechst dye and left for five minutes to stain the cells. The cells
were subsequently washed with PBS and stored in 4°C fridge for subsequent
scanning on the plate reader.
2.2.7.2 RNA Fluorescence in situ Hybridisation (RNA.
FISH)
RNA-FISH analysis was performed on wild type and OM 1 fibroblasts to
identify RNA transcripts with expanded repeat units that appear as foci. Cells
were prepared for RNA-FISH analysis by washing with PBS followed by
fixation with 4% PFA for 10 minutes. The cells were then washed thrice in
PBS and subsequently permeabilised in 80% ethanol. This was followed by
three washes with PBS prior to denaturation. The cells were treated for 10
minutes with denaturation solution consisting of 40% formam ide and 20x sse
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in sterilised distilled water and subsequently washed in PBS. The cells were
then hybridised with Cy3 labelled oligonucleotide probe [CCAG)IOfor DM I
and CCCAG)IO for DM2] in hybridisation solution consisting 10% dextran
sulphate, 0.2% BSA, 40% formam ide, 20X SSC, 2mM Vanadyl Adenosine
Complex and I rng/ml salmon sperm DNA. The Cy3 labelled oligonucleotide
was used at a concentration of 0.07ngl~.d. The cells were then incubated
overnight at 37°C and washed thrice with 5mM MgCI2 in PBS. This was
followed by staining with Hoechst dye for five minutes prior to storage at 4°C
for subsequent scanning on the plate reader.
2.2.8 Compound Treatment of OM cells
Cells were treated with compounds in both 96-well plates and T-75 flasks.
For high throughput screens, initial concentrations of IOOJ.lM,48J.lM, 8 J.lMand
1.6 J.lMwere used. This was later adjusted by optimisation in the 96-well plates
depending on the effect of compound used. For secondary testing, compound
treatment was performed in T-75 flasks. These treatments were carried out in
conjunction with Professor David Brook and Professor Chris Hayes.
2.3 Molecular Biology Protocols
These techniques which include amplification, resolution and restriction of
DNA among others were carried out under specified conditions.
2.3.1 PCR methods
The PCR analysis was performed in a final volume of 20J.ll and consists of
1.0J.l1of DNA C50nglJ.llfor cell DNA or 5nglJ.l1for plasmid DNA), 2.0J.llof lOx
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PCR buffer [made up of 750mM Tris-HCI pH 8.0, 200mM (NH4}2S04,
O.l%(v/v) Tween 20] , 1.21l1of 15mM MgCh, 0.8 III of 20mM dNTPs, 1.01l1
each of 10pmol forward and reverse primers, 13.7 III of distilled water and 0.3
III of 5UI III of ABgene red hot Taq polymerase or 0.02U/IlI Phusion
polymerase.
The primers used for PCR analysis were 19-26 nucleotides long having GC
content between 40-60%. The primers used to amplify CLCNI in pGR-CLCNl
were sinCLCNf and DsRedORFr; SERCA2f and DsRedORFr were used for
SERCA2 in pGR-SERCA2; while pEGFP-C IF and DsRedORFr amplified
PGR-vector (primer sequences in the appendix).
For CLCN 1 PCR, the following conditions were used: Denaturation at 95°C
for 5 minutes followed by 20 cycles (for plasmid DNA) or 30 cycles (for
genomic DNA) of 95°C for 1 minute; 55°C annealing of primers for 1 minute
and extension at ire for 2 minutes. Final extension was carried out at ire
for 10 minutes.
For SERCA2 amplification, the following conditions were applied:
Denaturation at 95°C for 5 minutes followed by 20 cycles (plasmid DNA) or
30 cycles (genomic DNA) of 95°C for 1 minute; annealing of primers at 58.7°C
for 1 minute; and rrc extension for 50 seconds. Final extension was carried
out at the same temperature for 10 minutes.
The PGR-vector PCR involved the following conditions: Denaturation at
95°C for 5 minutes .followed by 20 cycles (plasmid DNA) of 95°C for 1
minute; 59°C annealing for 1 minute and rrc extension for 2 minutes with
final extension carried out at rrc for 10 minutes.
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For colony PCR, plasmid DNA from extracted miniprep samples for each
colony were subjected to PCR conditions mentioned above.
For GFP-MBNLI and GFP-MBNL2 deletions, PCR was carried out at 33
cycles consisting of denaturation at 9SoC for 30 seconds, repeating cycles of
9SoC for 5 seconds; and extension at nOc for 5 minutes. Final extension was
performed at nOc for 5 minutes and it was cooled immediately to 4°C.
The primers and their respective sequences used for PCR are listed in
appendices.
2.3.1.1 Reverse Transcription peR
RNA samples for cDNA synthesis were treated with DNase! prior to reverse
transcription using New England Biolab protocols (for those involving IR
splicing). 1.0-2.0~g of RNA was added to an eppendorf tube containing 4.0~1
of dNTP, 2.0~1 of random hexamers with DEPC H20 were added to give a
volume of 16~1.The mixture was subsequently heated for 5 minutes to remove
secondary structures, centrifuged and cooled on ice. This was followed by
addition of 2.0~1 lOx NEB reverse transcriptase buffer (consisting of 500nM
Tris-HCI, 750mM KCI, 30mM MgCh and 100nM dithiothreitol), 1.0~1 of
RNase inhibitor and 1.0~1of 200U/~1 reverse transcriptase before it was left in
the water bath for an hour at 42°C. The samples were subsequently heated at
90°C for 10 minutes to inactivate the enzyme prior to its use in PCR.
For insulin receptor splicing analysis, amplification was carried out using
1120thof the synthesized cDNA with forward primer (lRfor) and reverse primer
(lRrev). Thirty cycles of PCR was performed, consisting of denaturation at
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95°C for 5 minutes, followed by repeating cycles of 95°C for 30 seconds;
annealing at 60°C for 30 seconds; and extension at rrc for 30 seconds. This
was followed by a final extension of rrc for 5 minutes. RT-PCR products
were resolved by electrophoresis on 3% agarose gels with bands scanned under
UV light. For quantification of insulin receptor isoforms, a fluorescently-
labelled primer (lRfor) was used as the forward primer and PCR products was
analysed on Genescan following 26 cycles of amplification.
For SERCA] splicing analysis, I1201h of cDNA was amplified with Serca 1for
and Serca 1rev primers at thirty four cycles consisting of denaturation at 95°C
for 5 minutes, repeating cycles of 95°C for 30 seconds; annealing at 60°C for 1
minute and extension at rrc for 1 minute. This was followed by a final
extension at nOc for 5 minutes. Quantification of SERCA] splice isoforms was
carried out at 27-28 cycles using fluorescently-Iabelled Sercal rev.
For MENL] splicing, 1/20,h of cDNA was amplified with MBNU for and
MBNL 1rev primers at 30 cycles consisting of denaturation at 95°C for 5
minutes, repeating cycles of 95°C for 30 seconds; annealing at 62°C for 30
seconds; and extension at n °c for 45 seconds. Final extension was performed
at rrc for 5 minutes. Quantification of MENL] splice isoforms were
performed at 22-24 cycles using fluorescently- labelled MBNLfor primer.
For MENL2 splicing, 1/20,h of cDNA was amplified with MBNL2for and
MBNL2rev primers at 30 cycles consisting of denaturation at 95°C for 5
minutes followed by repeating cycles of 95°C for 30 seconds; annealing at
60°C for 30 seconds; and extension at rrc for 45 seconds. This was followed
by final extension of nOc for 5 minutes. The quantification of MENL2 splice
isoforms was carried out at 22-24 cycles using MBNL2for fluorescent primer.
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For Bpm! analysis of DMPK, 1/20th of the synthesized cDNA was used for
PCR amplification using NIl as forward primer with 133 as reverse primer.
Amplification was performed by modifying protocols used in Hamshere et al
(1997). Conditions included denaturation at 95°C for 5 minutes, with repeating
cycles of 95°C for 30 seconds; annealing at 58°C for 1 minute; and extension at
rrc for 1 minute. This was followed by a final extension of 5 minutes at
rrc. The PCR product was subsequently subjected to 98°C for 1 minute
followed by rapid cooling at 4°C for 10 minutes to promote formation of
homoduplexes for overnight Bpm! restriction digestion. The final products
were resolved on 3% agarose gels. In order to quantify relative levels of
expression of normal and mutant DMPK alleles, a fluorescently-Iabelled
primer NIl was used to amplify DMPK between 22-26 cycles and the resulting
products were restricted overnight with Bpm! prior to analysis on Genescan.
2.3.1.2 DNA sequencing
Miniprep samples of pGR-CLCN], pGR-SERCA2, pGR-vector and pGFP-
MBNL] & 2 were diluted to give a final concentration of 50ng/~1. PCR
products were diluted to give a concentration of IOng/ul.The primers used for
sequencing were subjected to I: I 0 dilution to give a concentration of
IOpmol/ul.
Primers used to sequence pGR-CLCN] were sinCLCN 1f, sinCLCN 1r,
DsRedMonoF and pEGFP-CIR. For pGR-SERCA2 sequencing, SERCA2fand
pEGFP-CIR were used while pEGFP-CIF and pEGFP-CIR were used to
sequence PGR-vector and GFP-MBNL ]&2.
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For peR products, the primers IRfor and IRrev were used to sequence insulin
receptor splice isoforms; and NIl and 133 were used for the DMPK gene.
All sequencing reactions were carried out by Geneservice and also ABI prism
377 automated sequencer at the University of Nottingham.
2.3.1.3 Fragment Length Analysis
peR products from reverse transcription-PCk were analysed on ABI prism
3130 genetic sequencer to quantify the levels of expression of splice isoforms
of insulin receptor, SEReAJ, MBNU and MBNL2 as well as in DMPK for
Bpm! analysis of normal and mutant transcripts in both nuclear and
cytoplasmic extracts. The resulting peaks from the sequencer were analysed
using Genescan peak scanner software in which areas of the respective peaks
were used to calculate the relative proportions of isoforms and transcripts.
2.3.1.4 Mutational Analysis of DNA fragments
DNA mutational analysis was carried out on a Transgenomic Wave DNA
fragment analysis system, a form of high pressure liquid chromatography
(HPLe), which consists of a detector, an oven for heating to specific
temperature, and an autosample compartment for loading samples into the
machine by 96-well plate. The wave machine has separation columns fitted
which are constantly infused by a mixture of Tri-ethylammonium and
acetonitrile. Alteration of the proportions of tri-ethylammonium and
acetonitrile determines the separation of DNA from peR products.
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Tri-ethylammonium provides a hydrophobic coat for the DNA molecule. The
charged nitrogen in tri-ethylammonium bonds with the negatively charged
phosphate backbone of DNA so as to bind it to the column and separate it from
unused dNTPs, primers, MgCh and Taq polymerase. DNA fragments are
released from the column by reducing the relative proportions of tri-
ethylammonium and the DNA is analysed by the detector for the presence or
absence of mutations. Furthermore, smaller molecules and those with
secondary structures are released more readily from the column. DNA
fragments without mutation form homoduplexes while those having the
mutation form heteroduplexes. The homoduplexes are read on the detector as
the long standard peak while heteroduplexes are detected as shorter peaks that
appear beside the long peaks. Mutational analysis was used to identify a
polymorphism in DMPK that is associated with DM.
2.3.2 Gel Electrophoresis
Gels of different concentration were used to separate DNA fragments of
different size ranges. For DNA of lkbp and above, a 1% gel was used.
Fragments above 300bp were separated using 2% agarose and, 3% agarose was
used to separate DNA sizes of less than 300bp. The 1% agarose gel was made
by dissolving 0.5g of agarose in 50ml of Ix TAE (which is composed of 40mM
Tris-Acetate, 10mM EDTA) and heating in microwave oven followed by the
addition of ethidium bromide dye to a final concentration of 1.0Ilgl~.d.On
cooling, the gel was poured into its rack and allowed to solidify for subsequent
transfer to gel tank. 21ll of the gel loading buffer containing 30% glycerol,
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0.025% bromophenol blue and 0.025% xylene cyanol was added to DNA and
the mixture was loaded into agarose gels followed by running under electric
current. The gels were then visualized under UV fluorescence for identification
of bands.
2.3.2.1 DNA molecular weight marker
Determination of DNA fragment sizes were carried out using both 100bp and
1kb ladder (from Invitrogen) on agarose gels.
2.3.2.2 Quantification of DNA and RNA
DNA samples were quantified either on a nanodrop spectrophotometer or on
agarose gel using a quantitative IJ-lindlll ladder, while RNA was quantified
on a nanodrop.
2.3.2.3 Restriction Digestion of DNA
Restriction digest of DNA was carried out using enzymes and reagents
obtained from New England Biolabs in accordance with manufacturer's
instructions. The components of the restriction mixture consisted of 1~g of
DNA, 1OU/~l of restriction enzyme, lOx restriction buffer (buffer 3 consisting
of 100mM NaCI, 50mM Tris-HCI, 10mM MgCh, and 1mM dithiothreitol
while buffer 4 is made up of 50mM potassium acetate, 20mM Tris-acetate,
10mM Magnessium acetate and ImM dithiothreitol), 1ug bovine serum
albumin and distilled water. The mixture was incubated in a water bath for 1-2
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hours at the optimal temperature and specifically overnight for Rpm! restriction
digest. This was followed by separation to its respective sizes using agarose gel
electrophoresis.
2.3.2.4 DNA Recovery and Purification
The extraction and purification of separated DNA fragments from agarose
gels was carried out using the QIAquick gel extraction kit from QIAGEN in
accordance with manufacturer's protocols. Gel bands visualized on a UV
transilluminator were excised using a scalpel. The sample was then weighed
and 3 volumes of buffer added and incubated at 50°C to dissolve. Isopropanol
was added to the mix and transferred to spin column inside a collection tube
and centrifuged for a minute for DNA to bind to the column. DNA was then
eluted with water.
2.3.2.5 DNA Ligation
After amplification and visualisation on 1% agarose gel, restriction fragments
were extracted and plasmid DNA (pGFP-MBNL) was self-ligated in 20~1
mixture consisting 1.0 ~I of 400U/~1 T4 ligase, 2.0 ~I of lOx ligase buffer
composed of 500mM Tris-HCI, 100mM MgCh, 100mM dithiothreitol and
10mM ATP (both from New England biolabs) and 17.0 ~l of plasmid DNA
and left at room temperature for 4 hours.
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2.3.3 Plasmid DNA Purification
Plasmid DNA was purified using QIAGEN plasmid DNA purification kit
protocol following overnight incubation of bacterial cultures. Pellets of
bacterial cells were harvested by centrifugation followed by resuspension in
10ml of buffer PI composed of SOmM Tris.Cl, pH 8.0, 10mM EDTA and
100flg/ml RNase A. The cells were subjected to lysis for S minutes in 2S0fll of
buffer P2 [comprising 200mM NaOH, 1% (w/v) SOS] and subsequently
neutralized by 10ml of chilled buffer P3 (which consists of 3.0M potassium
acetate at pH of S.S) to precipitate proteins as well as cell debris followed by
incubation at room temperature for 10 minutes. The lysate was filtered using a
QIAGEN filter cartridge into a SOmltube. The filtered lysate was applied to the
QIAGEN column previously equilibrated with buffer QBT [composed of
7S0mM NaCl, SOmMMOPS at pH of 7.0, lS% (v/v) isopropanol and O.IS%
(v/v) Triton X-lOO] and washed twice with buffer QC made up of l.OM NaCl,
SOmMMOPS with pH of7.0 and IS% (v/v) isopropanol. DNA was eluted with
elution buffer QN [composed of 1.6M NaCI, SOmMMOPS at pH of 7.0 and
IS% (v/v) isopropanol] and precipitated in 100% isopropanol followed by
centrifugation. DNA pellets were subsequently washed with 70% ethanol and
centrifuged to concentrate the pellets. The supernatants were discarded and the
pellets were air-dried at room temperature prior to redissolution in 300fll of
distilled water. The concentration and purity was measured on the nanodrop.
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2.3.4 Fibroblast/Cell DNA Extraction
DNA extraction from C2CI2 and fibroblasts cell lines was carried out using a
Puregene-Gentra DNA purification kit in line with protocols specified by the
manufacturer with modifications. In summary, about 1,000,000 cells per flask
were trypsinized and transferred into an eppendorf tube with complete
medium. The cells were pelleted with centrifugation at 16,000xg for 5 seconds
and the supernatant removed leaving the cells and 2-3 !!I of residual medium in
the tube. The cells were resuspended by vortexing and 300!!1 of cell lysis
solution (pH 4.0) composed of Tris[hydroxymethyl] aminomethane,
ethylenediaminetetraacetic acid and sodium dodecyl sulfate was added to lyse
the cells. I.S!!I of RNase solution was added to the cell lysate and incubated at
37°C for an hour to remove RNA. This was followed by addition of 100!!1of
protein precipitation solution (pH 2.7) to the cell lysate to precipitate proteins
with vortexing at high speed to obtain a uniform mixture. The mixture was then
centrifuged at 16,000xg for 5 minutes to pellet precipitated proteins. The
supernatant containing DNA was transferred into a fresh eppendorf tube with
300!!1 of 100% isopropanol and inverted to mix prior to centrifugation at
l6,000g for 5 minutes. The supernatant was discarded and 300!!1 of 70%
ethanol was added to wash the DNA pellet. The sample was centrifuged for 3
minutes and ethanol was decanted and the tubes were air-dried for 20-30
minutes at room temperature. DNA pellets were dissolved by adding 50!!1of
dH20 and heated in a 65°C water bath for an hour. DNA concentration was
subsequently quantified on the nanodrop before use for DNA analysis.
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2.3.5 Cell RNA Purification
Cell. and fibroblast lines for total RNA extraction were carried out in
accordance with Purescript-Gentra purification protocols. Flasks of cells were
trypsinized and about 1,000,000 cells were pelleted at l6,OOOgfor 5 seconds.
Supernatant was discarded and lOul of residual media was left in the tube
along with the cell pellets. This was followed by addition of 20f.l1of DEPC
H20 to inhibit RNase and 300f.l1of cell lysis solution (consisting of citric acid,
ethylenediaminetetraacetic acid and sodium dodecyl sulphate) was added to
lyse cells. lOOf.l1of protein-DNA precipitation solution (made up of citric acid
and sodium chloride) was added and the mixture was inverted 10 times to mix
before incubation on ice for five minutes. It was subsequently centrifuged for 5
minutes at 16,000g to pellet proteins and DNA and the supernatant containing
RNA was transferred into la fresh eppendorf tube containing 300f.l1of 100%
isopropanol. The mixture was inverted 50 times to mix and subsequently
centrifuged to pellet RNA. The supernatant was discarded and RNA pellet was
washed with 75% ethanol and centrifuged. The supernatant was discarded and
RNA pellet was air-dried for 20-30 minutes. The pellets were dissolved by
adding 50f.l1of DEPC H20 and left on ice for 30 minutes. The amount of RNA
was quantified on the nanodrop and used for reverse transcription. The
remainder was stored in -80°C for further use.
2.3.5.1 Fractionated RNA Purification
Fractions of nuclear and cytoplasmic RNA were obtained from tissue culture
cells by modifying protocols used in Hamshere et al (1997). Cells were washed
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in ice-cold PBS followed by addition of lrnl ofO.6S% Nonidet P-40 previously
prepared by mixing 10% (v/v) Nonidet P-40 in I.SmM MgCI2, O.ISM NaCl
and O:OIMTris.HCL with pH of 8.0 all in OEPC H20. Addition ofNonidet P-
40 to cells in the flask for 1-2 minutes disrupts the cell membrane to liberate
cytoplasmic contents but the nuclear membrane is intact and appears grainy
under an inverted microscope. The solution in the flask was drained into a fresh
eppendorf tube for cytoplasmic extracts. A further 2mls of Nonidet P-40 was
added to dislodge the nuclei and the contents of the flask were drained into a
tube and nuclear extracts pelleted by centrifugation. The supernatant was
discarded. 400lll of OEPC H20 was added to nuclear pellet to resuspend it,
followed by addition of 100111of O.SMTris-HCI , O.OSMEOTA and 2.S% (v/v)
sodium dodecyl sulphate (SOS) to nuclear extracts. For cytoplasmic extracts,
2S01l1of O.SM Tris-HCI, O.OSMEOTA and 2.S% (v/v) SOS was added. Both
nuclear and cytoplasmic RNA extracts were purified by two phenol/chloroform
extractions. The RNA was subsequently precipitated in equal volumes of
isopropanol containing O.3M sodium acetate (pH S.3) by centrifugation. RNA
pellets were washed in 7S% ethanol, centrifuged and the supernatants
discarded. The pelleted RNA was air-dried at room temperature for IS-20
minutes and dissolved in 40lll of DEPC H20, prior to quantification on a
nanodrop. The sample was electrophoresed on an agarose gel to confirm its
quality. Cytoplasmic RNA samples found to contain genomic DNA on agarose
gel analysis were treated with DNase 1.
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2.3.5.2 DNA Removal from RNA
Both total RNA and some samples of cytoplasmic RNA containing genomic
DNA were treated with Dblasel in accordance with Promega protocols. I.OIlI
of lOx DNase] Buffer [composed of 400mM Tris-HCI (pH 8.0), IOOmM
MgS04 and IOmM CaCh) and l.01l1 of enzyme (1Villi for every 1ug RNA)
was added to RNA samples and incubated at 37°C followed by addition of
l.01l1of stop solution [consisting of20mM EGTA (pH 8.0)] to inhibit Dblasel
reaction. The mixture was subsequently heated in 65°C water bath for 10
minutes to destroy Dblasel prior to its use in reverse transcription.
2.3.6 Protein Extraction from cultured cells
Cells from 75cm3 flask were trypsinized and pelleted by centrifugation
followed by wash in PBS. The cells were subsequently pelleted and the
supernatant was discarded and put on ice. About 100-500IlI of ice cold RIPA
lysis buffer (composed of 50mM, Tris HCI, pH 8.0, 150mM NaCI, 1% NP-40,
0.5%DOC,0.1 %SDS) was added to the pellet and placed on ice for 20 minutes.
This was followed by two cycles of freezing at -80°C and thawing at room
temperature. The cell lysate was centrifuged at 13000rpm at 4°C for 10 minutes
and the supernatant containing the cell lysate was transferred to a fresh
ependorf tube for storage at -80°C.
2.3.6.1 Protein Quantification
Protein quantification was performed using BioRad D, assay. To 30 III of
protein sample, 100 III of reagent A' (prepared by mixing 1000 III of A with
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20 III of reagent S). This was followed by addition of 800 III of reagent B prior
to vortexing to mix. The sample was incubated at room temperature for 15
minutes before measurement on BioRad spectrophotometer at 750nm for
absorbance. BSA samples of known concentrations of 10, 20, 30 and 50 Ilg in
RIPA buffer were used to plot a standard curve from which the concentration
of protein samples were estimated.
2.3.6.2 Western Blot
Western blot of protein samples was carried out using NuPage system (from
Invitrogen) in accordance with manufacturer's protocols. The gels and buffers
used were all obtained from the same manufacturer.
To prepare protein samples for electrophoresis, NuPage LOS sample buffer
was mixed with NuPage reducing agent prior to addition to protein samples.
The protein sample mix was heated at 70°C for 10 minutes for SOS-
polyacrilamide gel electrophoresis.
800ml of running buffer was prepared by adding 80ml of MOPS buffer to 40ml
of methanol and addition of 680mI of SOW. The NuPage bis-tris gel's comb
was removed from the wells and the wells were rinsed with running buffer
before it was assembled in Xcell mini cell system. Its chambers were
subsequently filled with running buffer. Protein samples were then loaded to
the gels along with two markers namely prestained marker and MagicMarker.
Prestained marker enables visualisation during electrophoresis and after
transfer to PYOF membrane while MagicMarker reacts with secondary
antibody to serve as internal standard for final western blot. The NuPage gel
was run for 50 minutes at 200Y.
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Following separation of protein, NuPage gel was transferred to PVDF
membrane using XCell II blot method. The PVDF membrane was soaked for
30 seconds in methanol followed by brief wash with SDW and left to soak in
transfer buffer (prepared by mixing 80ml of methanol, 40ml of 20X transfer
buffer and 680ml of SDW) for 5 minutes. The transfer buffer was also used to
soak blotting pads for several minutes. This was followed by placing PVDF
membrane on top of NuPage gel and they were sandwiched between blotting
paper and soaked pads and placed in Xcell II Blot module. The iiner chamber
was filled with transfer buffer with its outer chamber filled with SDW and the
transfer was performed for 60 minutes at 25V.
After transfer, the membrane was washed twice and blocked overnight with 5%
blotto solution in TBS-T. It was subsequently washed with distilled water and
incubated with primary antibody for 4 hours. The membrane was then washed
thrice with TBS-T prior to incubation with HRP-conjugated secondary
antibody for 30 minutes. This was followed by three washes with TBS-T
(prepared by mixing 4.0g of NaCI, with 10mi of Tris-HCI, 500ml of distilled
water and 500~1 ofTween-T). ECL solution (made up of 3ml of solution A and
75~1 of solution B) was applied to the membrane on saran wrap for 5 minutes
and its excess blotted with bloting paper. It was subsequently exposed to
photographic film for protein bands detection.
2.4 Transgene generation and DNA transfer
Transgene splicing constructs generated previously by cloning gene segments
into plasmid vectors were confirmed by sequencing. Subsequently, gene
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transfer experiments were carried out using trans gene constructs to transform
bacterial cells, prior to transfection studies in C2C 12 and human fibroblasts.
2.4.1 Splicing gene constructs
The splicing constructs used in this project for the primary assay were
previously generated in the lab by Dr Javier Granados-Riveron from gene
splicing construct containing reporters- green fluorescent protein (GFP) and
Dioscorea red fluorescent protein (DsRed). Introns 2 of CLCNI with its
flanking exons as well as intron 19 of SERCA2 and its flanking exons were
independently cloned into pEGFP-CI plasmid of 4.7kb size to generate pGR-
CLCNI and pGR-SERCA2 respectively (Figure 2.1).
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Figure 2.1: Transgene constructs pGR-CLCNl and pGR-SERCA2 on pEGFP-Cl
plasmids used for transformation of E. coli DHSu and subsequent transfection in
fibroblasts for the splicing assay. pGR serves as the positive control of the splicing assay.
2.4.2 Transformation
Transformation of bacterial cells was carried out by electroporation.
Previously prepared frozen stocks of electrocompetent E. coli strain DH5a
were thawed on ice. 1J.lI of plasmid DNA was diluted at different
concentrations (1125, 1150, 1/250) in different test tubes and chilled on ice and
the cells and DNA were mixed together. Electroporation apparatus was set at
25J.lF capacitance and 2.5KY. The transformation mix was placed in the
bottom of chilled cuvette and placed in the tray to subject it to electrical pulse.
Immediately after electroporation, 200~ll of SOC was added to the
electroporated cells and subsequently transferred to a tube containing 800J.lI
SOC and incubated at 37°C for an hour in a shaking incubator. Cells were
harvested at lOOOrpm for 10 minutes and resuspended in 200J.lI of LB. Aliquots
81
of the cells were taken and plated at room temperature and incubated overnight
at 37°C under kanamycin selection.
2.4.3 Transfection
The C2C12 cell lines and human fibroblasts were transfected with plasmid
DNA or siRNA using the Amaxa Nucleofection kit in accordance with
manufacturer's instructions.
Cells in 75cm3 flasks were grown to a confluency of 80-90% cell density and
the medium removed; washed with PBS, trypsinized and harvested. Aliquots of
trypsinized cell suspension were taken for cell counts on a haemocytometer. A
million cells per nuc1eofection sample were pelleted by centrifugation and the
supernatant was discarded. This was followed by resuspension of cell pellets at
room temperature in 100~dofnucleofector V solution. The cell suspension was
subsequently mixed with 2Jlg of plasmid DNA or 100nM of siRNA and
transferred into an Amaxa cuvette. The Amaxa Nucleofector programme B-032
was selected and used to electroporate C2C 12 cells while U-23 programme
was used to transfect human fibroblast. To reduce damage to cells, the cuvette
was immediately removed after the electroporation and 500Jll of pre-warmed
culture medium was added to it. The contents of the cuvette were transferred
into one of the six well plates and incubated in 37°C/5% CO2 for 24 hours for
expression of fluorescent proteins and subsequently selected for clones using
0418 if plasmid DNA was used for transfection.
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2.5 Microscopy
The imaging of cells in this project involved both widefield and confocal
microscope as well as high content imaging device.
2.5.1 Widefield Microscopy
Cell imaging was performed using Zeiss inverted fluorescent microscope
together with Olympus CK2 microscope with 4x, lOx and 40x objectives.
Green and red fluorescence in fixed cells on slide was examined using a Zeiss
axioskop2 mot plus fluorescence microscope fitted with a digital camera
having brightfieldl phase contrast as well as DAPI, green and red fluorescent
filters. Fluorescence was analysed at 489nm excitation and 508nm emission
combined filter for green fluorescence with 558nm excitation and 583nm
emission wavelength for red fluorescence. Cells were viewed using lOx
objectives. Analysis of fluorescent images was carried out using Open lab
software.
Also, used for the imaging of fluorescence in cells, inverted fluorescent Nikon
eclipse 7S 100 extra long working distances (ELWD) with 4x and lOx
objectives were used and images were recorded on the computer screen.
2.5.2 Confocal Microscopy.
The fluorescent microscopes used to view fixed cells on slides include Zeiss
LSM510 confocal head on a Zeiss Axiovert 100M microscope, fitted with
Zeiss plan neofluar 40xll.3 oil objective and Zeiss plan Apochromat 63x11,4
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oil objective. Images from these microscopes were analysed using LSM
software.
2.5.3 High Throughput Imaging
The Molecular Devices Micro widefield high content plate reader fitted with
Nikon 40x ELWO was used for high content imaging in high throughput
screens of cells in immunofluorescence and RNA-FISH analysis. The plate
reader consisted of 488nm Argon laser to excite GFP with band path of 505-
530nm emission filter and 543nm Helium-Neon laser with long path 560nm
emission filter for TRITC. Images from the plate reader were analysed using
MetaXpress software.
For cells with transgene splicing double reporter construct, Molecular Devices
Ultra widefield high content plate reader fitted with Nikon 40x ELWO was
used for high content imaging of cellular fluorescence. The 488nm laser was
used to view GFP at 525150 emission filter; DAPI was excited with 405nm
laser using 447/60nm filter; while OsRed was observed using Texas Red which
was excited by 561nm laser with 593/40 emission filters.
2.6 Electronic Databases
Gene databases used to access nucleotide, transcripts and protein sequences
-
were from the National Centre for Biotechnology Information (NCBI) and
European Molecular Biology Laboratory (Ensembl). Primer sequences were
designed using version 4.0 of primer3 Input.
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CHAPTER THREE: DEVELOPMENT OF PRIMARY
ASSAYS
3.1 Introduction
This chapter deals with developing a set of primary assays based on molecular
events in myotonic dystrophy that can be utilised for screening on a large scale
in high throughput screens of thousands of small molecules and chemical
compounds to test their efficacy in reversing molecular features associated with
the disease. The main molecular events in the disease under consideration in
this section are ribonuclear foci formation by expanded repeat RNA and its
association with RNA binding proteins (MBNL) to trig ger DM-Iike molecular
cascades. The aim is to use nuclear foci as a tool for therapeutic screening of
compounds that can reverse toxic RNA disease mediation in DM.
3.2 Nuclear foci assay
This assay was developed based on the pathogenic features of the mutant
RNA containing expanded CUG or CCUG repeats which serve to sequester
splicing factor MBNLl leading to the formation of foci in DM cells thereby
preventing it from performing its cellular functions of regulating splicing of a
subset of pre-mRNAs. To test the idea that foci formation could be a
convenient tool for therapeutic screening, lines of both DM 1 and DM2
fibroblasts as well as control fibroblasts were initially screened for the
appearance of foci and ribonuclear inclusions using a Cy3 fluorescently-
labelled (CAG)IO and (CCAG)IO probe in RNA-FISH as well as for the
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presence of ribonuclear inclusions usmg fluorescently-labelled MBNLl
antibodies.
The cells used for the screening were DM 1, DM2 and wild type fibroblast lines
which had been previously telomerised and are designated as DMI Tel, DM2
Tel and wild type Tel respectively in this study. Furthermore, another cell used
for the screens was telomerised DMI fibroblast which had been induced with
lentivirus containing MyoD, a muscle differentiation factor (designated as
DMI Tel MyoD) which is activated by doxycyclin to differentiate into
myoblasts.
Cells were scored based on the appearance of foci and ribonuclear inclusions
in both RNA-FISH and immunofluorescence respectively (figure 3.1).
o DM1 Tel MyoD Dox
o DM1 Tel MyoD
.DM1Tel
.DM2Tel
• Wild type Tel
MBNL
Immunofluorescence
RNA FISH
Figure 3.1: Schematic diagram showing average numbers of ribonuclear inclusion and
foci distribution between wild type and OM cells. OM! Tel MyoO is the fibroblast line
containing MyoD, a muscle differentiation factor that can be activated by doxycyclin
(Dox)
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RNA-FISH was observed to be more robust than MBNU
immunofluorescence because it could clearly distinguish between wild type
and DM cells based on presence or absence of ribonuclear foci. In contrast with
MBNU immunofluorescence which was found to have a leaky background as
RNA-FISH had no such obvious limitations. In addition, the number of
ribonuclear inclusions were low in immunofluorescent screens of wild type
cells while foci was absent in wild type cells hence RNA-FISH analysis was
more robust in clearly distinguishing between DM and wild type cells.
This was to determine the approach that could easily be utilized in high
throughput screens (HTS) and also to establish baseline parameters for
assessing if on treatment with chemical compounds, the cellular distribution of
foci is reduced or absent.
Based on the ability of initial optimisation assays in clearly distinguishing
DM cell from wild type cells, RNA-FISH was optimised for screens (figure
3.2) in HTS to determine if on treatment of the DM cells with compound, it can
disrupt or dissociate interactions between MBNU and RNA expanded repeat
units in foci leading to disappearance of foci.
Figure 3.2: RNA-FISH screens for foci in DM2 cell. The arrows indicate foci in the
nucleus represented by blue background. Scale bar in all figures represent 50"m.
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The RNA-FISH showed that OM2 fibroblasts had more foci than OMl
fibroblast lines for telomerised cells and for those telomerised containing
inducible MyoO. It could be possible that the increase in foci number per
nuclei in OM2 over OMI might be due to the presence of larger repeat
expanded units in OM2.
Furthermore, it was observed that when OM I fibroblasts containing inducible
MyoO (a muscle differentiation factor) mediated by lentivirus having foci
number of 3.l±0.2, were induced by doxycyclin to differentiate into myoblasts,
the number of foci in its nuclei was increased to 4.8± 1.0. This difference in
nuclear foci number between OMI fibroblasts and OMI myoblasts which
increases on differentiation is similar to the observation reported by Holt et al
(2009) in which undifferentiated as well as differentiated OMl myoblasts were
used. This is due to induction of muscle genes and DMPK by MyoO which
results in more foci.
Thus, differences in foci numbers between OM fibroblast nuclei as well as in
myoblast nuclei could be exploited to assess the efficiency of any potential
therapeutic agent for the disease condition.
3.3 Use of GFP-MBNL to Generate Clones for RNA-MBNL
interactions in foci
As a parallel assay to the nuclear foci assay described above, pGFP-MBNLl
was used to transfect wild type and OM cells lines to generate clones for use in
studying RNA-MBNL interactions in the nuclear foci. It has been previously
demonstrated in transient transfections that MBNL co-localises with RNA
repeat units in the foci in OM cells (Fardaei et aI, 2001). The aim was to use
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the clones generated for screening chemical compounds that can disrupt GFP-
MBNL 1 from interaction with repeat transcripts in the nuclei of OM cells, as
foci are not seen in wild type cells. This assay would be ideal for therapeutic
screening as it would facilitate the tracking of exogenous MBNL 1 on treatment
with compound to determine if it results in its redistribution or if it is still
sequestered in nuclear foci.
Transient transfection of OM2 and wild type fibroblasts with GFP-MBNLl
showed that 32.2% and 39.8% respectively of the cells were positive for GFP
after 48 hours. Unfortunately, GFP-MBNLl was observed to kill all of the cells
(both wild type and OM cells) it was transfected into after a period of three
days. One possible explanation of this result is that the full length MBNL 1
protein was toxic to the cells or GFP was toxic to the cells. In order to
distinguish between these two possibilities and overcome this technical
difficulty, MBNLI was cloned in pSNAP-tagged vector such that MBNLl
would be expressed as a fusion protein. Transient transfection studies in OM I
fibroblasts with both pGFP-MBNL I and pSNAP-tagged MBNL I showed 27%
and 6.9% of the cells expressed GFP and SNAP proteins respectively (table
3.1) after 12 hrs post-transfection. At 24 hours post-transfection, the percentage
of transfectants decreased to 19.4 for GFP-MBNL 1 and 2.2% for SNAP-
MBNL I. The transfectants all died by the third day due to the toxicity of
MBNLl constructs. Because SNAP- tagged MBNLl was equally as toxic as
GFP-MBNLl, no clones could be obtained for selection for study of exogenous
MBNLl interactions with RNA repeats in nuclear foci. It was thought that the
full length MBNL protein might be toxic to the cells, so truncated versions
were proposed for further study. The study above indicates that it was not GFP
89
that was causing the toxicity as the SNAP-tagged construct had similar toxicity
to the GFP-expressing construct.
Post-transfection GFP-MBNLI SNAP tagged- Amaxa GFP
duration MBNLI (Control)
6 hours 4.3% (4 out of 1.3% (1 out of 26.3% (36 out of
94) 76) 137)
12 hours 27% (27 out of 6.9% (5 out of 56.4% (92 out of
100) 72) 163)
24 hours 19.4%(19 out of 2.2% (2 out of 72.8% (134 out
98) 89) of 184)
48 hours 5.0% (2 out of 1.5% (lout of 54.0% (108 out
40) 66) of200)
Table 3.1: Proportion of DMl fibroblasts expressing GFP-MBNLI and SNAP-tagged
MBNLI protein at different time points. The cells all died on the third day due to toxicity
of constructs.
3.3.1 Construction of truncated GFP-MBNL
As a result of technical problems encountered in using pGFP-MBNLl to
generate cell clones, several deletions of GFP-MBNL 1 were made (figure 3.3)
alongside truncated versions of GFP-MBNL2.
ZnFl ZnF2 ZnF3 ZnF4
1-------------1 dell
1--------11 del2
t-----tl del3
1-----11 de 14
Figure 3.3:MBNLI deletion in the pGFP-MBNL constructs showing deleted domains
designated as deletion 1 (linker, zinc finger 3&4, C-terminus), deletion 2 (zinc finger3&4,
C-terminus), deletion 3 (zinc finger4 & C-terminus) and deletion 4 (C-terminus).
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The work described above suggested that full length MBNL 1 was toxic to
cells, thus various deletions of the two GFP-MBNL constructs based on their
RNA-binding domains (Zinc fingers) were generated. Primers with flanking
Spel restriction sites (table 3.2) were used to facilitate cloning. The sequences
of these primers are listed in the appendix.
Reverse Primer for Forward primer for Region of deletion
deletion deletion
Linker, Zinc finger 3 &4
MBNLI-Dlr pEGFP-CldeIF and C-terminus
Zinc finger3 &4 and
MBNLI-D2r pEGFP-CldeIF C-terminus
MBNLI-D3r pEGFP-CldeIF Zinc finer4 and C-terminus
MBNLI-D4r pEGFP-CldeIF C-terminus
Linker, Zinc finger3 &4
MBNL2-Dlr pEGFP-CldeIF and C-terminus
Zinc finger3 &4 and
MBNL2-D2r pEGFP-CldeIF C-terminus
MBNL2-D3r pEGFP-CldeIF Zinc finer4 and C-terminus
MBNL2-D4r pEGFP-CldeIF C-terminus
Table3.2: Truncated constructs were generated after peR products were restricted and
subsequently ligated in figure 3.4.
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!peR
Spel
_____ GFP-MBNL
Restriction &
Ligation
__ • Deleted Region
____ Deleted GFP-MBNL
Figure 3.4: Schematic representation for generation of truncated versions GFP-M BNL
For MBNLl, two deletions 1 and 4 were generated. Deletions 1 and 2 were
obtained for MBNL2. However, truncated versions of GFP-MBNLI and 2 did
not generate any clones in DM cells as they were equally as toxic as the full
length protein. Furthermore, only wild type fibroblasts generated 4 and 7
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clones for GFP-MBNL2 dell and GFP-MBNL2 del2 respectively. Because of
these difficulties, RNA-FISH became the only viable option that was adapted
for use in high throughput screening in the primary assays.
Plasmid Number of cells GFP positive % GFP cells
cells
GFP-MBNL Idell 166 30 18.1
GFP-MBNL 1del4 174 38 21.8
AmaxaGFP 134 94 70.1
Table 3.3: The proportion of DMl fibroblast expressing truncated versions of GFP-
MBNLl after 24 hours. The cells all died under G4l8 selection.
Cell line Plasmid Number of Number of % proportion
cells GFP positive ofGFP
cells
OM2 GFP- 48 9 18.8
MBNL2deil
OM2 GFP- 33 3 9.1
MBNL2del2
DM2 Amaxa GFP 93 27 29.0
WT GFP- 56 2 3.6
MBNL2deil
WT GFP- 47 3 6.4
MBNL2del2
WT AmaxaGFP 91 28 30.8
Table 3.4: Truncated versions of GFP-MBNL2 m transiently transfected wild type (WT)
and DM2 fibroblasts showing low expression levels of the constructs in these cells.
3.4 Splicing Construct Assays
In order to design a further assay that would be of use in primary high-
throughput screening, we generated assays to determine the effect of
compounds on alternative splicing. These assays were designed to screen for
compounds that could correct the splicing misregulations that take place in
OM. Transgenes constructs which were produced previously by Or Javier
Granados-Riveron in the lab, based on alternative splicing events involving
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introns (figure 3.5) reported in muscle-specific chloride channel (CLCNI) and
Sarcoplasmic-endoplasmic reticulum Ca2+ ATPase 2 (SERCA2).
tWild type
~DM
Figure 3.5: Schematic diagram showing alternative splicing of intron2 of CLCNl and
intron 19 of SERCA2 in DM patients and unaffected persons
The constructs generated contain segments of genes; intron 2 CLCN 1 with its
flanking exons and intron 19 of SERCA2. The inserts were cloned into pEGFP-
Cl, a vector having green fluorescent protein (GFP) at its 5' end and a
dioscorea red fluorescent protein (OsRed) at its 3' end. Two constructs were
generated designated as pGR-CLCNI and pGR-SERCA2 respectively. The
third trans gene constructs (pGR) serves as a positive control of the splicing
assay was derived from pEGFP-Cl having both GFP and OsRed with no intron
cloned into its multiple cloning sites.
The intron 2 of CLCNI contains a stop codon while intron 19 of SERCA2
bases is not divisible by 3. In both cases, splicing of the introns result in
translation of the single open reading frame of the trans gene constructs to give
chimeric product with green and red fluorescent activities. However, if no
splicing occurs, the introns are retained and only green fluorescent activity is
produced as a result of stoppage of translation by a stop codon in pGR-CLCNl
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or out of frame translation leading to non-translation of red fluorescence by
pGR-SERCA2 (figures 1.9).
3.4.1 CLCN1 Splicing Construct Assay
This assay was designed based on intron 2 splicing of eLeN1 which is altered
in OM. The misregulated splicing of intron 2 of eLeN1 in OM was first
reported by Charlet et al (2002b) in which they demonstrated the retention of
this intron in OM patients. Furthermore, Charlet et al (2002b) also reported that
this intron contained Premature Termination Codons (PTCs) whose retention is
induced in wild type cells following CVG-BPI overexpression leading to OM-
like splicing patterns to cause loss of CLCN 1 function resulting in myotonia
found in OM patients.
To develop this assay, a splicing construct designated as pGR-CLCN 1 was
generated from enhanced green fluorescent protein plasmid vector (pEGFP-CI)
in which intron 2 with exon 2 and exon 3 was cloned into the Xho 1 and Sail
sites of its multiple cloning region. The intron 2 transgene was cloned into
pEGFP-CI coding for green fluorescent protein (GFP) at its 5' end and
Dioscorea red fluorescent protein (OsRed) at its 3' end to generate pGR-
CLCNI.
Based on the splicing model, pGR-CLCN 1will be spliced in wild type cells to
produce green and red fluorescent activities by these cells because of the
removal of intron 2 which contains PTC. However, in OM cells, there will be
production of only green fluorescence and not red fluorescence because intron
retention truncates the translation open reading frame as a result of PTCs
contained in the intron. In addition, the reporter activities of GFP and OsRed
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could be used to estimate the efficiency of the splicing assay based on
OsRed:GFP ratios with those of wild type cells being one or almost
approaching one while those of OM cells will be zero or very low.
3.4.2 SERCA2 Splici,ng Construct Assay
The SERCA2 splicing assay was derived from the work carried out by Kimura
et al (2005). Kimura et al (2005) described a splice variant (SERCA2d) as
containing intron 19 which they observed to occur in low proportions in OM I
skeletal ,muscle. Furthermore, it was suggested that the retention of intron 19 in
SERCA2 resulted in a frameshift leading to a PTC in exon 20.
The generation of SERCA2 splicing constructs followed a similar protocol to
that of pGR-CLCN 1 in which intron 19 along with its flanking exons 19 and 20
were cloned into the Xho 1 and Sall sites of pEGFP-C I with GFP at its 5' end
and OsRed at its 3' end. The constructs were designated as pGR-SERCA2 and
according to the splicing model, would undergo intron 19 splicing in wild type
cells to produce green and red fluorescence.
By contrast in OM, retention of intron 19 in these cells introduces a frameshift
in the open reading frame of pGR-SERCA2 resulting in only green
fluorescence by the cells or very low red fluorescence/green fluorescence ratio.
3.4.3 Proof of Concept
The splicing constructs were tested in mouse muscle cells, C2C 12. A proof of
concept study of the trans gene constructs was carried out in transient
transfection using C2C12 cells. Figure 3.6 shows cells fluorescing with GFP
and OsRed could be identified following transfection of both constructs, which
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demonstrates splicing of the introns from the relevant gene constructs to give
green and red fluorescent activities. This finding is consistent with the splicing
model shown in figure 1.10.
Figure 3.6: Mouse muscle C2C 12 cells transfected with splicing constructs express both
green and red fluorescence. This indicates the transgene construct has been spliced. pGR
is the positive control for the study.
The transfected C2C 12 cells were subsequently selected in G418. The
presence of the plasmid was confirmed by PCR amplification of cell DNA
using Oligos sinCLCNlf and DsRedOFr for CLCNl; with sinSERCA2f and
DsRedOFr for SERCA2, pEGFP-CIF and DsRedOFr were used to amplify the
pGR vector region consisting of GFP and DsRed. This confirmed that the
integration of gene constructs into the cell genome had occurred.
3.5 Generation of Stable lines from Controls and OM
fibroblast with transgenes
After validation of the splicing constructs in C2C 12 cells, transgenes were
subsequently transfected into wild type fibroblasts as well as DM I and DM2
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fibroblast lines. The transfected cells were then selected in 200~Lg/ml 0418 and
many of the clones were scanned for fluorescence. DNA from the clones was
tested by PCR amplification to confirm the presence of the relevant transgenes
using primers T IF and T IR for CLCN I, and MlR 1-2f and MlR 1-2r for pre-
microRNA 1-2, a house keeping gene, in genomic DNA to generate products of
208bp and 300bp, respectively, in a duplex reaction. For sinSERCA2, primers
SERCA2f and DsRedORFr were used along with the pre-microRNA 1-2
primers above to generate 423bp and 300bp products respectively (figure 3.7 &
3.8).
208bp
300bp
Figure 3.7: PCR amplification of cell clone DNA resolved on an agarose gel to confirm
the presence of splicing construct pGR-CLCN I in representative agarose gel for wild
type and OM fibroblasts
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423bp
300bp
Figure 3.8: Confirmation of the presence of pGR-SERCA2 on a representative gel for
isolated clones of wild type and DM fibroblasts
A total of 44 clones were obtained from human fibroblasts, pGR-CLCN I was
successfully introduced into all three cell lines (Table 3.5). Twenty six pGR-
CLCN I positive clones were derived from wild type fibroblasts, 4 clones from
OM I fibroblasts eKB TeloMyoO) and 1 clone for OM2 fibroblasts
(KAGOTelo). For the pGR-SERCA2 construct, 11 clones were obtained for
the wild type fibroblast line and 2 clones for the OM2 fibroblasts lines. As
shown in figure 3.10 the wild type and the OMI fibroblasts showed splicing of
the pGR-CLCN 1 transgene constructs in fluorescent scans that was similar to
that demonstrated in C2C12. This shows the splicing of introns to produce the
predicted fluorescence (figure 3.9).
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Transgene Cell line Number of Positive for Fluorescence
clones transgene
integration
pGR-CLCNl WT 67 26 6
pGR-CLCNI DMI 11 4 2
pGR-CLCNI DM2 1 1 -
pGR- WT 15 11 3
SERCA2
pGR- DM2 6 2 -
SERCA2
Table 3.5: Clonal cells generated by G418 selection from wild type and OM cells using
transgene constructs. The dash indicates those which were not scanned for fluorescence.
OsRed GFP
Figure 3.9: Fluorescent images of the cell clones transfected with transgene construct
pGR-CLCN 1 showing splicing of the construct and resulting fluorescence.
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The clones obtained from these lines will be validated before use in
therapeutic screening. Validation will involve differentiating OM 1 clones
containing splicing constructs to myoblasts to determine whether there are
changes in the splicing ratio of green: red fluorescence. These cells will also be
subjected to siRNA knockdown of MENL1 and MENL2 to assess its effect on
splicing of constructs since MBNL knockdown in wild type myoblasts has
been reported by Oansithong et al (2005) to alter IR splicing in addition to
reducing foci number in OM cells.
3.6 Summary
Two assays have been developed in this chapter for primary screening of
compounds for OM therapy. They include a nuclear foci assay and the use of
transgene splicing reporter constructs. The nuclear foci assay has been
optimised in high content imaging on the plate reader in both 96-well and 384-
well format. Furthermore, clones with trans gene splicing construct were
confirmed for fluorescent expression in confocal imaging scans.
Both assays will be validated in the next chapter of this report for their
applicability in HTS for compound screening by MENL downregulation to
assess its effect on these assays. In addition, OMl clones with splicing
construct will be subjected to differentiation to assess if it changes the
fluorescent ratio when fibroblasts differentiate into myoblasts.
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CHAPTER FOUR: VALIDATION OF PRIMARY
ASSAYS AND COMPOUND SCREENING
4.1 Introduction
The assays generated in the previous chapter, namely nuclear foci and splicing
construct assays were tested for confirmation of their efficiency and suitabi lity
for use in screening compounds. In one instance, DM 1 clones containing the
eLeN 1splicing construct were differentiated to determine whether this altered
the splicing profile. In another instance, wild type and DMI clones containing
the same splicing construct were subjected to MBNL downregulation to assess
its effect on the splicing assay. Furthermore, in order to assess the efficiency of
nuclear foci assay, DM 1 cells were also subjected to MBNL downregulation to
assess its effect on nuclear foci.
The primary assays were subsequently used for screening compounds and
molecules following optimisation for high throughput screening (HTS).
4.2 Validation of Splicing construct assay
To validate the splicing construct assay, a DM 1 cell clone containing the
eLeN1 splicing construct was subjected to differentiation to assess its effect
on eLeN 1splicing. In addition, clones of DM 1 and wild type cells containing
a eLeN1 splicing construct were also subjected to MBNL downregulation to
test its effect on eLeN1 splicing in these clones. The fluorescence ratio
(DsRed fluorescence/green fluorescence) was used as a measure of the rate of
splicing in the eLeN1 splicing constructs.
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4.2.1 Differentiation of DM1 clones containing CLCN1
splicing construct alters its splicing
The clone of DM! fibroblasts containing a eLeN] splicing construct, which
was generated in the previous chapter was subjected to differentiation by the
presence of doxycyclin .which induces MyoO expression, a muscle
differentiation factor, to convert the fibroblasts into myoblasts.
Based on the splicing concept, it was hypothesized that the fluorescence ratio
in the OM! clone containing the eLeN] splicing construct, which gives an
indication of the extent of splicing, would be altered as is reported in studies of
splicing of transcripts upon differentiation of OM I cells (Savkur et aI, 200 I;
O'Leary et aI, 2010).
Consistent with this proposal, the fluorescence ratio (ie OsRed to GFP)
observed in the DM! cells containing the eLeN] splicing construct changed
from 1.0 (100.0%) in fibroblasts to 0.0 (0.0%) in confocal scans showing no
red fluorescence in these cells after differentiation into myoblasts (figure 4.1).
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Figure 4.1: Intron 2 of CLCNI splicing transgene is spliced out in OMl fibroblasts as
shown by the expression of both GFP and OsRed in these cells. When fibroblasts undergo
differentiation into myoblasts, intron2 of the splicing transgene is retained resulting in
expression of only GFP. This represents a developmental switch from normal splice
patterns in OMl fibroblasts to OMl splicing pattern in myoblasts.
The switch in splicing as shown by the expression of GFP and DsRed in DMI
fibroblasts compared to the GFP-only expression in myoblasts, derived from
the same fibroblasts clonal lineage, is due to the retention of intron 2 of the
CLCNI splicing construct in myoblasts. This leads to the termination of
transgene transcript translation resulting in GFP expression only in the DM 1
myoblasts. The intron2 retention in the DMI myoblasts mimic the splicing
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pattern associated with OM. This demonstrates that the clonal fibroblasts,
which undergo developmental change to a OM-like splicing pattern on
differentiation, were suitable for use in compound screening for OM therapy.
4.2.2 CLCN1 splicing in DM1 fibroblasts clone is altered
by MBNL downregulation but not in wild type clone
In order to downregulate MBNL levels in OM I clone so as to assess its effect
on the CLCNI splicing construct, siRNA whose sequence (appendix B) is
directed against MBNLl and MBNL2 mRNA was used with scrambled oligo,
which is non-specific to any gene, as control. The siRNA binds to mRNA to
prevent its translation.
OM I clones demonstrated a decreased in OsRed/GFP ratio which was
observed to give 0.174 for MBNL double knockdown, 0.250 for scrambled
knockdown which was nonspecific to any gene while untreated was 0.251.
This indicates that MBNL downregulation alters CLCN 1 splicing by promoting
increased intron 2 retention in OMI clones thereby shifting its splicing pattern
towards that found in OM (Figure 4.2).
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Figure 4.2: MBNL doubleknockdown (MBNLI & 2) alters CLCNI transgene splicing in
OM! fibroblast clones by reducing the intensity of OsRed fluorescence in HTS when
compared to scrambled.
However, in wild type clones, MBNL downregulation did not show any effect
on DsRedJGFP ratios as both MBNL and scrambled knockdown had the same
ratio of 0.289 while untreated had a ratio of 0.228 (figure 4.3). This seems to
suggest that MBNL downregulation did not have any effect on CLCNI splicing
in wild type clones.
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Figure 4.3: MBNL downregulation in wild type clone of CLCNI transgene showing no
effect on fluorescence ratio when compared to scrambled which serve as the control.
In order to confirm the possibility MBNL 1 and 2 were actually
downregulated in both wild type and DM 1 fibroblast clones, western blotting
of protein extracts from both MBNL double knockdown and scrambled
knockdown samples were performed.
Western blotting results normalized to tubulin showed that MBNLl was
greater than 95% downregulated in DMI fibroblasts clone (figure 4.4) and
about 90% reduction was achieved in wild type clone (figure 4.5).
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Figure 4.4: MBNLI was reduced in MBNL doubleknockdown in DM I clonal cells in
comparison with controls (scrambled and untreated)
MBNL1
Tubulin
Figure 4.5: Downregulation of MBNLI in wild type clonal cells confirmed on western blot
normalised with tubulin as loading control. I
The loading control (tubulin) was slightly less in scrambled knockdown than in
MBNL knockdown in wild type clones suggesting that MBNLl levels in
scrambled knockdown is more than that observed on the blot and could be
similar to levels seen in untreated samples.
On the other hand, MBNL2 was downregulated by 80-85% in both DMI and
wild type clones (figure 4.6 and 4.7).
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MBNL2
Tubulin
Figure 4.6: MBNL2 protein levels were decreased in MBNL doubleknockdown of OM!
clonal cells when compared to scrambled and untreated controls. Western blot was
normalized with tubulin.
MBNL2
Tubultn
Figure 4.7: MBNL2 protein levels were reduced in MBNL doubleknockdown sample in
comparison with controls (scrambled and untreated) with tubulin as loading control.
However, the loading control (tubulin) for scrambled knockdown indicates
that the amount of MBNL2 protein is more than what is shown on the blot and
could be similar to the levels seen in untreated sample.
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Taken together, these results confirm that the splicing assay in OM 1 clone is
suitable for application in therapeutic screening of compounds that could
reverse' splicing defects seen in OM.
4.3 MBNL downregulation reduces Nuclear foci in DM1
cells
To validate the nuclear foci assay, OM 1 fibroblasts were subjected to testing
by MBNL knockdown using siRNA directed against its mRNA to assess its
effect on nuclear foci number. The aim was to establish if MBNL depletion
would result in reduction of nuclear foci as was previously demonstrated in a
report by Oansithong et al (2005). This would provide a positive proof for the
nuclear foci assay to justify its application in compound screening therapy in
high throughput screens (HTS).
In accordance with this proposal, MBNL] and MBNL2 double knockdown
from four replicates demonstrated 59.3±9.7% reduction in nuclear foci of OMI
fibroblasts when compared to scrambled (99.3±5.7%), a nonspecific
knockdown for any gene, which served as negative control (fig 4.8). This result
shows that the nuclear foci assay lends itself to further application for
compound screens.
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Figure 4.8: siRNA MBNLI and 2 double knockdown reduces the number of nuclear foci
while siRNA scrambled knockdown which is a nonspecific to any gene does not have any
effect on nuclear foci in DM1 fibroblasts. Nuclear foci are indicated by the arrows.
4.4 Compound Screening
After validation, the primary assays were applied to screening compounds in
the following sections for their efficacy in reduction or clearance of nuclear
foci as well as in improving misregulated splicing in CLCNI reporter construct
assays.
4.4.1 Compound Library for Screening
The initial library screen consisted of inhibitors of phosphatases and kinases.
The kinase inhibitor collection consisted of 80 compounds including inhibitors
of BTK, CaM Kinase II, CDK, CKl & II, EGFR, GSK, IKK, IR, JAK, JNK,
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MAPK, MEK, MLCK, PI 3-kinase, PDGFR, PKA, PKC, RAF, SAPK, Src-
family and VEGFR (Table 4.1). Some of these kinase inhibitors have been
used by others to demonstrate their effect on alternative splicing. For instance,
LY294002, an inhibitor of PI 3-kinase has been shown to block SRp40
phosphorylation and insulin-,mediated exon inclusion of PKC~II isoform (Patel
et aI, 2001).
Kinase Name
BTK Bruton tyrosine kinase
CaM Kinase II Calcium/calmodulin-dependent kinase II
CDK Cyclin-dependent kinase
CKI & II Casein kinase I & II
EGFR Epidermal growth factor receptor
GSK Glycogen synthase kinase
IKK I Kappa B kinase
IR Insulin receptor
JAK Janus kinase
JNK Jun N-terminal kinase
MAPK Mitogen-activated protein kinase
MEK MAPKIERK kinase
MLCK Myosin light-chain kinase
Pl3-kinase Phosphatidyl inositol-3-ki nase
PKA Protein kinase A
PKC Protein kinase C
PDGFR Platelet-derived growth factor receptor
RAF Proto-oncogene serine/threonine-protein kinase
SAPK Stress-activated protein kinase
Src- family Non-receptor tyrosine kinase
VEGFR Vascular endothelial growth factor receptor
Table 4.1: List of protein kinase inhibitors hbrary and their respective names
The phosphatase inhibitor library was composed of 33 compounds including
PP2B designated as calcineurin, CD45, CDC25, JSP-I, PPI, PP2A, PRL-I,
PRL-3, PTEN etc (Table 4.2). One of the inhibitors in this group of
compounds, calyculin A, an inhibitor of both protein phosphatase I (PPI) and
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protein phosphatase 2A (PP2A) blocked alternative splicing of Bc1-x(L) and
caspase 9b variants (Chalfant et aI, 2002).
Phosphatase Name
PP2B Protein phosphatase 2B
C045 Cluster for differentiation 45
COC25 Cell division cycle 25
JSP-I JNK stimulatory phosphatase 1
PPI Protein phosphatase 1
PP2A Protein phosphatase 2A
PRL-I Pleiotropic regulatory locus 1
PRL-3 Pleiotropic regulatory locus 3
PTEN Phosphatase and tensin homolog
..Table 4.2: Phosphatase inhibitor library and Its nomenclature
The initial screening library was made up of 113 compounds. Primary screens
consisted of testing compounds at different concentrations of 481lM, 81lM and
I.6IlM. Secondary screening tests were used to establish toxicity and
sensitivity of the compounds in the screens.
The positive hits in HTS (defined as those which resulted in either clearance
or 70% reduction of foci) obtained from the screening library were PKC
inhibitors designated in the compound library as 08 and 09 and are named
hypericin and Ro-3I-8220 respectively. The optimal concentrations of 08 and
09 used in the screens were 50llM and 51lM respectively.
4.4.2 Protein Kinase C (PKC) Inhibitors
Protein kinase C has been shown to be activated by the expression of
expanded CUG repeat containing RNA in its natural context of DMPK but the
mechanism is yet to be understood (Kuyumcu-Martinez et ai, 2007).
Furthermore, it was demonstrated that PKC activation by expanded CUG
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repeat induces hyperphosphorylation ofCUG-BPl leading to an increased half-
life of the protein. It is the hyperphosphorylated forms of CVG-BPI that are
involved in alternative splicing.
PKCs are serine and threonine kinases that exist in twelve isoforms and are
activated by phorbol esters like PMA (Mellor & Parker, 1998). A PKC
inhibitor Ro-3I-8220 was used in a functional study by Wang et al (2009) to
test the role of CVG-BPI in OM in an inducible cardiac-specific mouse model
of the disease. Administration of PKC inhibitors to this mouse model was
observed to relieve cardiac conduction defects as well as cardiac abnormalities.
In addition, these inhibitors were found to reduce misregulated splicing events
in exon2l of Ank2 and exonI6 of Mtmr3 which are specifically regulated by
CVG-BPI (Wang et aI, 2009). Taken together these reports demonstrate that
inhibition of PKC activity could be a useful target for therapy of OM hence its
justification for inclusion in the library of compounds used for OM therapy
screening in this project.
4.5 PKC Inhibitors 08 and 09 clear nuclear foci from OM
cells
Two of the compounds identified in our primary screens, 08 and 09, gave a
positive result in compound screening assessment by clearance of foci in both
OMl and OM2 cells (figure 4.9) when compared to untreated cells which had
nuclear foci.
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Figure 4.9: Compound screening analysis of OM cells showing the clearance of nuclear
foci in both OM! and OM2 fibroblasts by PKC inhibitor 09.08 also gave similar effect
on treatment.
These results demonstrate that D8 and D9 treatments could be of potential
value in the therapy of DM. However, from this assay, it is not possible to
determine whether D8 and D9 treatment results in the redistribution ofMBNLI
following dissociation of nuclear foci.
OH 0 OH
HO
HO
Me
Me
OH 0
08 09
Figure 4.10: Chemical structures of PKC inhibitors 08 (hypericin) and D9 (Ro-31-8220).
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Furthermore, we need to establish whether the RNA containing the expanded
repeat units is released from the nuclei into the cytoplasm on clearance of foci
from OM cells. The latter possibility will be tested in the next chapter of this
report while the former can only be deduced based on data for the confirmation
of positive hits by alternative splicing assays developed and tested in the next
chapter of this report.
4.6 Correction of misregulated splicing in CLCN1
reporter construct by PKC inhibitors 08 and 09 in OM1
myoblasts
In parallel, we applied the CLCNI splicing construct assay to assess
compounds identified in the primary screening assay. This would serve as a
double check against false positives for the identification of compound with
therapeutic value in OM. Analysis of the expression of GFP and OsRed by
OM I myoblasts on treatment with compounds serves as a test for the
effectiveness of compound treatment on correcting the OM-like splicing
pattern. This would determine whether intron 2 of CLCN 1 in the reporter
splicing constructs is retained in OM 1 differentiated cells (myoblasts)
following treatment.
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Figure 4.11: D8 and D9 treatment reverses DM-Iike splicing patterns of intron 2 retention
of the CLCNI splicing transgene in DM1 myoblasts. Confocal images from laser scanning
microscope are shown in treated and mock control (DMSO) and untreated myoblasts.
Both D8 and D9 treatments of differentiating DM1 fibroblasts restored
CLCNl misregu1ated splicing in DM1 myoblasts (figure 4.11). The confocal
images show the presence of both green and red fluorescent cells in contrast to
mock control (DMSO treated) and untreated cells which exhibit only green
fluorescence. The expression of only GFP in controls is an indicator of CLCNI
misregulated splicing due to the retention of intron 2 which contains a
premature termination codon leading to the truncated translation of the CLCNl
open reading frame.
The assay was optimised on the Molecular Devices Ultra scanning device
used for HTS which is more sensitive than laser scanning microscope. It
showed different intensities of DsRed fluorescence in relation to GFP
following treatment. The ratios of DsRedlGFP were quantified and analysed
using metaXpress software multi wavelength cell scoring. D8 showed a greater
DsRedlGFP ratio of 1.14 which was three times greater than that of D9 which
was 0.36. Both DMSO treatments and untreated had fluorescence intensity
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ratios of DsRed/GFP of 0.06 and 0.07, respectively, which were significantly
less than the measures following D8 and D9 treatments. The HTS scans
confirmed the result from confocal scans that both 08 and D9 treatments
improved intron 2 splicing in differentiated DMI reporter construct clones.
Furthermore, 08 showed a greater effect on splicing than 09 with the eLeN]
reporter splicing assays in HTS as demonstrated by higher DsRedlGFP ratio
(figure 4.12).
09 08 OMSO Untreated
Figure 4.12: HTS scans on plate reader of DMI myoblast containing CLCNl splicing
construct showing diminished DsRed fluorescence in mock control (DMSO) and
untreated in comparison with treatments (D8 and D9).
In addition, both DM1 fibroblasts and wild type fibroblasts containing the
Cl.Cbll splicing construct were analysed untreated by compounds as additional
controls (figure 4.13 and 4.14). However, wild type myoblast were not used in
these experiments as these cells would have served as a better control.
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Figure 4.13: HTS scans of untreated wild type fibroblasts (non-DM) exhibiting GFP and
DsRed fluorescence which is an indication of the extent of splicing of the CLCN1
transgene construct in these cells.
In order to determine if the PKC inhibitors D8 and D9 affect splicing of the
transgene in DMI fibroblasts and wild type (non-DM fibroblasts), treatments
of D8 and D9 were applied to these lines. The treatments in both wild type and
DMI fibroblasts showed that D9 had no effect on altering the splicing of the
intron 2 of CLCNI construct while D8 seems to show a very minor alteration in
intron 2 splicing (4.15 and 4.16). This implies that D9 does not affect CLCN 1
splicing in the fibroblast lines. However, due to the toxicity of D9 in the
CLCNI splicing construct assay, the initial concentration was scaled down
from 51lM to 311M. Compound treatment was applied to differentiating
myoblasts on day 5 of the six days differentiation period and DMI myoblasts
were exposed to 25 hour treatment before fixation for HTS. Both DMI and
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wild type fibroblast lines with the CLCNI splicing construct were subjected to
48 hour treatment exposure because these cell lines have a greater tolerance for
D9 toxicity than DMI myoblasts.
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Figure 4.14: HTS imaging of DMI fibroblast with CLCNl splicing transgene untreated
with compounds showing splicing of intron 2 of CLCNI transgene as shown by intensities
of GFP and DsRed.
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Figure 4.15: 09 treatments of wild type fibroblasts containing the CLCN1 construct did
not alter its splicing in comparison to controls (DMSO and untreated).
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Figure 4.16: OMI fibroblast containing CLCN1 splicing construct showing a slight
increase in its splicing on treatment with 08 and 09.
4.7 Summary
The applicability of the nuclear foci assay was confirmed by siRNA
knockdown of MBNL on HTS prior to use in compound screening. The nuclear
foci assay yielded two positive compound hits for clearance of nuclear foci
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from the kinase and phosphatase inhibitor library. The compound hits obtained
were 08 and 09 which are protein kinase C inhibitors.
In a parallel assay, the CLCN 1 splicing construct assay shows a suitable read-
out with a developmental switch in its intron 2 to OM splicing patterns in
myoblasts. Furthermore, DMI fibroblasts clone of CLCNI splicing construct
was confirmed by MBNL 1 and MBNL 2 downregulation for its effect on
switching the splicing to OM pattern for optimisation on plate reader.
Differentiating DMI myoblasts containing the CLCNl splicing construct were
used to confirm hits from the nuclear foci assay. Both 08 and 09 showed
positive effects on reversing CLCNl intron 2 spliceopathy in differentiating
DMI myoblasts in both confocal scans and in HTS.
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CHAPTER FIVE: DEVELOPMENT OF
SECONDARY ASSAYS AND TESTING
PUTATIVE HITS
5.1 Introduction
This section deals with assays developed based on downstream effects of
ribonuclear foci formation in DM cells, namely entrapment of repeat expanded
transcripts and spliceopathy which contribute to symptoms observed in OM
patients. The assays developed were subsequently applied in testing the
efficacy of putative compound hits (defined as compounds which cleared
nuclear foci and corrected intron2 missplicing of CLCNl in DMI myoblasts)
obtained from primary screens in the preceeding chapter.
5.2 Secondary Assays
The aim was to develop a set of assays for OM therapy screening validation
that follow on from primary assays for splicing misregulation and mutant
DMPK transcripts that trigger OM-like molecular cascades. To enable
validation of compound hits obtained from primary screens, secondary assays
were developed based on analysis of compound effects on mutant allele of
DMPK and splicing defects as the readout for the disease process.
5.2.1 Mutant DMPK analysis
Based on the effect of expanded repeat RNA containing DMPK transcripts in
initiating molecular cascade of DM, two assays were developed for
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optimisation. They include DNA mutation analysis and Bpml polymorphism
which occur in mutant DMP K transcripts.
5.2.1.1 Mutational analysis of DMPK exon 10 for Bpml
polymorphism
Initial DNA mutational analysis was carried out using PCR amplicons of
DMPK exonlO from genomic DNA ofDMI, DM2 and wild type fibroblasts in
order to determine which cell was heterozygous for Bpm! polymorphism by the
presence of mutant and wild type allele of DMPK in these lines. Using primers
(designated as GdmpkF and GdmpkR) located on flanking introns of exonlO
(intron 9 and 10), a PCR product of 233bp was amplified, which was used for
mutational analysis.
9 10 11
Figure 5.1: The location of primers on flanking introns of DMPK exon 10 used for
amplification for analysis in dHPLC wave machine
Crude PCR amplicons from genomic DNA were subsequently subjected to 50
repeated cycles of heating at 9SoC and cooling to -1.5 °C in order to promote
heteroduplex formation. The products were then subjected to analysis in a
denaturing HPLC Wave machine to produce elution profiles for the presence or
absence of heterozygosity for Bpm! polymorphism in fibroblasts defined by the
presence mutant allele which has Bpml restriction site and normal allele of
DMPK which lacks it. The elution profiles generate peaks for the normal allele
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and mutant allele. Only one DMI and one wild type fibroblast line were
heterozygous for the Bpml polymorphism which was present in mutant DMPK
transcripts containing expanded repeats in this analysis showing the presence
of two peaks in contrast to DM2 and another wild type line which showed a
peak. The higher peak represents the normal DMPK allele while the lower
bulging peak represents the mutant DMPK allele and the lower peak was
absent in only DM2 fibroblast indicating it was not informative for BpmI
polymorphism (figure 5.2).
v
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Figure 5.2 Elution profiles of mutational analysis of Bpml polymorphism of DMPK in wild
type, OMl and OM2 fibroblasts indicating the presence of the polymorphism in wild type
and OMl cells only
The mutational analysis was subsequently applied to cDNAs produced from
nuclear and cytoplasmic RNA extracts from DM1 fibroblasts since it has been
reported that the mutant DMPK transcripts are trapped in the nucleus hence are
not transported to the cytoplasm (Hamshere et al, 1997; Davis et al, 1997).
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These cDNAs were amplified using primers located on exon 9 and exon 10 to
give a peR product of 154bp for the mutational analysis.
Amplicons were heated and cooled for heteroduplex formation prior to dHPLe
elution analysis which gave two peaks for the nuclear fraction, indicating the
presence of normal and mutant DMPK alleles. On the other hand, the
cytoplasmic fraction only gave a high peak showing the presence of only the
normal DMPK transcripts (figure 5.3) .
• v
mu
- KBNuCiear
- KB Cytoplasmic
- control
Figure 5.3: Mutational analysis of nuclear and cytoplasmic cONAs of OM 1 fibroblasts
cytoplasm
showing the presence of mutant DMPK transcripts in the nucleus which are absent in the
Subsequently, analysis was applied to compound treated cells whose nuclear
and cytoplasmic RNA extracts were reverse transcribed, amplified by peR and
subjected to 50 cycles heating and cooling for heteroduplex formation. In
addition, peR amplicons of these reverse transcribed fractionated RNAs were
sequenced to confirm results from dHPLe analysis.
Comparison of dHPLC elution profiles with sequencing analysis showed that
every other sample exhibited similar results except for cytoplasmic sample
from D9 treatment which demonstrated the presence of mutant DMPK
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transcript in the cytoplasm (figure 5.4) which was not confirmed in the
sequencing analysis. AU mutational and sequencing analysis was carried out
using PCR product of 32 cycles.
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Figure 5.4 DMPK mutational analysis of nuclear and cytoplasmic cONAs from PKC and
OMSO treated OM cells showing that only 09 treatment effected the release of mutant
transcript into the cytoplasm
Due to conflicting results for the cytoplasmic fraction of 09 treated cells in
dHPLC analysis and sequencing which showed the presence of mutant
transcript in cytoplasm in dHPLC which was not confirmed by sequencing, the
wave machine mutational analysis was abandoned in favour of BpmI restriction
analysis of DMPK for the mutant allele which will be discussed in the
following section.
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5.2.1.2 8pml Restriction analysis
This ~as based on previous work in the lab reported in Hamshere et al (1997)
in which primers flanking the polymorphic site on exon 10 of DMPK were
designed on exon 9 and exon 10 (figure 1.11).
RNA extracted from nuclear and cytoplasmic fractions was reverse transcribed
prior to PCR at 30 cycles. The RT-PCR amplicon yielded a l54bp product
which was normalised to GAPDH as control.
The BpmI restriction site is present only m mutant DMPK transcripts
containing expanded CUG repeat units but absent from the normal transcripts.
BpmI restriction of 154bp amplicon gives l54bp and 138bp representing
normal and mutant transcripts respectively on 3% agarose gel (figure 5.5).
154bp
138bp
Figure 5.5: Bpm I restriction of RT-PCR amplicons from total RNA extracts of DMJ
fibroblast showing the normal DMPK (J54bp) and mutant transcripts (J38bp)
This was applied to a DMI line that was informative for the BpmI
polymorphism and a wild type line that was a carrier for this polymorphism.
BpmI restriction analysis of amplicons obtained from nuclear and cytoplasmic
cDNAs showed the presence of mutant transcripts in the nucleus of DM cell
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and its absence from the cytoplasm. However, in the wild type cells, the mutant
transcript is present in both nuclear and cytoplasmic compartments of the cell.
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Figure 5.6: Bpml polymorphism analysis of nuclear and cytoplasmic RNA fractions from
DM 1 and wild type (WT) lines demonstrating the release of mutant DMPK transcripts
into cytoplasm in wild type cells while that of DM I cells is trapped in the nucleus.
5.2.2 Alternative Splicing assays
These assays were based on detecting the m isregulated spl icing events that
contribute to the symptoms of OM phenotype. Alternative splicing events
utilized in these assays were those involving insulin receptor (IR),
sarcoplasmic/endoplasmic reticulum Ca2+ -ATPase 1 (SERCA I), and
muscleblind-like (MBNL).
5.2.2.1 Insulin Receptor Splicing assays
This assay is based on alternative splicing of exon 11 whose isoform is
reduced in OM muscle cultures but increased in wild type muscles. Primers
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used in this assay were located on exon 10 and exon 12, flanking the
alternatively spliced exon 11. This generated RT-PCR products of 167bp and
131bp' based on inclusion (IR-B) or exclusion of exon 11 (IR-A) respectively
(figure 5.7).
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Figure 5.7: Alternative splicing scheme for IR involving exon 11 splicing analysis
Screening of OMl, OM2 and wild type fibroblast cONAs was performed
using PCR of 30 cycles. This showed a predominance of the isoform lacking
exon 11 in OM2 fibroblasts. Wild type fibroblasts had almost equal proportion
of both splice isoforms while OM I fibroblasts had slightly more of the splice
isoform containing exon 1 t (figure 5.8).
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Figure 5.8: IR splicing screens of wild type, DMI and DM2 fibroblast lines showing
predominance of IR-A isoform in DM2 lines while IR-B is the major isoform in both
DMI and wild type fibroblasts.
Initial genescan analysis of IR splice isoforms in these fibroblast lines showed
that the proportion of IR-B isoforms in OMl, OM2 and wild type fibroblasts
were 52.3%, 10.8% and 49.1 % respectively.
Only the OM I fibroblasts, of those cell lines used above, contained an
inducible MyoO transgene which in the presence of doxycyclin activates its
myogenic programme to differentiate into myoblasts. The OM! fibroblasts
containing inducible MyoO were differentiated prior to IR alternative splicing
analysis. It was observed that there was a splice isoform shift from IR-B, which
occurred in OM I fibroblasts to predominance of IR-A in differentiated
myoblasts (figure 5.9).
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Figure 5.9: IR splice isoforms in DM I and wild type myoblasts showing greater
proportion of IR-A in patients' myoblast in contrast to wild type which show almost
equal proportions of IR-A and IR-B.
The splice isoform quantification analysis of wild type fibroblasts, wild type
myoblasts and DM 1 myoblasts showed that the proportions of IR-B isoform
were 56.8± 1.1%, 38.9±3.1 % and 9.8±0.9% respectively.
5.2.2.2 Sarcoplasmic/endoplasmic reticulum Ca2+-ATPase
1 Splicing assay
In order to examine further the effect of compound treatment on DM
molecular features, another assay was designed based on splicing of exon 22 of
SERCA1. Alternative splicing of this exon generates two isoforms: SERCAI a
which contains exon 22 and SERCA 1b which lacks exon22. Primers designed
for SERCA 1 spl icing were located on exon 20 and exon 23 of the SERCA 1.
This generated RT -PCR products of 277bp and 235bp for SERCA Ia and
SERCA 1b respectively (figure 5.10).
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Figure 5.10: Scheme for SERCAI alternative splicing analysis involving exon 22
The splicing assay was applied to DM and wildtypefibroblasts. Each of the
cell lines showed predominance of the SERCAla isoforms (figure 5.11).
%SERCA1a
SERCA1a
SERCA1 b
Figure 5.11: SERCAJ splice isoforms in wild type and DM fibroblasts showing
predominance of the SERCAla isoforms.
Genescan quantification analysis of SERCAla isoforms were 89.5±3.6%,
69.0±17.0% and 72.9±3.0% for wild type, DMI and DM2 fibroblast
respectively.
When DM 1 fibroblasts were differentiated into myoblasts, there was a shift
from splice isoform SERCA Ia to SERCA 1b. Wild type myoblasts
demonstrated a slight increase in SERCA 1a spl ice isoform over SERCA Ib
(figure 5.12).
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Figure 5.12: SERCAI splice isoforms in wild type and DM] myoblasts. Wild type
myoblasts display roughly equal proportions of the SERCAI splice isoforms whereas
DM 1 myoblasts display predominance of the SERCA] b isoforrn.
Quantification of the SERCAla splice isoforms by Genescan analysis gave a
value of 5.0±1.6% for OMl myoblasts compared to 61.5±10.1% for wild type
myoblast.
5.2.2.3 Muscleblind-like Splicing assay
Due to the significant role of MBNL proteins in splicing misregulation in OM
as a result of its depletion, two assays for MBNL splicing were included for
study.
5.2.2.3.1 Muscleblind-like 1 Splicing assay
The muscleblind-like 1 splicing assay was based on primers designed to
exons 5 and 8 of the flanking alternately spliced exon7, which gives RT-PCR
products of 270bp and 216bp for the presence and absence of alternatively
spliced exon7 respectively.
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In OM fibroblasts, as well as in wild type fibroblasts, there was less of the
MENU exon 7 splice isoforms than the -7 isoforrn on 3% agarose gels (figure
5.13).
270bp (+Exon7)
216bp (-Exon7)
Figure 5.13: Wild type and DM fibroblasts showing similar decreased proportions of
MBNLI exon7 isoforms on 3% agarose gel.
Analysis of exon 7 splice isoforms by Genescan showed 7.8±2.4%, 13.4±4.4%
and IO.I±1.2% for the +7 isoform in wild type, DMI and DM2 fibroblasts
respectively.
However, when DMI fibroblasts were differentiated into myoblasts, there
was an increased proportion of the MENU plus exon 7 splice isoform in DM I
myoblasts compared to wild type myoblasts which showed a decrease in this
splice isoform (figure 5.14).
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70bp( +Exon 7)
216bp(-Exon7)
Figure 5.14: MBNLJ splice isoforms in wild type and DM I myoblasts showing greater
proportion of +exon7 isoform in DM 1 compared to wild type cells.
Genescan quantification analysis of the + exon 7 splice isoform revealed
7.2± 1.6% for wild type myoblasts and 57.8±6.1 % for OM 1 myoblasts
5.2.2.3.2 Muscleblind-like 2 splicing assay
The MBNL2 splice assay is based on the alternative splicing of exon7.
Primers located in exon 5 and exon 8 and were designed to amplify a peR
product of 212bp for exclusion of alternately spliced exon 7 and 266bp for its
inclusion. Fibroblasts from OM 1 and OM2 patients show a similar decreased
proportion of the exon 7 isoform while the wild type line is almost absent on
3% agarose gel (figure 5.15).
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2bp (-Exon7)
Figure 5.15: DM fibroblasts a showing decreased proportion of the +exon 7 isoform in
comparison to wild type lines where it appears less on agarose gel.
The quantification of the +exon7 isoforms revealed 4.7±1.7%, 7.8±4.0% and
2.0±O.5% for DM 1, DM2 and wild type fibroblast respectively.
In rnyoblasts, there is an increase in the proportion of the +exon 7 isoform in
DMI in contrast to the wild type where it is almost absent (figure 5.16). The
quantification by Genescan shows that DMI exhibits a greater proportion of
the +exon 7 isoform (39.0±9.0%) while the wild type cells show a decreased
proportion (2.1±O.6%).
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Figure 5.16: The DM1 cell line exhibited increased MBNL2 + exon 7 splice isoforms,
which is almost absent from the wild type cell line.
5.3 Validation of Compounds
To test the hypothesis that compounds which clear or reduce nuclear foci in
DM cells could lead to: (1) release of the RNA containing expanded repeat
units into cytoplasm and, (2) produce a subsequent redistribution of MBNL 1,
released from foci, resulting in rescue of misregulated splicing, secondary
screening assays were utilized. Secondary assays developed in the preceeding
sections were used to validate positive compound hits from the HTS in primary
screens. Among the positive hits obtained from the primary screens were
protein kinase C (PKC) inhibitors designated as D8 and D9. These compounds
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were applied to secondary assays that have been developed previously to test
their effect on downstream targets of disease and are discussed below.
5.3.1.1 Mutant DMPK transcripts were not released into
cytoplasm by MBNL downregulation
Since MENL] and MENL2 double knockdown was demonstrated in chapter
four of this report to effect 59.3±9.7% reduction in nuclear foci, it was also
tested in Bpm! polymorphism assay to determine if MBNL downregulation
could effect the release of mutant DMPK containing expanded repeats. The
siRNA double knockdown which was performed in parallel with nuclear foci
assay showed that the mutant DMPK transcript was not released into the
cytoplasm (figure 5.17).
However, the MENL double knockdown effected a reduction in the proportion
of mutant DMPK transcript in nucleus. Genescan analysis of normal and
mutant DMPK transcripts showed that the percentage proportion of mutant
allele in the nucleus was 18.0, 38.4 and 53.3 for MBNL double knockdown,
nonspecific knockdown (scrambled) and untreated respectively. This correlates
with what was observed on agarose gel (figure 5.18)
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154bp
138bp
GAPDH
Figure 5.17: MBNL down regulation does not release mutant DMPK transcripts into
cytoplasm but results in its reduction when compared to controls (scrambled which is a
nonspecific knockdown and untreated)
5.3.1.2 PKC inhibitors do not release mutant transcripts
into cytoplasm
In order to assess whether mutant transcripts are released from the nucleus
following treatment with the hit compounds, BpmI polymorphism analysis was
carried out on nuclear and cytoplasmic RNA following PKC inhibitor
treatment of OM] fibroblasts. Such treatment cleared nuclear foci from OM
cells. Initial analysis showed that PKC inhibitors (08 and 09) did not release
the mutant transcripts into the cytoplasm indicating that these transcripts are
still trapped in the nucleus (figure 5.18).
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Figure 5.18: PKC inhibitor treatment of OMl cells did not release the mutant transcript
from the nucleus into the cytoplasm
Further analysis was carried out on DM 1 fibroblasts in triplicate (figure 5.19a
&b) which confirmed the results from the pilot study (figure 5.18).
Figure 5.19a: Cytoplasmic DMPK showing non-release of the mutant DMPK transcript
on treatment with PKC inhibitors
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% mutant
Figure S.l9b: PKC inhibitor 09 treatment shows a reduction of the mutant transcript in
the nucleus which was not demonstrated in 08 treated OMl fibroblasts.
Nuclear DMPK transcripts from these treatments were analysed USIng
Genescan to quantify the relative proportions of the mutant and normal
transcripts. Genescan analysis give peaks for the mutant and normal transcripts
and the areas of the peaks were exported to calculate the relative proportions
(figure 5.20).
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Figure 5.20: Analysis of the mutant DMPK (double peaks on the left) and normal allele
(peak on the right) as shown by Genescan. Information below each peak gives the length
in bp of product (S), height (H) and area (A) of the peak. The relative proportion was
estimated using the area of the peaks for each allele. The yellow peaks are the size
ladders.
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The quantification of the DMPK transcript alleles on Genescan was carried out
using PCR with 22-26 cycles in compound treated fibroblasts. The relative
proportions of nuclear DMPK transcripts were assessed to determine whether
compound treatment increased or decreased the proportion of mutant
transcripts.
In DM1 fibroblasts, PKC inhibitor treatment affected the ratio of non-
expansion transcripts to expansion DMPK transcripts. In nuclear RNA D9
produced 61.5±5.4% non-expansion transcripts compared to 45.S±3.5%
following DS treatment and 56.3±3.0% and 4S.6±O.S% in DMSO and untreated
cells respectively. The effect of D9 treatment was found to be statistically
significant while D8 treatment was insignificant.
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Figure 5.21: Statistical analysis of the effect of various treatments on nuclear DMPK in
OMI fibroblasts showing that only 09 had a significant effect on increasing the
proportion of normal DMPK transcripts when compared to 08 treatment and untreated
but it was not quite significant when compared to OMSO at p= 0.061.
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The effect of PKC inhibitors was tested further in OM I fibroblasts
differentiated to myoblasts which also confirmed that they were not able to
released mutant DMPK transcripts into the cytoplasm following treatment
(figure 5.22 and 5.23).
% normal DMPK
DMPK
GAPDH
Figure 5.22: Analysis of nuclear DMPK following treatment of myoblasts showing that
PKC inhibitors do not reduce the proportion of mutant DMPK transcript from the
nuclear fraction. RT-PCR was normalised against GAPDH
In OM 1 myoblasts, the proportions of mutant nuclear DMP K transcripts were
increased in comparison to the relative amounts in fibroblasts (3S.4±2.3% for
fibroblasts and 4S.7±O.S% for myoblasts). Furthermore, it appeared that 09
and DS treated myoblasts had more DMPK mutant transcripts than controls. It
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was also revealed by genescan analysis that D8 and D9 treatments did not
reduce the proportion of mutant DMPK transcripts, neither did it release the
mutant transcript into the cytoplasm when compared with wild type myoblasts
(figure 5.23).
DMPK
GAPDH
Figure 5.23: The non-release of mutant DMPK transcript into the cytoplasm of DM1
myoblasts following treatments by PKC inhibitors (D8 and D9). DM 1 fibroblasts are
included as controls on 3% agarose gel normalised to GAPDH as a control
The difference between D9 and DMSO treatments were statistically
significant (p=O.037). In addition, a very significant difference was observed
between D9 treatment and untreated controls (p=O.00509), as well as between
D8 treatments and untreated controls (p=O.00395). Also, a very significant
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difference was observed between D8 treatment and DMSO treatment (figure
5.24) which was a mock control (p=O.00227).
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Figure 5.24: Statistical analysis of effect D8 and D9 treatments in comparison with
controls showing that both PKC inhibitors have a negative effect of reducing normal
DMPK in myoblast.
From the studies above, it would appear that both D8 and D9 treatments did
not release mutant DMPK transcripts into the cytoplasm in both DM1
fibroblasts and myoblasts when compared to wild type fibroblasts and
myoblasts in which mutant DMPK transcripts were released into cytoplasm.
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5.3.2 08 partially rescues IR splicing defect in OM1
myoblasts but not in OM2 fibroblasts
The IR splicing assay developed previously in section 5.2.2.1 was applied to
compound treated DM2 fibroblasts and DMI myoblasts to test its efficacy in
reversing IR spliceopathy in DM. Initial application in DM2 fibroblasts showed
that 08 treatment was effective in rescuing IR splicing as demonstrated by
slightly increased IR-B isoform. D9 treatment has no such effect.
I 10 111 112
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Figure 5.25: D8 shows partial reversal of JR splicing defect in DM2 fibroblast in the pilot
study as indicated by the increased presence of IR-B.
However, replicating the above result in subsequent treatments of DM2
fibroblasts has been very challenging. Subsequent compound treatments of
DM2 fibroblasts showed no difference between D8 and D9 treatments in
comparison with controls (figure 5.26) following treatment with compounds
for 24 hours.
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Figure 5.26: PKC inhibitors (D8 and D9) have no effect on improving the proportion of
IR splice isoform B following treatment in DM2 fibroblast. RT·PCR was normalised
using GAPDH
Isoform quantification of IR-B in triplicate treatments of 08, D9 and DMSO
treated as well as untreated fibroblasts were 9.6± 1.4%, 14.3±6.2%, 8.1± 1.0%
and 10.4±1.7% respectively. Wild type fibroblasts had IR-B proportion of
42.6±5.1 %. Statistical analysis showed there was no difference between
treatments (D8 and D9) on between treatments and controls (DMSO and
untreated) (figure 5.27).
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Figure 5.27: Analysis of IR splice isoforms in OM2 fibroblasts showing that PKC
IR-B isoform.
inhibitors 08 and 09 treatments did not have significant effects on the proportion of the
In DM 1 differentiated myoblasts, D8 treatments slightly increased the
proportion of IR-B splice isoform in comparison with controls (DMSO and
untreated myoblasts). However, D9 treatment appeared to degrade both
isoforms of IR by 48 hour of treatment (figure 5.28).
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Figure 5.28: D8 treatment produces a slight increase in the IR-B isoform in DM 1
myoblasts while D9 has a degradative effect on IR splicing when compared with controls
(DMSO and untreated). GAPDH was used as loading control.
Splice isoform TR-B quantification gave values of l4.4± 1.3%, 8.2±O.6%,
IO.2±O.6% and 37.2±7.3% for triplicate treatments of 08, OMSO, untreated
myoblasts and wild type respectively. Statistical analysis showed a very
significant difference between 08 treatments and the mock control COMBO)
(figure 5.29) and there was also a significant difference when 08 treatment was
compared with untreated myoblasts control (p=O.025l8).
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Figure 5.29: 08 treatment showed a statistically significant effect on the proportion of the
IR-8 isoforrns in comparison to controls (OMSO and untreated) in OM1 myoblasts
5.3.3 PKC inhibitors do not increase SERCA1 splicing in
DM2 fibroblasts
In order to examine the effect of PKC inhibitors on another alternatively
spliced transcript in DM, SERCA 1 splicing was assessed in triplicate
compound-treated DM2 fibroblasts and controls. On a 3% agarose gels, there
was no obvious shift in splice isoforms between compound treated DM2
fibroblasts and controls involving DMSO and untreated (figure 5.30).
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Figure 5.30: D8 treatment does not alter the ratio of SERCAJ splice isoforms while D9
has the effect of reducing the isoform containing exon22 in DM2 fibroblasts in
comparison to controls (DMSO and untreated) on agarose gel
Genescan analysis showed slight differences between compounds treatments
(08 and 09) as well as with controls. Exon22 splice isoform (SERCA Ia)
quantification analysis gave 62.6±6.3%, 71.6±8.3%, 70.0±3.l %, 72.9±3.0%
and 76.0±3.9% for 09 treatments, 08 treatments, OMSO treated, untreated and
wild type respectively on Genescan using PCR with 27-28 cycles. Statistical
analysis of SERCA Ia isoform using t-test showed no significant difference
between treatments (08 and 09) as well as between treatments and controls
(OMSO and untreated). However, when treatments and controls were
compared to wild type fibroblasts, 09 treatment was observed to be statistically
significant (figure 5.31).
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Figure 5.31: Analysis of SERCAla isoforms showing no significant effect of PKC
inhibitor treatments
5.3.3.1 D8 treatment increases SERCA1 splicing in DM1
myoblasts
The SERCAI splicing assay was utilized in triplicate compound-treated
differentiating myoblasts and controls. However, following D9 treatment, there
was no evidence of any SERCAla isoform due to degradation by 48 hours of
treatment. In contrast to D9 treatment, D8 treatment showed a slight increase in
the SERCA Ia splice isoform in comparison to controls (figure 5.32).
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Figure 5.32: D9 treatment shows absence of SERCA 1a isoforms while D8 treated OM 1
myoblasts shows an increase in SERCAla isoform when compared with controls on gel
normalised using GAPDH
Genescan quantification analysis of SERCA 1a (exon22) splice isoforms was
observed to be 22.6±4.7%, 10.9±2.7%, 12.7±l.S% and 62.S±13.7% for OS,
OMSO, untreated and wild type respectively. Statistically, there was a
significant difference between DS and OMSO treatments as well as DS
treatment compared to untreated myoblasts. In addition, there was a significant
difference between OS treatment and wild type (p=O.Ol156) as well as wild
type compared to controls- OMSO treated and untreated myoblasts (figure
5.33).
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Figure 5.33: Statistical analysis shows that D8 treatment improves SERCAI splicing in
DM 1 myoblasts when compared to controls (DMSO treatment and untreated). The
asterisks represent significant level of difference in the analysis.
5.3.4 D8 increases MBNL 1 splicing in DM1 myoblasts but
not in DM2 fibroblasts
The analysis of efficacy of PKC inhibitors in reversing the spliceopathy of
MBNLI splicing in DM was performed on compound treated DM2 fibroblasts
and controls in triplicate. Only D9 treatment showed a very slight decrease of
MBNLI +exon 7 isoform in comparison with D8 treatment and DMSO
treatments, as well as untreated control (figure 5.34).
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Figure 5.34: MBNLl splicing in PKC inhibitor treated DM2 fibroblasts and controls,
demonstrating D8 and D9 treatments have no effect on its splicing. Fragments were
analysed on 3% agarose gel normalised to GAPDH
This was confirmed by Genescan analysis of MBNLJ splice isoforms, which
showed that +exon7 isoform was present at 21. 7±2.6%, IS.1 ± 1.5%,
20.2±2.9%, 22.0± 1.1% and 11.7± 1.3% for DS-treated, D9-treated, DMSO,
untreated and wild type respectively. Statistical analysis showed there was no
significant difference when treatments CDS and D9) were compared to controls
(DMSO and untreated). However, there was significant difference between D8
and 09 treatments (figure 5.35).
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Figure 5.35: PKC inhibitors were ineffective in reversing missplicing of MBNLl +exon7
On comparison of treatments and controls with wild type, it was observed
that there was significant difference between DMSO treatment and wild type
(p=O.O1046) but the level of significance was higher between wild type and
untreated controls (p=O.00235). In addition, a very significant difference was
observed when wild type was compared to D9 treatments.
157
In OMI differentiated myoblasts, triplicate treatments of 08 were observed to
reduce the proportion of MBNLI exon 7 isoforms in comparison with 09 and
OMSO treatments as well as untreated controls (figure 5.36).
+Exon7
-Exon7
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GAPDH
Figure 5.36: PKC inhibitor D8 treatment effects reversion of MBNLl exon 7 splicing
while D9 treatment has a mild effect in DM I myoblasts when compared with control.
This was confirmed by Genescan analysis of the MBNU +exon 7 isoform
which gave 36.1±2.5%, 47.6±4.1%, 53.6±O.6%, 51.7±2.1% and 6.2±1.1% for
D'S-treated, 09-treated, DMSO-treated, untreated and wild type respectively.
Statistically, a very significant effect was observed between 08 and OM SO
treatments as well as between D8 treatment and untreated control (figure 5.37).
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Figure 5.37: D8 treatment produces a very significant effect on MBNLI exon7 splicing in
DM 1 myoblasts in comparison with controls
In addition, there was a significant difference between D8 and D9 treatments as
well as between D9 and DMSO treatments. Furthermore, a very significant
difference was observed when wild type was compared with DMSO
(p=O.00022) and untreated (p=O.00029). A very significant difference was also
observed when treatments (D8 and D9) were compared to the wild type.
However, there was no significant difference between D9 treatment and
untreated or between DMSO treatments and untreated cells.
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5.3.5 PKC inhibitors are ineffective in reversing MBNL2
exon7 splicing in DM2 fibroblasts while D8 demonstrates
marginal rescue in DM1 myoblasts
Next I examined the effect of PKC inhibitor treatments on alternative splicing
of MBNL2 exon7 splicing in both DM2 fibroblast and DM1 myoblasts.
Neither of the PKC inhibitor D8 showed any increase in MBNL2 exon7 splice
isoform in DM2 fibroblasts while D9 increases the proportion of this isoform
(figure 5.38).
Figure 5.38: MBNL2 exon7 splice isoform in OM2 fibroblasts is not affected by 08
treatment while 09 treatment seems to increase the proportion of this isoform. The wild
type fibroblasts show decreased proportion of exon 7 isoform in comparison with OM2
fibroblasts.
Quantification analysis by Genescan for 09, D8, DMSO treatments as well as
untreated showed 20.4±3.3%, 10.5±J.I%, 9.7±2.1% and 12.4±0.3%
respectively for the +exon 7 isoform. The wild type cells which provided an
additional control had 4.5±0.4% proportion of exon 7 isoform. Statistical
analysis showed no significant effect of D8 treatment in comparison with
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controls (DMSO and untreated). However, there was significant effect of D9
treatment compared to D8 and DMSO treatments (figure 5.39).
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effect on MBNL2 exon7 splicing in OM2 fibroblasts
Figure 5.39: 08 treatment shows no significant effect while 09 treatment has a significant
In DM 1 myoblasts, D8 treatment produced decreased proportion of the +exon
7 splice isoform while D9 treatment actually increased the isoform on agarose
gel analysis (figure 5.40).
161
Figure 5.40: 08 treatment produced a decreased +exon 7 isoform of MBNL2 when
compared to controls (OMSO) while 09 treatment increases it in OM 1 myoblasts. The
wild type cell line which is an additional control lacks this isoform
The quantification of exon 7 splice isoforms by Genescan gave SO.S±6.1 %,
20.S±1.7%, 3S.6±1.2% and 33.6±O.S% for D9, D8, DMSO treatments and
untreated respectively, for the +exon 7 isoforms indicating that D8 treatment
has a significant effect in reducing this isoform. The wild type myoblast had
2.S±O.2% +exon 7 isoform proportion.
Statistical analysis demonstrated that D8 treatment had a very significant
effect on the +exon 7 isoform splicing in comparison to untreated. D9
treatment had a significant negative effect in contrast to D8 treatment by
increasing the proportion of+exon 7 splice isoform (figure 5.41).
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Figure 5.41: 08 showing a significant effect on exon7 splicing in OMI myoblasts while the
difference between wild type myoblast and the various treaments were very significant
5.4 Summary
Secondary assays were developed and applied in confirmation of positive
compound hits obtained from primary assays in the previous chapter. The
secondary assays used to validate testing of putative compound hits were Bpm!
polymorphism, JR, SERCAJ, MBNLl and MBNL2 splicing. Bpm!
polymorphism assay was utilized in assessing the effect of compounds on
mutant DMPK containing expanded repeat RNA. Alternative splicing assays
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(JR, SERCAI, MBNLI and MBNL2) were used to test the downstream effect of
compound treatments in OM therapy screen.
From the studies in this chapter, 08 treatments were effective in reversing
spliceopathy of JR, SERCAI, MBNLI and MBNL2 in the OMI myoblasts but
not in OM2 fibroblasts. Furthermore, 09 treatments had no effect on
improving spliceopathy of JR, SERCAI, MBNLI and MBNL2 in both OMI
myoblasts and OM2 fibroblasts.
Finally, neither 08 and 09 treatments nor MBNL double knockdown effected
the release of mutant transcript from the nucleus into the cytoplasm in OM I
cells. However, 09 treatment and MBNL double knockdown showed a
reduction effect on the mutant DMPK transcript while 08 treatment showed no
reduction on the same transcript.
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CHAPTER SIX: DISCUSSION
6.1 Translocation of Nuclear mutant DMPK Transcript
The expanded CUG repeat RNA is localised in the nucleus of OM cells where
it is proposed to be trapped in the nucleus to form foci due to its inability to be
transported to the cytoplasm as is the case with the normal transcript
(Hamshere et al, 1997; Davis et aI, 1997). To track the location of the mutant
DMPK transcript on treatment of OM cells with compounds, an assay was
developed based on a BpmI polymorphism which occurs in the DMPK gene
and as it is present in the mature mRNA, it permits identification of the
location of wild type and expanded CUG repeat RNA in OM cells. Cells were
screened for the presence of this polymorphism to assess the effect of
compound treatment in the BpmI polymorphism assay.
To determine whether compound treatments that clear nuclear foci would
liberate mutant DMPK transcripts from the nucleus into the cytoplasm, the
BpmI polymorphism assay was used to examine the effects of treatment on the
mutant allele. The data from chapter four demonstrates that both PKC
inhibitors 08 and 09 remove nuclear foci. However, the mutant DMPK
transcript was not released into cytoplasm as shown in chapter five of this
report. In siRNA MBNLJ and MBNL2 double knockdown, which showed a
reduction in nuclear foci, a similar effect was observed with non-release of the
mutant transcript into the cytoplasm.
If compound treatment that reduces or clears nuclear foci in OM cells is not
able to effect the translocation of the expanded CUG repeat RNA from nucleus
to cytoplasm, then what is the possible effect of treatment on the mutant
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DMP K that is still trapped in the nucleus? The possible answer to this question
lies in the proposition that the compound treatments would either eliminate or
inhibit the mutant DMPK transcripts in the nucleus from interacting with
muscleblind-like proteins to form foci. To determine which of the two
possibilities is valid for the treatments used in this study, analysis of the
relative proportion of normal and mutant DMPK transcripts in the nucleus was
performed. In DM 1 fibroblasts, D9 treatment reduced the proportion of mutant
DMPKtranscripts while D8 treatment did not show any reduction in the mutant
allele. This suggests that D9 either has a destructive effect on mutant DMPK
or it could affect transcription mutant allele thereby resulting in low production
of the same trancript while D8 inhibits expanded repeat RNA interactions with
MBNL. Furthermore, when DMI fibroblasts were differentiated into
myoblasts, the proportion of the mutant transcripts in the nucleus was increased
and this could account for the presence of more foci in DM I myoblasts than in
DM 1 fibroblasts. MYOD induces the repertoire of muscle genes including
DMPK. This gives more RNA and therefore more foci.
The result obtained from this study deviates from that reported by Wheeler et
al (2009) which suggested that expanded CVG repeat RNA was transported to
cytoplasm by CAG25 (a morpholino antisense oligonucleotide directed against
CVG repeats) treatment resulting in an increase in its translation.
Indeed, the BpmI polymorphism assay could be a useful tool for assessing the
effect of compound treatment on the mutant DMPK allele. Releasing the
mutant transcript into the cytoplasm has been suggested to be beneficial in
alleviating DM symptoms. It has been demonstrated that a woodchuck post-
transcriptional regulatory element (WPRE) causes transport of expanded CVG
166
repeat RNA from nucleus into cytoplasm thereby alleviating its toxic effect on
cell differentiation (Mastroyiannopoulos et aI, 2005; Mastroyiannopoulos et aI,
2008). This was further validated in a study by Dansithong et al (2008) which
demonstrated that the cytoplasmic location of expanded CVG repeat RNA did
not cause misregulated splicing and DM features in a mouse model even
though it formed foci in the cytoplasm.
Thus any compound that induces the transport of expanded CVG repeat
transcripts from the nucleus into cytoplasm would be useful in reversing DM I
symptoms and the BprnI polymorphism assay used in this study can facilitate
identification of such compounds. It stands to reason that any compound that is
capable of facilitating nuclear export of expanded CVG repeat RNA into the
cytoplasm would have a disruptive effect on its hairpin formation. This is
because in wild type cells DMPK transcripts with normal length CVG repeats
are relatively short and do not fold to form secondary structures like hairpins.
Hence, they are easily transported into the cytoplasm, as opposed to DM cells
where long expanded repeats form hairpin structures. Indeed, a study by
Garcia-Lopez et al (2011) has shown that D-amino acid hexapeptide (ABPl)
reduced foci formation and causes the disruption of CVG hairpin to single-
stranded CVG RNA. It would be interesting to test the effect of ABP 1 in the
BprnI polymorphism assay to determine if this compound can liberate
expanded CVG RNA into cytoplasm of DM 1 cells.
Since the expanded CCVG RNA in DM2 is intronic, application of this assay
to test compound mediated export of expanded repeat transcripts would not be
feasible.
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6.2 Spliceopathy as a Potential Target for OM Therapy
In DM, alternative splicing is altered due to changes in the relative ratios of
the splicing factors MBNL and CUG-BP 1 (Kalsotra et ai, 2009). To assess the
use of alternative splicing of transcripts for OM therapy, lines of patient
fibroblast cells were tested for their ability to mimic OM splicing patterns for
subsequent application for screens. Since defective splicing of some transcripts
has been associated with DM phenotypes, five alternative splicing events were
utilized in therapeutic screenings in this study.
Four of the five alternative splicing events under consideration in this study
were used in secondary screening. The splicing in these screens involves exon
exclusion or inclusion. The splicing of IR and SERCA 1 involves exclusion of
exon 11 and exon 22 respectively in OM while both MBNLI and MBNL2
involve inclusion of exon 7 in DM.
Differentiated DMI fibroblasts (DMI myoblasts) and DM2 fibroblasts
showed splicing patterns for IR similar to those observed in OM samples.
However, only OM 1 myoblasts demonstrated OM-like splice patterns for
SERCAI, MBNLI and MBNL2.
Other defective splicing events that were considered were exon inclusion of
CLCNI involving exon7a and ZASP exon 6a. This work was not included in
this study because both CLCNI and ZASP are sarcomeric proteins which are
absent from fibroblasts and derived myoblasts. However, CLCN 1 is present in
derived myotubes and muscle biopsies of wild type and patients' cells (Charlet
et ai, 2002b; Mankodi et ai, 2002; O'Leary et ai, 2010). The cell lines used in
this study have leaky expression of MyoD hence they can only differentiate
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into myoblasts and not myotubes because only 90% of the cells were infected
with inducible MyoO.
The other spliceopathy in OM used in this study is the intron retention which
was utilized in the transgene splicing construct assay with double reporters
(GFP and OsRed) for stable transfection in patient cell lines. This was applied
to primary screens and optimised in HTS.
Spliceopathy of CLCN] and SERCA] have been used in screening therapy
studies of OM (Mulders et aI, 2009; Warf et aI, 2009; Wheeler et aI, 2009).
Therapeutic reversal of spliceopathy in OM has been demonstrated using
antisense RNA against cva repeats (Francois et aI, 2011), antisense
oligonucleotides (Mulders et aI, 2009; Wheeler et aI, 2009), MBNLl
overexpression (Oansithong et aI, 2005, Kanadia et aI, 2006; Hino et aI, 2007)
and morpholino antisense oligonucleotide (Wheeler et aI, 2007). This justifies
the use of reversal of spliceopathy in OM as a measure of identifying
molecules or drugs that can alleviate OM phenotypes.
In the screening analysis carried out on spliceopathy of OM in this project,
only PKC inhibitor 08 treatments showed the potential to alleviate OM
features in the cell model for all the five defective splicing events used in this
study namely: exon II of JR, exon 22 of SERCA], exon 7 of both MENL] and
MENL2, and intron 2 of CLCN]. 09 treatment only had a positive effect on
correction of splicing in intron 2 of CLCN1 and to a non-significant extent on
MENL1. However, it is very toxic to the cells as it resulted in 85-90% cell
killing of OM I myoblasts with splicing constructs, by 48 hours. As a
consequence, 09 does not lend itself for further consideration as it was
ineffective in other splicing assays beside CLCN 1.
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Based on the effect of the two PKC inhibitor treatments on alternative
splicing assays for DM in this study, it is possible that D8 causes redistribution
of MBNLl as it improved the misregulated splicing of IR exon 11, SERCA1
exon 22, exon 7 of both MBNL1 and MBNL2 as well as intron 2 of CLCN1 in
DMI myoblasts. Western blotting of both nuclear and cytoplasmic protein
obtained from PKC inhibitor-treated cells will clarify these possibilities.
Furthermore, it is open to speculation that D8 could hinder phosphorylation of
exon 7-containing isoforms of both MBNL1 and MBNL2 thus preventing its
transport to the nucleus since exon 7 is necessary for its nuclear localisation
and has affinity for sequestering MBNL 1 to expanded CUG repeats (Botta et
aI, 2008; Cardani et al, 2009; Tran et al, 2011). Separation of MBNL 1 and
MBNL2 proteins on coomassie gel and their purification for mass spectrometry
analysis will confirm this proposal.
However, in DM2 fibroblasts, both PKC inhibitors did not reverse splicing
defects. This could be a result of low CUG-BPI levels in DM2 in contrast to
very high levels found in DM 1 myoblast cultures (Savkur et aI, 2001; Lin et aI,
2006) hence PKC inhibition would be ineffective in DM2 as the spliceopathy
could be accounted for primarily by MBNL 1 sequestration alone and is not a
contributory effect of MBNL1 and CUG-BPI as seen in DMI (Kalsotra et al,
2009).
Finally, the expression levels of alternatively spliced transcripts were not the
same across treatments as only D9 had a degradative effect on IR and SERCA1
transcripts and to a lesser extent on MBNL1 and MBNL2 transcripts.
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6.3 Cell-based model systems for HTS Drug Screens in
OM
In this study, two model assays have been developed and successfully applied
on a large scale in HTS. The first assay that was developed and optimised in
HTS was the nuclear foci assay. The nuclear foci assay is a good workable
model on the plate reader and shows compatibility in HTS as it is currently
being used in 96-well plate and also in 384-well plates.
The second model assay system developed in this project is the splicing
construct assay with double reporters for intron splicing. The CLCN} splicing
construct assay used for compound screens in this study has the advantage over
those of 0'Leary et al (20 10) because it is a double reporter system allowing
quantification of the splicing efficiency of transgene construct in both DMI
fibroblast and OM1 myoblast. The quantification of splicing is absent from the
luciferase CLCN} construct of O'Leary et al (2010) because it assesses the
efficacy of compound by measuring its effect on intensity of the luciferase
expression which is at the 3' end of the transgene construct. Their assay is
limited by being qualitative in nature therefore the degree of efficacy of
compound or drug can be estimated in the system reported here. Furthermore,
the bichromatic fluorescent reporter system developed in this study differs
from those used by Orengo et al (2006) by having both reporters in the same
open reading frame as opposed to having the reporters in alternate reading
frames used in their study. The splicing construct assay model system has been
optimised for miniaturisation in HTS and the ratios of DsRed/OFP
fluorescence intensity serve as a measure of the efficacy of compound
treatment on CLCN} intron2 spliceopathy in this system.
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Figure 6.1: Model for compound screenings used in this study
6.4 Limitations of Study
The main technical limitation of this study was that the quantification of the
isoforms for both the alternatively spliced transcripts and BpmI polymorphism
was not linearly determined by qPCR but was performed by optimisation on
Genescan. Furthermore, the expression levels of the various alternatively
spliced transcripts from across different treatments were not equal. D9
treatments of DMI myoblasts which in addition to showing degradative effect
on transcript did show reduction in RNA pool in some treatments (figure 5.28)
when normalised to GAPDH. It may have been due to side effects of the
compound on RNA pool in the cell.
There was also a reduction in RNA from D8 treatment for the DMPK allele
(figure 5.21) which was not observed in other independent replicates involving
the same treatment.
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6.5 Recommendations
Since MBNLI and MBNL2 knockdown did not alter the CLCNl splicing in
wild type clones to OM patterns, it would be necessary to subject the wild type
clone to either combined MBNL I & 2 knockdown with overexpression of
CUG-BP I or overexpression of CTG expanded repeat. The results obtained
from chapter four of this report in wild type clone seem to indicate that OM
molecular features are not due to MBNL sequestration alone. This therefore
makes a case for combining both downregulation of MBNL with CUG-BPI
overexpression or CTG expanded repeat overexpression in the wild type clone
to test its effect on altering CLCN 1 splicing. This is because it has been shown
that overexpression of CVG-BPI, or overexpression of expanded CTG repeats
or MBNL knockdown in wild type cells changes its splicing features to that of
OM cells.
In order to determine if the PKC inhibitors 08 and 09 would be effective in
correcting CLCN 1 misspJicing in OM2, it would be necessary to apply the
PKC inhibitor treatments to OM2 clones containing CLCNl splicing construct
to determine if the treatment can also reverse intron 2 CLCNl spliceopathy.
This would confirm whether PKC inhibitors which cleared nuclear foci from
OM2 (figure 4.9) can reverse downstream consequences of ribinuclear foci
formation.
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6.6 Conclusion
The assays developed in this project have been utilized in compound screens
and have been demonstrated to be relevant in identifying potential therapeutic
hits that could alleviate DM features.
Based on the efficiency and ease of usage in primary screens in HTS, both
nuclear foci assay and CLCN 1 double reporters are compatible good model
assays. Both assay models have been demonstrated to be efficient and are
directly applicable for high throughput analysis of compound libraries that
reduces or removes completely nuclear foci and rescues misregulated splicing-
both hallmarks ofDM pathology.
Furthermore, other assays such as the BpmJ polymorphism assay permit
identification of molecules that can either inhibit, eliminate or remove
expanded COG repeat transcript from the nucleus.
The alternative splicing assays of transcripts developed and used in this study-
JR, SERCAl, MBNL1 and MBNL2 are applicable to identifying therapeutic hits
for DM with SERCA 1 and MBNU which showed clearer effects with PKC
inhibitor D8 treatment than others in many replicates.
Finally, the hit compounds identified by the assays from this project were
PKC inhibitors D8 and D9. Both PKC inhibitors were effective in clearing
nuclear foci from DMI and DM2 fibroblasts but only D8 showed a therapeutic
beneficial effect on the downstream consequences of expanded repeat RNA, i.e
improving spliceopathy in all the alternative splicing assays tested in this
project. The effectiveness of D8 treatment in reversing or improving splicing in
DMI myoblasts could be as a result of absence of COG-BPI mediated
spliceopathy in DM2 since PKC inhibitors blocks COG-BP 1 activity.
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Furthermore, even though both 08 and 09 clear nuclear foci from OM cells,
08 showed inhibition of mutant DMPKtranscript in OMI fibroblasts while 09
has a degradative effect on mutant DMPK transcript, is toxic and has some off-
target effects namely- reduction of RNA in some treatments, degrades IR and
SERCAl alternatively spliced transcripts and tends to increase the relative
proportions of MBNL2 isoforms associated with OM.
08 could be used as positive control hit for comparison with other therapeutic
hits in future drug screens for efficacy in OM therapy. Futhermore, 08
treatment could be applied to in vivo (mouse) models of OM to assess its
efficacy in reversing OM symptoms in animal models.
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APPENDIX A
Primer Sequence15'-3'1
sinCLCNlf GATTTATGGCCATCACAAAGAACAATT
sinCLCNlr GCTGAAGGCTTTTGGCACTGAC
sinSERCA2f GTTGTCCGAAAACCAGTCCTTG
pEGFP-CIF CCTGAGCAAAGACCCCAAC
pEGFP-CIR TTCAGGTTCAGGGGGAGGT
DsRedORFr ATCTCGAAGTAGTGGCCGTTC
DsRedMonoF GACCGGCCGCGGGCATGGACAACACCGAGGACG
MIRI-2F TGCCATGCTTCAGGTAAAC
MIRI-2R CACGTAGAAAGAAGCAAGAGC
TlF AAAGACCCCAACGAGAAGC
TIR GATCCTCATCCTTGCTGTCC
GdmpkF GTTCTCCACCAGAGAATCAGC
GdmpkR GAAGCCCTCACCTTTTCTCTC
NIl CACTGTCGGACATTCGGGAAGGTGC
133 GCTTGCACGTGTGGCTCAAGCAGCTG
IRfor CCAAAGACAGACTCTCAGAT
IRrev AACATCGCCAAGGGACCTGC
Sercalfor TTCGTTGCTCGGAACTACC
Serca1rev GGTTGGGAAGGGGAATTTAC
MBNLlfor GCTGCCCAATACCAGGTCAAC
MBNLlrev TGGTGGGAGAAATGCTGTATGC
MBNL2for ACAAGTGACAACACCGTAACCG
MBNL2rev TTTGGTAAAGGATGAAGAGCACC
GAPDHf GATGACAAGCTTCCCGTTCTCAGCC
GAPDHrev TGAAGGTCGGAGTCAACGGATTTGGT
pEGFP- GCCCGGGACTAGTCGGATCTAGATAACTGATCATAATCA
CldelF GCCATACCACATTTGTAGAGG
MBNLl-Dlr TGAAAACACTAGTACGGGTTGTAATGGGGCACCAGGCA
TCATGGCATTGG
MBNLl-D2r CTCAAGTACTAGTGTTCGCATTAATTTCTGTGCAGCAGCT
GCAG
MBNLl-D3r CAGGTACACTAGTGTCATTGGTGTCAATCATTGTGCTTC
AGCAGGATGAGC
MBNLl-D4r TGGCTTGACTAGTTGCAGGGGGATGAAAGTATTTGCACT
TTTCCCGAGAG
MBNL2-Dlr TTTTTAAACTAGTCGGAGGGTGAAGATACTTGCAGTTCT
CTCTCGAAC
MBNL2-D2r CCTCCAGACTAGTAGTCCTGAGAAGTTTCTGAGTTGCAG
TTGAGCCCG
MBNL2-D3r GTCACTTACTAGTATCATGGTGCTGTCTGCGGGGTGTGC
AAAG
MBNL2-D4r GCCTGCAACTAGTCAGGAGGGTGAAAATATTTGCATTTC
TCCCTCATGCAACG
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APPENDIX B
siRNA Sequence (5'-3')
MBNLI CACUGGAAGUAUGUAGAGAdTdT
MBNL2a CACCGUAACCGUUUGUAUGdTdT
MBNL2b GAGGAACAUGCUCACGCUCdTdT
Scrambled GCGCGCUUUGUAGGAUUCGdTdT
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APPENDIX C
Supplementary Data
Nuclear foci screening assay for PKC inhibitor GFI09203X designated as 07 showing its
non-clearance effect on nuclear foci of OMl cell
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